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QUOTATIONS 
r 
The more we know 
The more we have yet to learn. 
Aristotle 
It is a wise man 
Who does not spread 
Too much wisdom 
Saladin 
Discovery consists of seeing what everybody has seen 
and thinking what nobody has thought. 
A. Szent-Györgyi 
What is man in nature? Nothing before infinity, 
everything before nothing, middle term between 
the nothing and the everything. 
B. Pascal 
Do not force me on the treadmill of mathematical 
calculations - leave me time for philosophical 
speculations, which are my only delight. 
Johannes Kepler 
Declare the past, diagnose the present, foretell the 
future. 
Hippocrates 
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(i) 
SUMMARY 
A molecular orbital treatment of biological analysis of' 
anti-cancer drugs and related topics is presented which 
lead to the formation of Quantitative Structure-Activity 
Relationships (QSARs). Series of compounds studied include 
phenyl aziridines, aniline mustards, nitrosoureas, poly- 
aromatic hydrocarbons, and DNA bases. 
The modes of action of individual compounds together with 
interaction with DNA bases of active congeners is discussed. 
(i i) 
FOREWORD 
This thesis consists of material presented in three parts. 
The first part deals with a preamble regarding cancer research 
in general, and then sets out to formulate factors involved 
in biological 'activity and how they may be calculated. 
The second part comprises the five series of compounds studied, 
the results of MO calculations, and correlations between bio- 
logical activity and electronic and structural parameters. 
The third part contains appendices referred to in the main 
bulk of the text. These supply additional information and 
more rigorous mathematical treatments than those encountered 
in the body of the text. 
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CHAPTER 1 
THE SCOPE OF CANCER THERAPY 
1 
INTRODUCTION. 
Ever since Pythagoras initiated the philosophy, over 2500 years 
ago, that the universe could be interpreted by numbers1, Man 
has sought to relate the workings of Nature-with mathematical 
equations. The Pythagorean doctrine has continued via Kepler, 
Newton, Eins. tein and others through to the present where most 
of physics and much of chemistry can be explained by mathema- 
tical analysis. Only recently has biology started to become 
quantified, and it is in the field of medicine, or strictly 
pharmacology, where empirical relationships can be of benefit. 
The subject of this work lies in the field of cancer research 
although the methods expounded here have a far wider scope of 
. 
applicability to chemistry, biochemistry, pharmacology and 
drug design. For, although there is a great interest in 
assessing biological activity, it is also of intrinsic interest 
to comprehend more fully the molecular basis of drug action. 
In this work it is hoped that the usefulness of a theoretical 
approach to a biological problem can be demonstrated, and also 
that knowledge of the electronic structure of drug molecules 
is an essential pre-requisite to an understanding of their 
relative potency and mode of action. 
1.1 Cancer and Chemothera 
Cancer is not one disease: it is many. In its varying forms 
it is characterized by transformed and 'misguided' cells. 
Their growth control mechanisms malfunction to such an extent 
that they can multiply at an increased, and often catastrophic 
2 
rate. By perfusion of normal tissue, constriction of blood 
vessels and other vital organs and release of toxins into 
the circulatory system, they eventually bring about death of 
the host organism(Table1. l).. This rate is often increased by the 
2 
ability of cancer cells to metastasize. Metastasis is the 
Table 1.1 Causes of Death in Cancer Patients 
Cachexia 46% 
Haemorrhage 18% 
Organ failure 10% 
Respiratory failure 19% 
cardiovascular insufficiency 7% 
action by which cells become detached from the main body of 
the tumour and travel via the blood or lymphatic system to 
other sites within the organism to initiate secondary tumours, 
or metastases. 
Cancer cells differ from normal cells in a number of ways. 
Cancer cells are non-specific in function, show altered glyco- 
proteins and glycolipids3, have an increased lectin agglutin- 
ability4, possess an unusual surface-charge density 
S. 
and 
show a loss of cohesion of cellular membranes. Through 
6 
comprehension and exploitation of these cellular differences 
effective methods of therapy may be devised. Since there are 
many different types of malignant tumours, affecting different 
organs and tissues of the body in different ways, specific 
methods of therapy have been found to be more effective than 
others in curing certain cancers. 
3 
At present there are four main areas of cancer treatment: - 
surgery, radiotherapy, immunoiherapy and chemotherapy7. 
Sometimes a combination of two or more of these methods is 
used to bring about tumour regression and removal. Surgery 
and radiotherapy have been shown to be highly successful in 
some cases (e. g. retinoblastoma), which would be untreatable 
by other methods, but there are many instances where these 
techniques are not appropriate (e. g. leukemias and lymphomas). 
Immunotherapy is a comparatively new method and its useful- 
ness and applicability have not yet been fully investigated 
and assessed. However, the advent of antiviral substances 
such as interferon8 into cancer treatment, showing an albeit 
mixed response, indicatesa major role for immunotherapy in 
" future developments. 
Chemotherapy has achieved a considerable degree of success in 
9 
the treatment of certain cancers. For example, child leukemia 
can be cured in 90% of all cases by chemotherapy. There are 
chemotherapeutic agents available. that cän inhibit processes at 
either all or certain stages in the cycle of cell divisionl0. 
The theory behind this tactic is to arrest tumour growth 
whilst causing the least possible harm to normal tissue. 
However, there are some types of normal cells which are also 
characterized by rapid division, e. g. bone-marrow, hair 
follicle, kidney and liver cells. These may also become ad- 
versely affected by chemotherapeutic agents and it is not 
fully understood why certain anti-cancer drugs are specific 
in their action toward some neoplasms. A more profound 
understanding of cancer cell structure and function and of 
cancer DNA should yield information which would assist in 
4 
Table 1.2 Chemotherapy and Cancer9 
k Prolongation 
Disease Drugs % Remissions of life 
Leukemias 
Acute lympho- Prednisone 
blastic Vincristine 
6-mercaptopurine 
methotrexate 
cyclophosphamide 
cytosine arabinoside 
L-asparaginase 
BCNU 
Chronic Bisulphan 
granulocytic 6-mercaptopurine 
methotrexate 
hydroxy urea 
thioguanine 
Chronic Chlorambucil 
lympholytic cyclophosphamide 
prednisone 
cytosine arabinoside 
Lymphomas 
Hodgkin's Vinblastine 
disease chlorambucil 
cyclophosphamide 
procarbazine 
BCNU 
prednisone 
Lympho- Chlorambucil 
sarcoma cyclophosphamide 
thiotepa 
vincristine 
vinblastine 
prednisone 
BCNU 
Polycythemia 
vera 
Bisulphan 
chlorambucil 
Waldenstrom's 
macroglobulinemia 
Carcinomas 
Chlorambucil 
melphalan 
cyclophosphamide 
" 90 
90 
50 
80 
50 
80 
60 
Gestational Dactinom ycin 6-MP 75 
choriocarcinoma methotrexate 
vincristine 
vinblastine 
Definite 
Uncertain 
Uncertain 
Uncertain 
Uncertain 
Uncertain 
Uncertain 
Definite 
5 
Table 1.3 Cell Cycle Specific Agents10,44 
Class of compound Molecular basis Cell cycle Examples 
effect 
Inhibitors of Nucleic Acid Synthesis 
Folic Acid antagonists Dihydrofolate reductase S phase Methotrexate 
inhibitor blocking ` 
nucleotide (thymidylate) 
synthesis 
Purine antagonists Purine nucleotide inhi- S phase Azaserine 
bitor (conversion of 
inosinic acid to ade- 
nylic acid) 
Glutamine antagonists 
Pyrimidine synthesis 
inhibitors 
Polynucleotide 
Inhibit de novo purine 
synthesis 
Inhibit thymidylate 
synthetase + nucleotide 
(thymidylate) synthesis 
Inhibit DNA-dependent 
DNA polymerase 
Inhibit nucleotide 
reduction 
S phase Azaserine 
S+ possibly 5-Fluorouraci 
G1 phase 5-Fluoro-2- 
deoxy uridine 
G1 S phase Cytosine 
arabinoside 
S phase Hydroxyurea 
Antibiotics 
Inhibitors of protein 
synthesis 
Inhibitor of RNA 
Inhibitor of DNA 
Plant Alkaloids 
mitotic inhibitors 
Alkylating Agents 
Prevent transfer of 
DNA information into 
polypeptides 
Prevent DNA-dependent 
RISA synthesis 
Intercalate with DNA 
and inhibit DNA-depen- 
dent RNA synthesis 
Inhibits incorporation 
of thymidine into DNA 
G1, S, G2 Puromycin 
phases 
G1, S, G2 Actinomycin D 
phases Mithramycin 
G2 phase Damomycin 
Adriamycin 
Streptomycin 
G1, S, G2 Bleomycin 
Prevent spindle formation S phase Vincristine 
and inhibit ribosomal RNA Vinblastine 
and protein synthesis 
Alkylate proteins and 
cross link with DNA 
causing breaks 
G1, S, G2 Nitrogen mus- 
and possi- tard, Cyclo- 
bly Go phosphamide 
phase Chlorambucil 
Bisulphan 
Melphalan 
BCNU 
CCNU 
Me-CCNU 
5 
chemotherapeutic drug design. Tables 1.2 and'1.3 show how 
various drugs are applied in cancer treatment. 
The majorityof anti-cancer drugs produce their action by 
alkylation and/or intercalation of DNA, although it would 
appear that alkylating agents are not very"selective in their 
attack on cellular nucleophilesll. 
The first group of alkylating agents that have found use in 
cancer chemotherapy are the so-called nitrogen mustards 
because of their derivation from the analogous sulphur com- 
1 2. 
pound mustard-gas 
S., 
CH2CH2C1 
R_N ý-CH2CH2C1 
ýCH2CH2C1 "CH2CH2C1 
mustard gas nitrogen mustards (R=H, alkyl, or a 
It is generally accepted that the nitrogen mustards effect 
their alkylating action via an azirdinium ion intermediate 
(shown below) which is an active electrophilic agent capable of 
R- NýH21 rearrangement ,RN 
2Nu 8 
' nucleop ýCH2CH2C1 *%-ICH2 
CH2CH2C1 
R-N,,, 
CH2CH2 - Nu 
ýCH2CH2C1 
attack on nucleophilic species like those found in proteins 
and nucleic acids. 
1.2 The Differences between Cancer Cells and Normal Cells 
Cancer cells differ from normal cells in a number of ways. 
7 
The often exhibit a lower pH' 
13-16 
They p -, they show alteration : 
in enzyme activity 
17, 
possess different levels of cyclic 
nucleotides 
18,19,20, they have unusual amounts of certain 
amino acids, display an alteration in the cell membrane 
21222 
23 
and have abnormal nuclei as a result of chromosomal changes 
brought about by DNA damage and histone depletion24,25,26. 
It is because of these cytological differences that many 
cancers have the known characteristics of an uncontrolled 
proliferation of cells (hyperplasia), a structural abnormality 
in which they, resemble embryonic cells and have a disorien- 
tated, undifferentiated appearance (anaplasia), and a 
27 
propensity to metastasize. It is of interest to consider 
a specific experimental tumour, the Walker 256 carcimoma. 
This is a laboratory transplantable tumour which arose spont- 
aneously 
28 
and is used extensively in this country for the 
testing of anti-cancer drugs. The following Table (l. 4)shows 
the spectrum of activity of several chemotherapeutic agents 
toward various transplantable animal tumours. Note the 
29 
high activity of CB 1954 towards Walker 256 and its negligible 
activity in other experimental tumour systems. 
Table 1.4 
Tumour T. I. T. I. % ILS % ILS 
Agent system Walker 256 PC6 RI TL X5 
Cyclophos- 
phamide 
(RNH2)2 Pt C12 
Methotrexate 
DTIC 
BCNU 
CB 1954 
30 136 0 0 
7 200 0 0 
1.7 0 65 55 
1.5 86 98 67 
20 96 - 197 
70 <1 <1 <1 
T. I. = Therapeutic Index öILS = Perc. Increase in Life Span 
DTIC = 3,3-Dimethyl Triazeno-Imidazole Carboxamide 
BCNU = 1,3-Bis (2-chloroethyl)-1-nitrosourea 
CB1954=2,4-Dinitro 5-amido phenyl aziridine 
8 
In the Walker carcimoma there is one particular histone 
fraction (RB 2-L) which is highly rich in lysine with a 
r 
molecular weight of around 34,000. This fraction does not 
occur in normal cells and has not been found in other tumours. 
This high lysine content may have arisen as a result of DNA, 
mutation because as tumour cell DNA is different from normal 
DNA and since various combinative sequences of DNA base trip- 
lets code for amino acids, it is likely that at least one DNA 
base has been transformed in some way. 
Lysine is derived from the codon AAA (or AAG) which is trans- 
ferred via RNA (which may have also undergone mutation). 
The possible codon changes underlying some amino acid replace- 
ments in mutant haemoglobins is given below31, and it can be 
Table 1.5 
Amino Acid in normal 
haemoglobin 
Amino Acid in mutant 
haemoglobin 
Base 
transformation 
Lysine (AAA) Glutamic acid (GAA) A+ G 
Glutamic acid (GAA) Glutamine (CAA) G+ C 
Glycine (GGU) Aspartic acid (GAU) G+ A 
Histidine (CAU) Tyrosine (UAU) C+ U 
Glutamic acid (GAA) Valine (GUA) A+ U 
Glutamic acid (GAA) Lysine (AAA) G+ A 
Glutamic acid (GAA) Glycine (GGA) A+ G 
Asparagine (AAU) Lysine (AAA) U A 
A= Adenine, G= Guanine, C= Cytosine, U = Uracil 
seen that Lysine (AAA) is arrived at by two types of base 
transformation: 
Asn (AAU) Lys (AAA) U -ý A 
Glu (GAA) -ý Lys (AAA) G -º A 
9 
The second of these two mutations is the more likely because 
it involves purine-p urine changes, and may have arisen from 
the loss of the hydrogen-bonding functions on guanine causing 
it to appear as adenine in the formation of complementary 
strands. For example, 0(6)-methylation of guanine causes it 
to pair with uracil instead of cytosine and thus produce a 
miscoding which would lead to lysine and instead of glutamic 
to cha 
However, this may not be the cause of the mis-coding; for 
example tautomerism of guanine will preclude the formation 
of the three hydrogen-bonds necessary for pairing with 
cytosine. This type of transformation would be reversed 
specifically by CB 1954, thus explaining its selectivity for 
* refer to page 87 
0(6)methyl guanine uracil 
Text cut off in original 
10 
the Walker tumour. The possible reasons for this are discussed 
later. It is known that cancer DNA is histone depleted and 
this can be exploited by anti-tumour drugs that interact with 
DNA in various ways, e. g. alkylation, intercalation, and 
incorporation of base analogues. The nucleohistone sheath 
changes during certain stages of the cell cycle, for example 
DNA appears more compact in its duplication phase, possibly 
due to a lack of histone protection32. Therefore, during the 
stage where unravelling of the helical strands occurs, the 
DNA bases would be exposed, and hence, prone to interaction 
with cyto. toxic. agents. Clearly, chromosomal changes occur in 
cancer cell nuclei because, for example, a deletion of 
chromosome 22 of the G group (the Philadelphia Ph chromosome) 
33 
Is associated with instances of chronic myelocytic leukemia. 
A mapping of these chromosomal changes and elucidation of 
the precise types of DNA mutation in all known cancers would 
be very useful in the design of more specific anti-cancer 
drugs. The difference in enzyme levels in cancers can be 
exploited by chemotherapeutic agents. One such enzyme which 
is'present in higher levels in cancer cells is ß-glucuroni- 
dase34. This could be responsible for the activation of 
3 
drugs like laetrileS (L-mandelonitrile-ß-glucuronic acid) 
at a tumour site to produce benzaldehyde and hydrogen cyanide 
CN HO 
2H 
I ß-glucuronidase 
O-CH 
0 
--> -0 O+ HCN 
H 
H 
laetrile 
"+ glucuronic acid 
11 
that are able to undergo condensation to form cytotoxic 
products. 
Cancer cells resemble embryonic cells in their undifferentiated 
appearance and lack of cellular control mechanisms present 
in growing tissue. Interferon is an anti-viral agent which 
acts by "ageing" cells so that they quickly mature into cells 
with adult characteristics. This initiates a control of 
cell proliferation and enables the cancer cells to be recog- 
nized by T-lymphocytes of the immune system so that they may 
36 be dealt with in a similar manner to a viral infection. 
The differences in levels of cyclic AMP and cyclic GMP may 
be utilized to arrest tumour cell growth. For example, 
dibutyryl cAMP increases the breakdown of tumour cells as 
it doubles the activity of RNAase, the enzyme responsible for 
37 
the breakdown of RNA. 
An important and interesting difference between cancer cells 
and normal cells is that cancer cell pik is generally lower, 
14 
though there is a degree of variation between cell types. 
Various authors have reported a spread of values between pH 
7.0 and 6.4 which is certainly more acidic than the accepted 
value of 7.4 for normal tissue38. The reason for this 
acidity is due to the fact that cancer cells utilize anaerobic 
glycolysis as the main metabolic pathway for obtaining energy 
for growth and other cellular functions. Glycolysis produces 
lactic acid17 from glucose by a series of metabolic pathways(Fig. 1.2 
combined in the equation: - 
OH 
C6H12O6 -2 CH3CH CO 
e+ 2H8 
glucose lactate 
12 
Figure 1.2 Glycolytic Pathways. *t'o 'Lactic acid (via pyruvic 
acid) from glucose 
HOCH2 
OH 
H 
4H 
H 
$-D-Glucose 
ATP ADP 
Hexokinase 
or 
Glucokinase 
? dg2+ 
H2O3POCH2 
OH 
HH 
ß-D-GlucoseH6-phosphate 
CHO IH2OH 
CHOH 
Phosphoglucose C=0 
I ispmerase I 
HOCH HOCH 
CHOH 
CHOH 
CHOH CHOR 
I CH2OPO3H2 
H2OPO3H2 C 
D-Glucose-6- 
phosphate 
CHOR 
CH2O® 
D-Fructose-6- 
phosphate 
CH2_c 
Phospho, fructo C=0 
kinase I 
M g2+ 
HOCH 
CHOH 
ATP ADP I 
CHOH 
CH2O® 
NADH+H HO-®NAD+ 
1,3-Diphospho-D- 
glycerate 
ADP 
Mg2+ 3-phosphoglycerate 
ATP 
1-kinase 
C02H Phosphoglycero- 
mutase 
CHOR 
H20® 
Mgz+ 
3-phospho-D- 
glycerate 
D-Fructose-1,6- 
diphosphate 
phospho- 
fructoaldolase 
CHO 
I 
'CHOH 
CH2O® 
D-Glyceraldehyde- 
3-phosphate 
H20 
C02H ý C02H 
CH-0® Enolase C-00 
Mg2+ 11 
CH2OH CH2 
2-phospho-D- Phospho-enol- 
glycerate pyruvic acid 
P03Hr Continued on the next page 
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I 
OH lactate dehy- CO2H drogenase I 
CH3CHCO2H C= 0 
NAD NADH Lactic acid CH3 
ADP 
Mg2+ kinasete 
ATP 
tautomerism C02H 
C-OH 
II 
CH2 
(keto form) Pyruvic acid (enol form) 
Thus, one glucose molecule produces two molecules of lactic 
acid, which is 99% dissociated (pKa = 3.86) to yield two 
hydrogen ions. It has been shown that hepatoma homogenates 
produce more than twice the amount of hydrogen ions than 
normal liver homogenates39; for example: - 
H3683-homogenate 108. x 10-6 moles of lactate sec. -1 L'1 
Liver homogenate. 43. x 10 it if it it -6 
The excess acid production of 65 x 10-6 moles sec. '' L-1 is 
quite substantial when one compares this with the normal 
physiological hydrogen ion concentration of about 10-7 moles. 
L-1. Cancer cells have a propensity to reduce this vast 
excess of hydrogen ions by extracellular diffusion40 which 
is likely to be via an active transport mechanism, rather 
than passive. Some data13 for Walker 256 tumour cells show 
that this dissipation of high acidity can bring about a rough 
equality between intracellular and extracellular pH, viz: 
pH value 7.19 7.37 
intracellular extracellular 
This yields hydrogen ion concentrations of 6.4565 x 10-8 and 
4.2658 x 10-8 moles. L-1 for intracellular and extracellular 
14 
phases respectively. A proton current of this magnitude will 
give rise to Fa membrane potential of about 11 mV as calculated 
by the Nernst expression, as follows: - 
eintracellular 
concentration C2 = xtracellular concentration = 
1.5136 ;' loglp 
C=0.18 
potential = E2 - E1 = 
RT log10 (Nernst equation) difference 2.303nF C1 
. '. E2 - Ei = 0.06155 log10 
(T = 310 K- 37°C) 
. '. E2 -E1=0.011 volts 
However, measurements of the pH of cancer cells in vivo using 
a glass electrode (microelectrode) show that, on average, 
tumour cells display a pH of about 7.0 and that this falls 
to about 6.4 after a glucose injection. This will produce 
a hydrogen ion gradient of 2.512 and will give rise to a 
transmembrane potential difference of about 25 mV. This 
fact probably explains the abnormal cell surface charge 
characteristics of tumour cells which are thought to 
contribute to the reduction in adhesiveness and contact 
inhibition of the growth of tumours. Also this surface 
charge phenomenon may be the reason for the activation of 
lectin receptors on tumour cell membranes and explain the 
agglutination process not displayed by normal cells. 
A corollary to these findings is their possible use in cancer 
chemotherapy. If one considers an incoming therapeutic agent 
undergoing transport through a cancer cell membrane, it 
will be subjectedtoa proton current flowing in the opposite 
l5 
direction. This will bring about protonation of any weakly 
basic groupings (e. g. nitrogen atoms) and therefore many 
alkylating agents, such as phenyl aziridines and, to a 
lesser extent, nitrosoure-as and aniline mustarAs, will 
diffuse into the cell as their protonated species. This is 
dealt with more fully when the mechanism of action of phenyl 
aziridines is considered. 
It has been previously stated that excess hydrogen ions are 
removed extracellularly by active transport mechanisms. This 
implies that an enzymatic process is involved, and it is 
known that 2., 4-dinitrophenol is a substance which inhibits 
active transport4l. The 2.4-dinitro-phenyl moiety is in- 
trinsically interesting because it is part of the tumour- 
inhibitory phenyl aziridine CB 1954. Dinitrophenyl com- 
pounds have been shown to bind with serum protein 
42 
, and 
also 2., 4-dinitrophenol interferes with aspects of mitochon- 
drial function by decreasing ATP production without bringing 
about a comcomitant decrease in oxygen consumption 
43. In 
view of the known large energy requirements of tumour tissue, 
this uncoupling of oxidative phosphorylation is likely to 
be a relevant factor in the mode of action of 2.4-dinitro- 
phenyl aziridines and their metabolites. - 
This work deals with the formulation of structure-activity 
relationships based on the results of molecular orbital 
calculations. Specifically alkylating agents of the phenyl 
aziridine, aniline mustard, and nitrosourea series are in- 
vestigated since these comprise an important group of 
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anti-cancer drugs. Also, their possible mode of interaction 
with DNA has been studied and, in addition, some carcinogenic 
agents of the polyaromatic hydrocarbon series have been 
looked at from a theoretical point of view. 
Outlined below is a flow diagram of the processes involved 
in this aspect of cancer research. 
CANCER CARCINOGENESIS Nmechanisms of carcinogens the - 
3'initiation and DNA interaction; Poly- 
problem promotion Aromatic Hydrocarbons 
methods of solution ----: ), understanding of cancer biochemistry I \, 
X oncology; exploitation of cellular 
CURE (, --fe-e-d 
differences 
prevention back 
I radiotherapy 
immunological 
approach 
CHEMOTHERAPY 
Structure-Activity relationships 
I '- Biochemical Pharmacology (SARs) 
other agents 
ALKYLATING AGENTS 
other 
alkylating 
agents 
ANILINE PHENYL NITROSOUREAS 
MUSTARDS AZIRIDINES 
conformational<_-MO calculations -* formulation 
studies of MOQSARs 
, Molecular Electrostatic 
Prediction of Biological 
, Potential Maps 
Activity by assessment of 
main factors in structure- 
activity relationships 
Receptor mapping; DNA bases 
and base-pair interaction 
I 
Understanding of drug-receptor 
events at the sub-molecular 
level 
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Theoretical Basis of Drug-Activity 
Essentially.., the biological study of a drug molecule can be 
explained in terms of biochemical and physico-chemical 
processes. 
The ease with which a drug molecule moves through cellular 
fluids and barriers is determined by its shape and size, and 
by the presence (or absence) of hydrophilic and lipophilic 
groups. Once at the cellular receptor site,, the drug (which 
may have undergone transformation) is able to exert its 
action by virtue of its molecular structure. The drug mole- 
cule may have to adopt a different conformation in order to 
fit the receptor 
45 
and such a conformation may be energetically 
unfavourable in the gaseous or solid state. 
substrate molecule 
receptor 
conformational change in 
substrate to fit receptor 
receptor-substrate complex 
Schematic diagram of the formation'of a drug-receptor complex 
The formulation of quantitative structur.. e-activity relation- 
ships (QSARs) relies on the predominance of one or more 
factors in order to simplify the complicated pharmacodyn- 
amic picture. , 
First of all, it is convenient to list the factors which 
are contributory to the biological mode of action of a drug 
molecule. 
1. The ease of transport through biological fluids (extra- 
and intracellular) and passage across cell membranes. It 
should be mentioned here that some drugs act on receptors 
present on the cell. membrane itself (e. g. cyclic-AMP produced 
by drugs acting on s-adrenoreceptors) 
2. The relative ease of chemical modification to a readily 
removable entity, i. e. metabolism to a non-toxic form. The 
build-up of drug levels brings about toxicity and this is an 
important quantity to evaluate. It must be remembered that 
drug metabolism is'not always a de-toxification procedure. 
3. The possible metabolic modification to a more efficacious 
form - or metabolic activation. This process'is often ex- 
ploited in drug design and related to this is the use of 
carrier groups which assist the transport of the active moiety 
to the site of action. The carrier group may be a recogni- 
zable bio-molecule capable of being incorporated into DNA, 
for instance, by virtue of some enzymic pathway. 
4. The interaction with a cellular receptor site. This is a 
pr6cess about which, little is known, though it is likely to 
depend on the alignment of functional groups as a progression 
from the 'lock and key' formalism46. The formation of a 
I 
drug-receptor complex is believed to be e'ssential for effect- 
ing a biological response 
47. 
These four contributory factors can be assessed to an extent 
by experimentally determined quantities. For example, trans- 
membrane passage is thought to be related to partition co- 
, efficients 
48between aqueous and non-aqueoussolvents, such as 
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ether/water and octanol/water. The rationale for this arises 
from the fact that partition coefficient measures the relative 
solubility o. fa compound between two phases and this can be 
seen to be, albeit naively, similar to the movement of a 
molecule from an aqueousmedium (extra-cellular fluid) through 
a lipid barrier (the cell membrane) and into another aqt! eous 
medium (intra-cellular fluid). 
The partition coefficient, P, is given by 
P= (concn. )Xsolvent/(concn. )X water 
N 
and it has been found that the logarithm of the partition coe- 
fficient is more widely acceptable in describing the transport 
process. The Hansch iýethod 
49 
relies heavily on the hypothesis 
that this is the predominant factor in drug action, and the 
substituent hydrophobic parameter, w, 
50 has been successfully 
employed in a whole range of structure-activity relationships 
(SARs). This additive substituent parameter, 7r, is defined 
as follows: 
7f subst 
lo, g Psubstd log Pparent 
compound compound 
and tables of 7r values have been listed by Hansch 
51 
and others 
to assist in the formulation of SARs. Other hydrophobic 
substituent constants have been proposed, notably the f para- 
meter of Rekker and Nys 
52 
. and Rf factors from chromatographic 
studies can also be related to activity. 
The toxicity of a drug is an experimentally measurable quan- 
tity. based on animal experiments and subjected to statistical 
20 
constraints. It is usual to relate the toxicity of a drug. 
to the lethal dose (LD) required to kill 50% (LD 50 
) or 10% 
(LD 10 ) of the test animals. The logarithm of the inverse 
of lethal dose is the quantity normally employed in SARs as 
a measure of toxicity, 
toxicity = log 
1- log LD LD so -, 50 
The therapeutic activity or effectiveness of a drug can be 
measured as the dose required to produce a biological res- 
ponse in 50% or 90% of the test animals. This is called the 
effective dose (ED 50 or ED90) and activity bears the same 
relationship to ED as toxicity does to LD, 
activity = log 
1 log ED ED so so 
Therapeutic index (TI) or chemotherapeutic index (CI) is the 
ratio of LD to ED and is a way of expressing the therapeutic 
value of a drug. It is frequently employed in cancer chemo- 
therapy where therapeutic range is particularly important., 
LDSO Clearly a large CI will be 
hence CI = r-Dso achieved for a compound with 
low toxicity (high LD) and 
high efficacy (low ED) 
and log CI = log LD 50 - log ED 5P 
log CI = log log ED LD 
1 
50 50 
In vitro tests, for example kinetic studies yielding rate 
constants (k) for a specific reaction, egý alkylation, hydro- 
lysis, etc. which parallel cellular activity can be related 
to the Hammett 
53 
substituent constantsp a, and these provide 
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an additional method of relating structure with activity. 
In fact, Haných54 has employed these, together with Taft 
55 
steric parameters in his a-w-E. analysis, which is an im- 
provement over the original scheme. 
The stages in the biological action of a drug can be treated 
mathematically under theheadings of membrane transport, 
pharmocokinetics, metabolic pathways and receptor binding. 
Trans-membrane kinetics (see also Appendix 1) 
There are known to exist two forms of transport mechanism, 
passive ddiffusion and active transport. 
Passive diffusion is governed by Fick's lst Law56 which 
states that the rate of diffusion is Proportional to the 
concentration gradient through the membrane. Mathematically, 
this may be expressed as follows: 
where J is the flux or quantity 
J= -D 
( do diffusing per unit time per unit dx 
area; D is the diffusion ooeffi- 
oient o= concn. x= distance 
This can be rewritten as 
dm DA (c, - cq) where 
A= area; d= thickness 
dt d of membrane, cl = concn. 
outside membrane, C2 
concn. i'nside membrane 
m= amount transferred 
The diffusion coefficient, D, depends on the type of membrane, 
and the molecular weight, steric configuration, lipid solu- 
bility,, and dissociation constant of the drug. The lipid 
solubility of a drug is clearly related to its octanol/ water 
partition coefficientS. 
7. Octanol is chosen for its Similarity 
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with membrane lipo-protein characteristics. However, for 
. 
drugs that arý weak acids or bases, ionization occurs at physio- 
logical; pH which gives misleading values of partition co- 
efficients since the distribution law no longer holds. 
In fact. -the relationship 
between overall pa rtition coeffi- 
cient, P0.9 and the partition coefficient for the unionized 
form, P N' is given 
by 
loj 
(-; mo -, 
)= 
pH - pKa 
where pH is th6 negative logarithm of the hydrogen ion con- 
centration, and pKa is the negative logarithm of the dis- 
sociation constant. Generally, the diffusion of charged 
species is slower than for uncharged species, though the 
ionic permeability differs from one type of membrane to an- 
other. The precise structure of cell membranes is not fully 
understood, but it is thoughtthat cells are bounded by a 
tri-laminar membrane of proteins and lipids. This lipo- 
protein 'sandwich' is not of constant thickness and is com- 
prised of globular and helical proteins (to allow passage of 
iorfs) in a viscous l, ipid layer. The fluid mosaic mode158 
which possesses a certain degree of disorder in membrane 
components is the currently accepted description. 
me rubrane 
protein -protein 
extracellulat 
lipid 
intracellular 
neutral 
fluid 
species 
ionic 
species 
helical channel for 
protein ion transport 
Model of membrane transport 
3 
Water solubility is the first requirement for drug transport 
to the membrane surface, then diffusion across the membrane 
depends on lipid solubility. Therefore the rate of diffusion 
of a neutral molecule depends on the concenýration gradient 
and on the lipid/water partition coefficient (the main factor 
in the diffusion constant, D). Although one might expect a 
drug with high lipid solubility to pass freely through a cell 
membrane, and hence have fast transport capabilities, it may 
be too insoluble in aqueous media to diffuse out of the mem- 
brane at an aýpreciable rate. Pence an optimum value of P 
(lipid/water) is about unity (i. e. log P= 0). 
Passive diffusion is governed by Fick's 2nd Law which is a 
differential equation of the second order, as follows: 
ax D a2c at a 
Integration and employment of boundary conditions yields the 
following expression for concentration 
59 
x2 vrD-t 
C2+2 
e- 
s2 da 
where a 
20x 
2 /D-t 
cf. Gaussian error 
function 
A graph of this function produces a sigmoid curve of c vs. x 
and the derivative yields a Gaussian-type function since 
dc 
_C e-x2/4Dt dX 2 rTrDt 
as shown in the following graphs. 
24 
bell-shaped - 
probability curve 
C 
X 
dc 
ýFx 
X 
width at in- 
flectionýpoint 
Da2 
2t 
or c=V7-Dt 
It is of interest to list values of diffusion coefficients 
60,61 
in aqueous media for certain species as shown in Table 2.1 
Table 2.1 Diffusion coefficient (D) for some biological species. 
Substance D (105 cm2 sec-1) at 250C 
H2 0 2.13 
Sucrose 5.23 
Na+ (aq) 1.30 
Ribonuclease 0.119 
Serum Albumin 0.0594 
Hoýur 
62 has outlined a quantum-mechanical treatment of mem- 
II 
brane transport based on Schrodinger's equation (another se- 
cond order Differential Equation) and his results parallel 
previous findings about the gating currents of ions. 
63 - Active transport is that which occurs against a concentra- 
tibn gradient or potential gradient of charged species (ions). 
Such transport differs from passive diffusion in that the rate 
is independent of drug concentration and, therefore, zeroth 
order. 
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i. dx k 
and' x= kt (integrated form) 
Active transport mechanisms display a high degree of chemical 
specificity, e. g. the sodium pump mechanism in which the energy,. 
is provided by ATP. This is of interest to cancer thera- 
pists because ATP synthesis is inhibited by certain subst-ances, 
e. g. 2,4-din_itrophenol 
64, 
and active transport of sodium ions 
ceases. Specifically an efflux. rather than an influx of sodium 
ions is inhibited and this effect may partially explain the 
different surface characteristics (i. e. ionic conductances and 
mobilities) of tumour cells. The importance of this phenomenon 
is discussed elsewhere in this work. Active transport me- 
chanisms are thought to exist for certain molecular species 
of biological importancefor example L-phenylalanine 
65 
. and 
melphalae is thought to be transported into tumour cells by 
this carrier mechanism. The D-isomer, however, is less active 
and this may b'e due to the lack of an effective active 
carrier mechanism. 
* refer to page 186, 
Bioavailability and Drug Disposition 
Pharmacokinetics describes the absorption and elimination of 
drugs. It seeks to derive expressions for the concentration 
of the drug in the biosphere which determines the bioavaila- 
bility to effect a response by combination with a cellular 
receptor. 
'It is convenient to depict pharmacokinetic processes as 
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equilibria between a number of compartments which signify 
biological pYases as shown in the following diagram. 
5-compartment model: 
unabsorbed membrane Plasma +E. C. F. membrane Intra-cel- 
drug lular fluid 
receptor ionized ionized 
sites 
non-ionized ___, n6n-ioni,,, %, ---lýnon-imized, r-non-bound 7- non-ionized-"non-ionized' k, 7 TS k, k2 34 III it 
ionized bound 
Passage through cell membranes has been dealt with, and from 
the above diagram it is clear that the-percentage of a drug-in 
its ionized/non-ionized form is important. For weak acids 
and bases, pK a values need to 
be known in order to determine 
the percentage ionized/non-ionized forms in body fluids of 
differing pH by usage of the Henderson-Hasselbalch 
67 
equation. 
As well as uptake through cell membranes from plasma, one 
has to consider the processes of metabolism, absorption and 
, excretion. 
First of all the rate of administration has some 
-effect on the pharmacokinetic picture since multiple 
dosing 
ienhances bio-availability. I 
a) Route of administration 
Injection, whether it be intravenous, intramuscular, or sub- 
'cutaneous, is a rapid method of introducing drugs into the 
-system. If a localized action is desirable (as in the case 
of anti-tumour drugs) injections are made directly into the 
"intended area of tissue. The safest and most economical 
, route of administration 
is orally; however, the kinetics are 
r, 
7 
quite different as shown below. 
plasma 
level 
time 
b) Absorption 
i. v. lst order decay 
oral consecutive ist order 
rise and decay 
. =intra-venous 
Some drugs are absorbed in the buccal mucosa and the advantage 
of this is that the drug enters the circul_ation without being 
metabolised by the liver. 
The i. v. curve can be explained simply by applying lst order 
exponential decay kinetics to the situation, i. e. an ex- 
pre-ssion for the con 
, 
centration after time t is given by 
C=C0 e-kt where k rate constant 
Co initial concn. (dose) 
C concn. after time, t 
. 11 Since log C= log C0- kt, 
plotting log C vs time gives a slope of -k and intercept 
log Cop hence the rate constant for the process can be 
determined. 
Theýorai administration kinetics is rather more complex, since 
two consecutive 1st order 
66 
steps are involved instead of one 
(see Appendix 5 ). 
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Some drugs are absorbed partially by the stomach, though most 
are absorbed in the upper part of the small intestine. Since 
a fair proportion of drugs are weak acids or bases, the pH of 
the area of absorption is of great importance in determining 
the amount of non-ionized drug taken up the cells. The uptake 
via membranes can be by several mechanisms: 
i), diffusion'or passive transport., which depends on lipCPhili- 
city, is not saturable kinetics and polar drugs are better 
absorbed in the unionized form. - 
ii) active uptake through the alimentary tract requires meta- 
bolic energy from ATP and displays saturable kinetics. 
. 
(iii) pinocytosis and passage through pores take only a very 
minor r6le as displayed by fat-soluble drugs. Fat absorption 
occurs when small lipid particles are taken up by the vesicles 
which recombine to form fat globules capable of entering the 
lacteals of the intestinal lymphatic system. The storage and 
build-up of drugs in lipoid tissue can lead to chronic t6xic. ity 
as is the case with organo-chlorine pesticides like DDT. 
It is of some relevance to the treatment of lung cancer to 
mention absorption through the respiratory epithelium as drugs 
may be administered in an aerosol spray to act more effecti- 
vely on the infected area. The lungs comprise a large surface 
area (-160 square metres) and absorption is governed by solu- 
bility in pulmonary plasma and rate of pulmonary flow and 
respiration. For drugs with low plasma solubility, an in- 
crease in cardiac output will increase absorption but this is 
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not affected by respiratory rate. The converse is true for 
drugs which arevery soluble in pulmonary plasma, though 
equilibration is prolonged in this case. 
c) Elimination 
The majority of drugs or their conjugates and metabolites are 
removed by urinary excretion, although some are removed by 
sebaceous seare-tion, respiration (breathalyser test for 
alcohol levels), and via salivary, lachrymatory, and gastro- 
I 
intestinal secretions. 
It is appropriate, at this juncture, to'state the importance 
of pH to ionization and concomitant absorption of drugs 
-since they are primarily absorbed in the unionized form. 
The Henderson-Hasselbach equation for weak acids is as follows: 
log (unionizedl = pK aonized) a 
and for weak bases 
(ionized) 
pK - pH log Tunionized) a 
It -is therefore of 
importance to know pKa values of drugs and 
pH of various positions along the gastro-Intestinal tract when 
considering the kinetics of absorption and elimination. Table 
2.2 -'.. lists the variation in pH along the g-i tract and 
in body fluids. 
I 
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Table, 2.2 pH of body fluids 
Site Fluid pH rang'e 
buccal cavity saliva 5.5 -6.4 
stomacfi gastric fluid 1.2 -2.9 
duodenum pancreatic fluid 5 -6 
ileum bile .7 -8 
kidney urine 5.5 -7 
vascular 'system blood 7.3 -7.5 
So that if one considers a*drug like aspirin which is a weak 
acid with pKa = 3.6, ' the profile for ionization at varying 
pH is as shown below. 
100 
imized 
.C 
50 
lorm 
0 
blood 
gastric i urine T 
34567 
PH of medium 
Therefore aspirin is highly absorbed in its unionized (acid) 
form at gastric pH which is a contributory factor in the 
, toxicity of this 
drug via the stomach wall. However, it is 
present almost completely in the anionic form in plasma so 
there is no tendency for back diffusion. 
d)' Metabolism 
Basically, drugs are metabolized by two types of reaction: 
transformation (involving oxidation, reduction, or hydrolysis) 
and conjugation(with glucuronic acid, sulphate, or amino acids). 
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The latter increases the polarity of the drugs and thus ensures 
ease of excretion. 
transformations Metabolic conversions occur mainly in 
the liver (and to a very much lesser extent in the kidneys and 
lungs). The mitochondria are responsible for monoamine and 
lipid oxidation, and the cytosol for some hydroxylations and 
decarboxylations. The most important are the microsomes which 
contain endoplasmic reticulum membrane fragments. 
(a) endoplasmic reticular enzymic conversions 
(I) Oxidation 
The processes of aromatic hydroxylation, deamination, dealky- 
lation (demethylation), and S-oxidation require mixed function 
oxidase (MFO), reduced-NADP, atmospheric oxygen and a chain 
of co-enzymes which include cytochrome P. -450. Aromatic 
hydroxylation and demethylation are important pathývays in 
the metabolism of carcinogenic poly-aromatic hydrocarbons and 
DMN respectively. The hepatic microsomal electron-transfer 
chain is shown below 
ArOH 
NADPH +H+ oxidised reduced non- cytochrome flavoprotein haem iron protein -450 oxidisedkýý ArH 
NI ADP reduced oxidised non- cytochrome 
50-0 
flavpprotein haem iron protei n P-450 -reduced 
; 'ýý 
02 H20 
(H)'Reduction 
Reduced NADP-cytochrome c reductase or-reduced NAD-cytochrome 
bS reductase have the function of reducing FAD which in turn 
reduces the relevant grouping on the drug, e. g. -NO 2 -+ -NH 20 
3Z 
(III) Hydrolysis 
Esterases ard'present in the microsomal fraction which perform 
00 
IG 
the conversion RC 4L-ORI ; PRCIý 0, whereas amidases 
are responsible for the hydrolysis of amidejunctions. 
(ý) Non-microsomal drug metabolism 
Mitochondrial monoamine oxidase (MAO) brings about the oxida- 
tion of serotonin (5-HT) and catecholamines in general. 
Biogenic amines such as histamine and tyramine are oxidised 
as follows: - 
ýýCH2NH2 MAO CH2CHO (0-7 c> 
NN 
H histamine H 
CH2CH2NH2 CH2CHO 
MAO 
0 
OH tyramine OH 
Other enzymes present are pseudocholinesterase and alcohol 
dehydrogenase which perform the conversion ROH -+R_ 1 CHO. 
Reduction of double bonds occurs by non-microsomal enzymes 
and also esterases and amidases bring about hydrolysis. The 
hydrolysis of CB1954 (which is an amide) is thought to occur 
via the enzyme w-amidase which converts the drug into its 
carboxylate anion thus restricting its transport capabilities. 
(ii) ' Conjug'atiDns 
Glucuronide formation 
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This is a detoxifying reaction which involves the formation 
of the ester 6f glucuronic acid. The steps in the mechanism 
are as follows: 
UTP + glucose UDP glucose +P** 
uridine uridine diphosphate 
triphosphate- glucose 
oxidý UDP glucuronic acid 
UDP glucose (UDPGA) 
UDPGA + XOH XOGA + UDP 
drug glucuronide 
The enzyme responsible for effecting the final step is glucur- 
onosyl transferase present in the endoplasmic recticulum of 
-the liver, gut and kidney. 
(a) Other conjugation reactions 
The other conjugates formed apart from those mentioned pre- 
viously bring about methylationp acetylation and the forma- 
tion of peptides. Methylation can occur at oxygen or 
nitrogen, for example: 
catecholamines 
COOT O-methyl catecholamines 
COMT = catechol 0-methyl transferase 
NMT 
noradrenaline adrenaline 
NMT N-methyl transferase (requires a methyl 
donor) 
Acetylation of drugs (whichnormally lessens pharmacological 
activity, a notable exception is heroin (DAM) which is more 
active than morphine and MAM (mono-acetyl morphine) utilises 
acetyl transferase and. acetyl CoA as an acetyl donor. 
Metabolic activation could be exploited more fully and to a 
greater degree of sophistication in anti-cancer drug therapy. 
(iii) Factors affecting drug metabolism 
The factors which modify drug metabolism are physiological, 
pharmacodynamic and environmental in origin. 
(a) Physiological 
Some enzyme levels such as P-450 and glucuronidase are low at 
birth, but reach maturity after several weeks. The elderly 
and infirm often have impaired enzyme (and renal) function, 
and this is particularly important in cancer chemotherapy since 
cancer patients may show alteration in the levels of certain 
enzymes and this can have a marked effect on curative medecine., 
(a) Pharmacodynamic 
Protein blfiýding slows down excretion and decreases the amount 
of active unbound drug from receptors and metabolising sites. 
The aniline 4-mustards are one group of anti-tumour drugs 
which are strongly boundto protein by virtue of their ease 
of cyclization to the highly reactive aziridinium 
cation. 
/ 
CH 2 CH 2 Cl - C1 @ , -, 
CH 2 protein / 
CH 2 CH 2-protei 
R-NRNI- )- R-N 
CH CH Cl 
CH 2 CH CH -protei 2222 
CH 2CH 2C' 
N-mustards aziridinium species protein adduct 
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(c) Environmental 
Other substances can influence drug metabolism, and toxic 
reactions may be brought about by therapeutically useful 
drugs diminishing the metabolism of others. Stimulation of 
metabolism by other drugs occur, which is known as enzyme 
induction. It is well known that cigarette smokers often 
have an increased efficiency in metabolizing polyaromatic 
hydrocarbons and this is likely to be due to induction of 
aryl hydrocarbon hydroxylase. (See Reference 68 for a list 
of general reference works. ) 
Pharmacokin&tics(See Appendix 
The pharmacokine tics -Lof -the proce-sses involved in drug -action 
yields a series of exp. onential - expressions depending on the 
number of compartments considered. In most cases, a two- 
compartment model is satisfactory for explaining the varia- 
tion in plasma drug levels with time. 
Consider the following two-compartment model system . 
'Central' 
k 12 
Peripheral 
compartment compartment 
k 10 
k 21 
where the tentrall compartment signifies plasma and the 
peripheral compartment signifies tissue. There is a reversible 
transfer between these two as expressed by the rate con- 
stants k12 and k2l* A certain concentration of drug will 
enter the plasma depending on the dose and mode of admini- 
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stration, whether this is intravenous injection or absorption 
from other si-tes. Elimination, of, the drug by metabolism and 
excretion is'represented by the rate constant k it is 10* 
important to derive an expression for the drug level in the 
central (plasma) compartment since this usually shows good 
correlation with receptor site occupancy and consequent bio- 
logical response. For instance, there is a linear relationship 
between a-blocking index and log. propranolol concentration in 
plasma. 
Let Xc = amount of drug in central compartment 
and . Xp = amount of drug in peripheral compartment 
Then, the rate of change in drug level in central compartment 
is given by the differential equation 
dXc 
-=k 21 xp-k 2lXc -k ioxc dt 
Numerical analysis involving Laplace transformation, integra- 
tion and rearrangement yields the following expression for 
amount of drug in the central compartment. 
xo(a-k 21) 
e- at a-5- 
where X- = intravenous dose 
x0 (k 21-a) -, at 
a-a 
a+ O= k 12 +k 21 +k 10 (k 12+k 21 +klo)z - 4k 2 jklo 
1, k '21 10 
Assuming that a linear relationship exists between drug con- 
3 7, 
centration in the plasma C and the amount of drug in the 
central compartment, we can write 
xc = vc C 
where Vc is the apparent volume of the central compartment. 
Therefore the plasma concentration is given by 
Cx0 
(a-k 21) 
e- at vc(a-$) 
which is of the form 
C= Ae -at + Be- 
at 
Taking logarithms we get 
x0 (k 21- 
e- 
at 
vc (a- a) 
log C= log A at 109 B Bt f -. 3 T. 7 
which is a linear equation and provides a method by which 
A, B, a and ý can be determined graphically as follows: 
30.. 
20. 
Plasma 
concý 10. 
(Jig4ml) 
5.0' 
1.0. 
0.5. 
-Time profile of a drug. Experimental curve for plasma concentration 
with time following an i. v. dose of 10mg/kg 
of 2-pyridinium aldoximine methochloride 
t1l = 11 min. 
0.00855 min-1 
tj 81 min. 
0.00855min-1 
I 
Time (hr. ) 
0.5 1.0 1.5 2.0 2.5 3: 0 
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At t=o 
Co 
=IA+B 
where CO = zero time plasma concentration 
Substitution for A+B gives 
x0 (a-k 21) 
which simplifies to 
cx0 
Since Co = 
x 
VC ý-' A-+-F 
I 
so that the apparent volume of the central compartment may 
be estimated from the dose and the experimentally determined 
constants A+B. The rate constants can be found from the 
experimental values of a, a,, A +B due to the relationships, 
21 = 
As + Ba 
A+B 
10 : '-- kaB 21 
12 7- a+ý-k 21 
k 10 
Hence a good deal of information about the relative contributions 
of distribution and elimination processes can be. obtained from the 
time profile of a drug. This may also assist in the elu- 
cidation of mechanisms of drug metabolism and interactions, 
x0 (k 21- ý) 
vc (a- aT 
as well as showing effects of age and disease on drug dis- 
3-0 
position. 
It should be... mentioned here that in some anti-cancer drugs 
multi-compartment characteristics are shown, for example, DTIC 
72 displays the pharmacokinetics of a three compaTtment model 
For this drug the plasma level concentration variation with 
time is given by: 
C=3.05e- 0.117t + 10.2e- 
0.028t 
+ 11.4e- 
0.003t 
However, pharmacokinetics only deals with the time factor in 
drug analysis, and it is of greater interest in this work to 
investigate dose-response relationships. 
The third compartment is another peripheral one where compart- 
ment 2 is I'shallow" and compartment 3 is a"deep" peripheral 
compartment correspondi'fig to difýering types_oý binding sites. 
Diazepam 
73 
and bishydroxy coumarin 
74 
also display 3-compart- 
ment kinetics. 
Drug ReceptorInteraction 
75,76 
It is appropriate to consider the formation of a drug-recep- 
tor complex as the controlling process in dose-response re- 
lationships (and hence structure-activity relationships) and 
to formulate expressions based on receptor occupancy (or rate) 
theories. 
One must assume, a priori, that there is an attraction between 
drug and receptor. It then follows that the process of 
formation of the drug-receptor complex must be active rather 
than passive. 
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The generally accepted concept of a receptor is that of a 
specific arra - ngement of chemical groups on a cellular surface 
(membrane reCeptor) or intra-cellular macromolecule (e. g. 
DNA, enzyme, etc. ). It would appear that there can exist two 
types of binding: reversible and irreversibie. 
* The irrever- 
sible binding between drug and receptor site is likely to be 
brought about by covalent bond formation as this involves a 
0 
close approach of atoms (1-2A) and a high bond energy (200-400 
kJ. mol-1). - T-he other types of interaction which give rise 
to reversible binding, are distance dependent and can be 
summarised as (i) inter-ionic (electrostatic) 
(ii) dipolar interactions 
(iii) hydrogen-bonding 
(iv) hydrophobic (Van der Waals' forces, 
London forces, dispersion forces) 
(V) charge transfer. 
In any given situation where a substrate molecule binds to a 
receptor site (part of a macromolecule) there may be a combi- 
nation of the above interactions taking place which compris es 
the total effect. However, it is advantageous to consider 
each one in turn to estimate their relative magnitudes. 
(i) Inter-ionic (electrostatic) attract-'ion 
The interaction energy, AE, between two charges, Zl, Z2 at 
a distance d in a medium of dielectric constant D is given by 
zIz2 e2 where e is the unitary 
AE 
dD 
electronic charge. 
For water molecules, in the. region of a charged species, the 
local dielectric constant in the neighbourhood of a charged 
area on a molecule will be depressed by an amount which is 
distance dependent. It is found that the following expression 
fits the experimental facts: 
6d - 
. 0# AE ZZ 
l' Z2 e2 
. 
d(6d-7) 
Z1Z2 e2 
6d2 - 7d 
So that for a charge separation of between 5-8X electrostatic 
attraction plays a vital part, but water molecules would 
appear to contribute to a lessening of this effect. However, 
the approximate interaction energy of two opposite unit 
charge's separated by SR in an aqueous medium is about 250 J 
mole-'. Clearly, such forces are quite strong and are likely 
to be fairly widespread due to the abundance of biomolecules 
with acidic and basic groupings capable of ionization at 
cellular pH, e. g. 
RCO 2ý and NH 3 RI. 
ýJost ionic bonds formed between oppositely charged ions have 
bond strengths between 4 -* 8 kJmol-1. e. g. the strength of 
ionic bond formed in the inhibition of antigen-antibody 
reactions by the p(pl-hydroxyphenylazo)-phenyltrimethyl 
ammonium ion 
HOýaýN ý= N-ý 
ýONGM 
has been found experimentally to be - 6.3 kimol-1. where 
42 
the effective dielectric constant relationship with- inter- 
77 ionic distance is 
D= 6d - 11 
In the above case it is found that the interionic distance 
0 78 A is - 7A 
(ii) Dipolqr interactions 
(a) Dipole-dipýole 
The interaction energy, AE, between two dipoles,,,, 112 
orientated at an angle 6 with inter-dipolar distance d in 
a medium of dielectric constant D is given by the expression 
AE - 
111112 COS 
d3D 
This inverse cubic relationship indicates that closer 
approach than for ionic attraction is necessary for a 
strong interaction to occur and dipole-dipole forces are 
g-enerally weaker than ion-ion ones. Hydrogen-bonding can 
be considered as a special case of dipole-dipole interaction. 
Individual dipole-dipole interactions undoubtedly contribute 
to drug-receptor forces. This interaction energy, like 
ionic interactions, may assist or oppose drug-receptor 
attachment, depending on orientation and dipole polarity. 
For example Figure 2.1 shows how different orientations of 
ion and dipole can give rise of attraction or repulsion 
between a substrate and receptor. 
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Figure2,1 Acetylcholine interaction with charge on 
, receptor site 
0 6- 
\\6 + , 
0 %s, ', 
6+ (D 
c wo 
4- CH2CH 2N Me3 
Z F, t ile ED 
Case 1 repulsion 
Me 
6+ (D 
ý -ý', 6 ýý 
CHr-H2N Me3 
6-0 0 
ED 
Case 2 attraction 
These forces play a large part in drug-receptor binding 
when other forces are too weak to influence events. 
(0) Ion-dipole 
For an ion of charge Z interacting with a dipole v at an 
angle e and distance d in a medium of effe'ctive dielectric 
constant D where the length of the dipolar bond is r, the 
interaction energy is given by 
zv cose AE = 
(d2- r2 )D 
The force of this attraction (or repulsion depending on orien- 
tation) is intermediate between ion-ion and dipole-dipole. 
Ion-induced dipole 
The electric field of an ion can induce a dipole in a non- 
polar molecule and thus give rise to an interaction. This 
is an inverse quartic function with respect to ion-molecular 
distance of the type 
AE -a 
Z2 
d4D2 
where a is the polarizability of the molecule. These inter- 
action energies are quite small, requiring closer approach 
of interacting species and have been estimated to be_of the 
order of 2.0 kJ mole-1 . 
Table 2.3 summarises the distance functions and approximate 
energies of dipolar interactions. 
Table 2.3 Interaction Energies 
Type of Interaction Energy Function AE(kJ mole-') 
Ion-dipole AEa 1/d2 
Dipole-dipole AEa l/d3 
Ion-induced dipole AEa l/d4 
-4 -8 
-4 (higher for H-bonding 
8-32 
- 2.0 
(iii) Hydrogen bonding 
Hydrogen bonding is a very important and potent form of inter- 
molecular force. Its usual distance of interaction is nor- 
mally about 2.5 -, - 3A, and, depending on the nature of the 
atoms and molecules involved, varies 
. 
in energy from 8 to 
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about 32 kJ mole -1 .A hydrogen bond is formed between a 
hydrogen atom covalently bondedto a highly electro-ve atom 
and attractýd, by virtue of being partially +vely charged, 
to another electro-ve atom. 
Species 
9. o H N 
0 H .... 
N H .... N 
13 35 kJ mol- 
1 
20 30 kJ mol- 
1 
10 15 kJ mol-i 
Other electro-negative atoms which form H-bonds are Fluorine 
(not very common in biological structures), Chlorine and 
Sulphur. There is some evidence to suggest that carbon is 
capable of entering into H-bonding but this is likely to 
be very weak. H-bonding is an important feature of base- 
pairing in DNA where the phenomenon known as proton-tunnelling 
is thought to take place. As far as drug receptor interactions 
are concerned., it is very attractive to postulate the 
existence of H-bonding since many drugs and receptor sites 
are likely to contain hydrogen attached to electronegative 
atoms. However, it must be borne in mind that the hydrogen 
bonds formed between the drug and water molecules (due to 
solvation) and also those due to solvation of the receptor 
molecule, may well be stronger than those thought to exist 
between drug and receptor. 
Hydrophobic interactions 
These interactions which have also been called dispersion 
forces are weak, highly distance dependent forces brought 
about by a mutual attraction of non-polar species, usually 
hydrocarbon chains or rings. 
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The energy of attraction AE is given by the following expression 
3 
ct 2 
Il 12 
AE = 
4 d6 Il + 12 
where a= polarization of each group 
d= distance between groups 
IjI2= ionization energies of each group. This is an 
additive quantity so that, for example, increase in hydrocarbon 
chain length, increases the interaction 
Cli 2 CH2 
CH2 CH2 
CH2 CH2 
CH2 CH 2 / 
CH2 CH 2 
CH2 CH2 
AE = 0.4kJ mol-1 
AE = 1.6kJ mol-1 
AE = 3.80 mol-1 
Hydrophobic interaction and ionic attraction (and ion-dipole) 
forces are likely to be most important in long -range recog- 
nition of drugs by a receptor surface. As the drug moves 
into position over the receptor, hydrogen bonds, Van der 
Waalst forces, -and (if they occur) covalent bonding come into 
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play. During this process the associated water molecules 
are displaced - this is known as desolvation and is an 
important reason why Hansch analysis is so successful, since 
hydrophobic forces are responsible for desolvation. 
(v) Charge-transfer interactions 
Charge-transfer (CT). or electron-transfer complexes are 
formed by the transfer of charge from one molecule (electron 
donor) to another (electron acceptor). The energy AE for 
this type of interaction is given by the following expression 
AE AE DA 
where E= donor-acceptor interaction energy 
ID ionization energy of the donor 
AA electron affinity of the acceptor 
Z charge transferred 
RAD *2 donor-acceptor distance 
The range of energies of CT interactions are of the same order 
as for hydrogen-bonding, i. e. 2-8 kcal mole- 
1 
and usually act 
0 
over approximately the same distance 3-3.5 A. There is 
evidence to suggest that CT interaction is widespread in 
drug-receptor binding and may, in some cases, be a preliminary 
to covalent bonding. 
It should be stated that repulsive forces will also be en- 
countered between interacting species when their distances 
become small. In order to achieve a more realistic picture 
one should consider energy functions of the Lennard-Jones 
type, i. e. 
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AE ad- 
6b d-26 
repulsion attraction 
term term 
AE = interaction energy 
r= interaction distance 
a, rr)f = constants 
which combine repulsive and attractive forcps. to give an 
expression from which one can determine the type of inter- 
action by its distance dependence. A graphical representation 
of such a function is shown in Figure 2.2. 
AE Type 6 dp (X) 
ion-ion 1 2.000 
ion-dipole 2 1.414 
ad-2 - ad-4 H-bonding dipole- 3 1.260 dipole 
ion-dipole 4 1.189 
ion-induded dipole 
d ,,: equilT. distance 
dipole-induced 5 1.149 
e dinole 
, 
Zý 4 dispersion 6 1.123 
Figure 2.2 Interaction Energy functions 
So that if one can determine the equilibrium distance of 
interaction (e. g. by crystal studies or theoretical calcu- 
lations), the type of Lennard-jones function and hence the 
type. of interaction (dipolar, dispersiont charge-transfer, 
etc. ) can be found. It is believed that so-called second- 
order interactions (CT, dipolar) are of prime importance 
in drug-receptor binding forces. 
Having outlined the various contributions and effects respon- 
sible for bringing about drug activity, we shall now see how 
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a mathematical treatment of drug-receptor interaction can 
explain dose response relationships. 
Receptor-site Theory 
It is now generally recognized that the production of a bio- 
logical response is a result of occupation of receptor sites 
,I 
on the surface of a cellular macromolecule. The size of 
the response-depends on the number of sites occupied and on 
the effectiveness of drug-receptor binding. The effective- 
ness of the binding as measured by the binding constant, KDI 
depends on the compatibility of the alignment of interacting 
groups between substrate and receptor. Other than the inter- 
molecular bonding force previously mentioned, the size (i. e. 
bulk molecular volume) and shape (i. e. molecular conformation 
and configuration) of the drug molecule is important. 
First of all it is appropriate to define the following terms 
used to describe drug activity. 
Affinity 
79 is a measure of the binding free energy AGbind 
between a drug and its receptor site, i. e. 
AG bind =- RT In KD (binding constant) 
79 
Intrinsic activity is related to efficacy in being the 
I 
potential for different drugs having the same binding energy 
to produce differing leveis of response. 
Efficacy8o is the capacity of a drug to initiate a response 
once it occupies a receptor site. 
Activity of a drug is proportional to the product of its 
efficacy and'affinity. 
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Hence a maximal response may be achieved by a highly 
efficacious drug when only a fraction of the total receptor 
population is occupied. 
There are two main theories relating to rec&ptýor responsive- 
ness: 
(a) Occupation theory, which holds that response is a function 
of the fraction 6f occupation of receptors by a drug. 
-, (b) Rate theory, which holds that response is a function of 
the rate of occupation of receptors by a drug. 
According to the occupancy theory the response rises exponent- 
ially with time until it reaches equilibrium. When the drug 
is removed, the response decays exponentially. However, under 
the rate theory conditions the p. eak response is obtained 
instantaneously and then fades to an equilibrium level. On 
removal of the drug, the excitation ceases immediately. 
There is a good deal of experimental evidence to, suggest 
that the occupancy and rate theories are extreme cases of the 
true state of affairs. However, depending on the situation, 
either may be applied to a good approximation. 
Occupancy theories 
For the point of view of deriving dose-response relationships, 
, 
it has become an attractive analogy to liken receptor occu- 
pancy by a drug to the adsorption of vapour molecules on a 
solid surface. Such a situation has been examined experiment- 
, aIlly 
by Freundlich 
81 
who produced an empirical expression for 
the amount adsorbed, x. per unit mass of adsorbant, in terms 
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of the partial pressure, P, of the adsorbed material - known 
as the Freundlich adsorption iS'otherm: 
Kpn where K and n are constants 
taking the logarithms of both sides, we get 
1, 
log x= log K+n log P 
which is a straight line relationship between log x and log P 
with gradient n and intercept on the log P axis of -log 
K 
n 
The difficulty in fitting this relationship to drug-receptor 
theory is that there is no upper limit to the amount absorbed. 
ýangmuir 82 derived another adsorption isotherm (which bears his 
name) based on the following assumptions about surface adsorp- 
tion: 
The surface contains a fixed number of occupancy sites. 
At equilibrium, at any temperatureTand gas pressure P, a 
fraction e of the sites is occupied, and a fraction 1-e 
is left unoccupied. 
Each site can only accommodate one molecule at a time. 
3. The Gibbs free energy (heat) of adsorption (related to 
the adsorption coefficient K) is the same for all sites 
and does not depend on the fraction covered. 
There is no interaction between molecules on different 
sites. 
Hence, rate of evaporation =kde kd=rate constant dissociation 
and rate of condensation =ka (1-6) ka, =rate constant association 
rate at which molecules strike the surface aP (first order) 
52 
rate of-co_ndensation =Ka Pcl-e) 
At equilibrium, 
kd kap('-e) 
-k 
k 
e ap- KP where Ka kd+ kap T -+KP 
. 01 
or KP 
The amount of material x adsorbed per unit mass of adsorbant 
is directly related to e by the expression 
x= no 
M 
N 
where n= number of sites per unit mass 
M= molecular weight 
N= Avogadro's Number 
e 
p 
Limiting cases (a) at low P or K very small 
KP <<1 
KP which is linear lst order 
at high P or K large at low pressure 
KP >>1 
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KP 
fraction of unoccupied surface P 
which is the hyperbolic portion 
(c) as p-- 
e -** maximum (i. e. 
and graph shows zero order., i. e. does not 
depend on P 
The adsorption coefficient K and the Gibbs free energy of 
adsorption per mole AG are connected by the Van It Hoff 
relation I 
AG RT lnK R= gas constant 
T= absolute temperature 
The value. of AG will be determined by the strength of the 
binding forces. This model can be extended to the binding 
of compounds to plasma proteins, substrates to enzymes, 
haptens to antibodies and, in particular, drugs to receptors. 
If one compares the occupation of receptor sites by drug mole- 
cules with the adsorption of gas molecules on a solid surface, 
then an analogous expression to the Langmuir isotherm could 
be;: where K is the dru 
.g 
receptor 
K ED3 r binding constant 
-r 
Rearrangement yields 
r CD IK D 
and taking logarithms, we get 
-log r -log[D] - log KD 
ID3 is the concentration 
of drug molecules D 
in the biophase 
r is receptor site 
occupancy fraction 
and therefore log r= log[D] + log KD 
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so that receptor occupancy depends on dose and affinity of 
the drug as measured by the dr'ug-receptor binding constant. 
It is not known, however, how receptor occupancy is related 
to the size of the biological response which is actually 
measured. To examine this we need to investigate dose- 
response relationships. (See A-r)T)endix 4) 
Dose-resi)onse curves 
If the extent of a measurable biological response is plotted 
against the concentration of a drug (dose) to effect that 
response then an approximately hyperbolic curve results. 
However, if the logarithm of the dose is employed instead, 
the plot is a sigmoid curve. This so-called log dose- 
response curve is the preferr-ed-format in assessing the 
actions of drugs since it offers several advantages over 
the arithmetic dose-response plot. 
(i) it enables a comparison to be made between the actions 
of several drugs which may show agonist or antagonist proper- 
ties. 
, 
(ii) the middle region is approximately linear and can thus 
be readily subjected to statistical analysis. 
(iii) the dose required to effect a 50% response is related 
to the affinity constant and thus the affinities of different 
drugs competing for the same receptor can be measured. 
CiV) for chemotherapeutic drugs, the therapeutic range can 
be-assessed by displaying ED and LD curves on the same graph 
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and noting the difference between log ED 50 and log LD so as 
a measure of the dose ratio or chemotherapeutic index (log CI 
log LD log ED so - 50) 
loc 
respons 
5c 
JU 
s- 
se 
50- 
100 
of 
exhibi- 
ting 
----1--- 
ldg 
llog affi- affii- -' 
ýtllqi/-n: iiAjy of B 
D5 
50. 
IDo 
aa1 A 
log Dose concn. log Dose 
The philosophy behind mathematical analysis ofthe dose- 
response curve is that biological response is directly 
proportional to receptor occupation. Anoth er assumption 
is that binding at one site does not affect the binding 
at another site.. Clearly, this does occur in some cases 
of competitive antagonism, and the phenomenon of dynamic 
receptors and allosteric effects indicate a departure from 
the simple Langmuir isotherm model. 
However, 'these difficulties can be accounted for by in- 
corporating factors into the basic equation for drug- 
receptor interaction. 
83 
The work of Hill on the binding of oxygen to haemoglobin 
(which is an example of co-operative binding) gave rise to 
Dose-Response Curves 
Dose concn. 
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an alternative expression 
ID3n R 
Di-N 
I rearrangement gives 
KD [DI n 
+KD ED] 
where KD= binding or affinity 
constant 
[D] = dose concentration 
n= constant 
R fraction of response 
(cf. receptor occupancy) 
which yields a linear relationship when logarithms are 
taken, i. e. 
log R=n1 og ED] + log KD 
which is similar to the Freundlich isotherm. 
In order to explain the effects of antagonists, which bind 
to the receptor, yet produce no response, and of partial 
agonists, which show some stimulatory activity but are 
blockers due to a failure to dissociate from the receptor, 
80 Stephenson coined the terms efficacy, e, and stimulus) S. 
These'are related by the e'xpression: 
er where r= fraction of receptors 
occupied 
The biological response, R, is said to be a function of the 
stimulus produced at the receptor site, i. e.: 
f 
Inclusion of efficacy into the receptor Occupancy equation 
gives 
e, EDIK 
SD 
1+ CDI KD 
The stimulus is chosen to be 1 when R is half the maximal 
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response (i. e. R s/l+s). 
At this point, 
1 ED21 KD : -- e ED 21 KD 
from which we get 
-log [D21 = log KD+ log e 
? r? '' 
where CD23 signifies 
dose concentration to 
effect half of the 
maximal response 
which shows a linear. relationship between activity, 
affinity and efficacy and also explains the use of log 1/dose 
(pD2) values in structure-activity work. If this result is 
incorporatedinto a log dose-response curve, it is found that 
the slope of the linear portion at half maximal response is 
related to the efficacy as follows: 
slope a log e 
For example, for agonists with different efficacy but with 
the same affinity, aplot of the slope of the log dose-response 
curves (at R =0.5) against log efficacy gives the followling 
result: 
nsRF 
slope = 0.2264 log e+1.3287 6 0.1276 0.999 3996 
Paton 84 formulated a kinetic approach to drug-receptor binding 
by stating that the magnitude of the biological response 
depends on the rate of formulation of the drug-receptor complex. 
k1 
D+R 
w_ 
DR response 
k2 
The rate of occupation of receptors is given by 
dr 
=k ED] (1 ir-t 1 
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which, at equilibrium, is equal to the rate of dissociation 
of drug from-receptor, k r, i. p.: - 2 
kl[Dl(l-r) =k 2r 
ED3K 
Since r-D.., e get that: - 
I+IDIK D 
dr k2 IDIK DkI [D3 
a-t 1+LDJK D 1+ED3K D 
which is similar to the expression derived from occupation 
theory. If the rate of occupation determines the stimulus, 
then the rate constant k could be equated with efficacy. 2 
Thus the two theories are indistinguishable at equilibrium. 
However, if non-equilibrium conditions are considered then 
differences do arise, since analysis yields that the proport- 
I ioý of receptors rt oc . cupied . at . time t is related to-the 
proportion at equilibrium re by the equation: 
rt 
(k LD I+k 
r 
(1 
-e1 2)t 
,, and the rate of occupation of receptors 
is given by: 
1 '' - 
'dr k IDI (, I - rt)- kjEDl 
[1 
- re 1- e- 
(k 1 ED] + k2)tl] Tt 1 
dr 
at r e( 
k2+k1 ED] 
e 
ý-(k 
1 ED] +k 2)t 
The curves for variation of response with time show clear 
difference between the two theories. 
-. ýMe first diagram indicates that occupancy rises gradually 
..,. to, a maximum, then 
decays exponentially when the drug is 
Occupancy The6ry 
rec 
occup 
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Rate Theory 
ite 
)f 
-iat 
on 
f ade 
0. 4 
time (s) drug 
removed 
from sites 
"washed out" from the receptors. The second diagram shows 
that the rate of occupancy starts at a high value and then 
decays exponentially to an equilibrium level. This fading 
phenomenon has been noted in many systems but it is difficult 
to establish whether this is brought about by diffusion rather 
than by drug-receptor interactions. However, it is interest- 
ing to note that a plot, of y e- 
kt 
reveals a sigmoid (D-R) 
relationship, cf. rt=I-e -kt re 
I 
Rationgle of MO approach to SARs 
It has been shown that there are a number of factors which 
contribute to the overall activity of a drug. For a mathe- 
matical analysis of drug activity it is appropriate and 
necessary to start with a simplistic model from which to 
derive expressions and then consider other factors for 
arug 
removed 
from sites 
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possible inclusion in the treatment. It may be found that 
one or two factors predominate thus validating the straight- 
forward approach. However, it must be borne in mind that 
there are competing events in the molecular mode of action. 
One can state that the rate of biological response dR/dt to 
a given drug depends on the dose concentration Cx 1, and on 
the probability PX of the molecule reaching the site of 
action. This-can be expressed mathematically as follows 
dR pCK Tt- xxx 
where Kx is the equilibrium constant of the rate-determining 
step, i. e. the formation of the drug receptor complex54,85 0 
Absorption and transport is dependent on lipid solubility, 
i. I e. an ability to cross cell membranes 
86. This forms the 
basis of Hansch analysis which can be derived by employing 
an error-type function ae-("-"0? 
/b for the probability 
term where a and b are constants and Tr are Hansch 
substituent parameters for substituted and parent compo unds 
respectively. Tro refers 
I 
to the Tr value for maximum probability. 
dR 
ae- 
(7r- 7TO /b CK 2Ft xx 
If C is the applied dose necessary to elicit a constant x 
required response in given time, then taking logarithms 
we get the following expression: - 
log -1 ki 
Tr - k2 Tr2 + log Kx+ k3 
x 
where kl, k 2 and k3 are constants 
(which include 70). 
Hansch equates log Kx with pa from Hammett analysis on the 
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assumption that Kx depends on electron availability. 
-1 
.. 1.2 
j, og Ck 
Tr -k ?T+ pa ,x12 
where P is a constant and a is the Hammett (electronic) sub- 
stituent parameter. Hansch found that the 72 term was not 
essential except in complicated systems involving transport 
through many cellular components. In some cases, the Taft 
steric parameter Es is employed thus forming the general 
equation for structure-activity relationships. 
kl7r + pa +kE+k log c2s3 
The theoretical basis for this has been outlined by Cammarata87 
on the "hypothesis" (Ferguson principle) that the rate-deter- 
mining step is the formation of the drug-receptor complex. 
It is thus valid to equate activity with the free energy of 
formation of the drug-receptor complex AG DR* This can then 
be-expressed as a linear combination of free energy contribu- 
tions from electronic 
(e) 
. desolvation(d) , 
steric(s) , and 
conformation(c) effects. Thus, the acti vity Ax (which equates 
with log l/C ) is given by x 
AGe AGd + AGS + AGC Ax = AG DR =xxxx 
11,1 
For a-series of compounds n of similar structure the change 
1 1, 
in, activity is therefore: - 
6 (AG e 6(AGd )+ 8(AGS )+ 8(AG c xnxnxn x)n 
If one assumes that the conformation of drug with receptor 
I-I 
is constant for the whole series of compounds, then the last 
term vanishes to give: - 
I 
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6 (A ) `2 6(AGe )+6 (AG 
d) 
xnxn cons 
Then the electronic contribution-is equated with the Hammett 
electronic parameter, a; the desolvation, term can be. related to 
Hansch's 'hydrophobic parameter,, 7r; and the. steric term sub- 
stituted by the Taft steric parameter Es to give 
QA An " aa + bu + cE s+d where aod are constants 
The a-7r,; -E s m-ethod 
in formulating QSARs is preferable to the 
simplistic (albeit successful) method of Hansch. Utilization 
of the hydropýobic parameter, Tr, yields information about the 
relative lipoid transport capabilities of drugs which is often 
sufficient to correlate with drug activity providing movement 
across cell membranes, is the most important stage. However, 
no information is gained about the mode of action at the 
receptor, and consequently, correlations are often of low 
significance. The inclusion of electronic and steric para- 
meters is a step in the right direction, providing more in- 
formation about the receptor site binding and increasing the 
statistical significance, Nevertheless, the approach is still 
fairly nebulous as one is only considering bulk molecular or 
. _group 
properties. More precise and more relevant information 
can be obtained by determining the electron distribution in 
the molecule by MO calculation. This in effect enables one 
ýo de'cide on whereabouts in the molecule biological activity 
i-S''likely to be influenced and indicates how these proper- 
ties might be changed to design more efficacious drugs. The 
bulk'molecular properties are not forgotten either, since 
their contribution can be evaluated by the summation of 
various MO-derived parameters over the whole molecule. 
MO-'deriVe'd*param6ters 
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(See Appendix 2 and 3) 
The quantUm7mechanical approach to drug-receptor interaction 
is to employ perturbation theory 
88 to provide an expression 
for the energy of interaction between the two*molecules. The 
energy gained AE when the orbitals of two molecular species 
(drug and receptor) overlap, is given by: 
AE = -aý(q +q s ab ab ab k<l ER kl rssr 
2( l' CCß2 
ab ra sb ab) 
EE 
rs 
where qaqb electron densities in atomic orbitals (aos) a, b 
ýab'Sab resonance, overlap integrals 
QkI Q1 total charges on atoms k, l 
local dielectric constant 
R kc interatomic distance 
between k, l 
Cra coefficient of ao a in MO r. r refers to MOs 
in one molecule and s refers to those on 
other molecule 
Er= energy of the rth Mo. 
The first term is the lst order closed shell repulsion term 
due to-. interactions of filled orbitals on'one molecule with 
those of the other. The second term is the coulombic 
attraction term and is important when ions or dipoles inter- 
act'. ý This term can be evaluated from molecular electrostatic 
potential calculations as described in Appendix 3. The 
third term is the interaction of all filled orbitals with 
all unfilled orbitals of the correct symmetry. It is the so- 
occ unocc occ unocc QkQl 
ýrrrr 
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called 2nd order perturbation term and is only valid for 
inclusion if 'r' ýEs When Br t- Es the interaction is better 
described as charge transfer and the perturbation energy is 
Ist order and is equal to 12C ra 
C 
sb$ab*. 
Tf one only 
considers the highest occupied MO (HOMO) of the nucleophil 
and the lowest empty MO (LEMO) of the electrophil, the inter- 
action energy equation reduces to: - 
AE '-QiiucQe'lec + 
2(CnucCelec a) 
cRE HOMO E LEMO 
where the first term is coulombic and is determined by the 
net atomic charges on the relevant atoms of the two inter- 
acting molecules, and the second term is. called the frontier 
orbital term since HOMO and LEMO are frontier orbitals. 
When E(HOMO) > E(LEMO) the second term becomes negligible 
compared with the coulombic term, the interaction is largely 
dependent on'the charges, and is said to be a charge-controlled 
interaction. However, when E(HOMO) = E(LEMO) the second term 
becomes predominant leading to a frontier-controlled inter- 
action. The second order term in the first expression can be 
e-xpanded out and re-arranged to give 
AE' r 
occ sE Csf unocc sNC rf 
unocc SN +C occ sE 
rrs 
where ýs are constants and S El SN are the electrophilic and 
nucleophilic, superdelocalizabilities respectively. Superde- 
89 
localizability is a term coined by Fukiii et al. and is 
really an orbital related electron density parameter 
2c 
n2 SE =E 
nS 
for occupied orbitals a -* n 
2cM2 
for unoccupied orbitals m -, - z SIN ý F--T 
mm 
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The above expression for 2nd order interaction can usually 
be separated into 
occ unocc 
AE Is- 1rE CS, SN rs 
for charge transfer R 
and 
occ unocc 
, 6E 2sIsE-ýII SX srr 
for charge transfer S -)- 
Bulk molecular parameters 
In addition to the single atom properties of electron density, 
net atomic charge, frontier electron density, and atom super- 
delocalizability, bulk molecular parameters can be readily 
obtained from MO calculations that have great use in structure- 
activity work. It has been previously shown that dipole 
moments'and molar polarizabilities are important in drug- 
receptor binding. Many MO methods employ a routine which 
calculates dipole moments by vectorial addition of the net 
atomic charges. MINDO/3 is no exception to this and the 
dipole moments of many molecules calculated by MINDO/3 are 
found to be in close agreement with experimental values. 
Some of, these results are listed elsewhere in this work. (p. 82) 
Molecular""polarizability am is given by the relationship 
a 
3Vm n2 where Vm-=molar volume 
M 
ý7TL 
n7--+2 L =Airogadrols constant 
n =refractive index 
90 
In quantum-mechanical terminology molecular polarizability 
is the sum of all atomic polarizabilities given by the re- 
lationship 
m occ unocc 2 cu 2 j Cý'j k 
a-yx 
m n=l E k- E 
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where p refers to individual atom labels, 
EPSE k, are 'the energy levels (eigenvalues) of orbitals j, k 
C 11 -j ,c uk are 
the orbital coefficients in the LCAO expression 
It can be shown that am bears a close relationship to SUD-erde- 
localizability summed over the whole molecule. In fact am 
makes a substantial contribution to the hydrophobic parameters, 
7ror log P; so, therefore, does electrophilic superdelocaliza- 
bility for all the atoms in the molecule. Such relationships 
between the logarithm of the octanol/water or ether/water 
partition coefficients, log P, and total electrophilic super- 
delocalizabilities, ES 
n B, are 
tabulated in this work and show 
_a 
high statistical significance. In some instances, the sum 
of the total atomic charges over all atoms in the molecule 
is included in the regression equation to give a better 
correlation with log P. So the relative ease of transport 
across lipid membranes can readily be related to the theore- 
tical parameters QT and SE as follows: - 
log PaI SE +b 
nýI 
QT 
where SE electrophilic superdelocalizability and total QT 
(net) atomic charge are summed over the whole molecule. 
a, b, and c are constants arrived at by regression analysis. I 
In fact, each stage in a drug's activity can be related or 
put in theoretical terms which are evaluated by MO calcu- 
lation. 
, Other electronic properties of the whole molecule which are 
'of, interest in understanding pbarmacological processes are 
the energies of the highest occupied MOE(HOMO), and lowest 
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empty MO, E(LEMO)p protonation energy E(PROT), and molecular 
e1ectrostatic potentials. The inclusion of E(HOMO) or E(LEMO) 
in an activity correlation suggests that a charge-transfer 
interaction is operating between drug and receptor. The 
occupied MO constitutes nucleophilic attack on receptor, 
whereas the empty MO constitutes electrophilic attack. The 
E(HOMO) and E(LEMO) values are also important in chemical 
reactions, in particular those which parallel cellular 
processes like alkylation or hydrolysis. The protonation 
energy is another useful parameter for correlation with the 
rate constants of some. reactions. It is given by the numerical 
difference between the calculated heats of formation &Hf of 
protonated and neutral species. Therefore: - 
E(PROT) = AHf - AHf protd. unprotd. 
Molecular electrostatic potentials are useful in predicting 
likely sites of electrophilic attack in a molecule, for 
example: points of alkylation of DNA bases and base-pairs. 
They'are thus related to positions of electrostatic and 
covalent bond formation between molecular species. 
These bulk molecular properties do not always figure in 
activity correlations. One often finds that instead of the 
sum of electron densities, individual atom electron popu- 
lations are important in QSARs. This is due to the fact 
that i there are specific atoms where interaction and binding 
occurs and the magnitude of this electron charge population 
density is directly proportional to drug activity. This can 
be the predominant term if transport characteristics do not 
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figure highly in the regre. ssion. Also, more than one atom 
of the molecale, may display an effective binding site; these 
atoms may b6, widely separated on different moieties in the 
molecule. Sometimes whole groups take part in the binding 
interaction and it is of great interest in 'receptor mapping 
to identify the, areas of a drug molecule and their relative 
contribution to the overall formation of the drug-receptor 
complex. It is the aim of the medicinal chemist engaged in 
the design of new drugs with specific well-defined properties, 
therapeutic ratios, and selectivities to be able to relate 
the activity and other useful properties of a compound to its 
molecular structure. 
i 
Molecular conformation 
There is a lot of evidence to suggest that molecular confor- 
mation is important to drug-receptor binding interactions. 
Difficulties arise in the application of conformational ana- 
lysis to biological activity correlation. The problems lie 
in the methods of producing structure information, and in the 
fact that it is more than likely that none of the possible 
stable conformations correspond to the actual conformation 
of the drug molecule at its receptor site. Application of 
first principles for model systems usually enable one to 
arrive at one or more of the minimum energy conformations for 
a mole cu le, which are often substantiated by physical methods 
of structure determination, viz.. X-ray diffraction, electron 
diffraction, and NMR spectroscopy. It must be borne in mind 
that diffraction methods are carried out on a solid sample, 
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whereas NMR is normally in the solution phase. Because of 
the differenEe in time scale of experiment (NMR I minute, 
X-ray 30 minutes), and that solvation occurs in the NMR 
method, molecular structures are likely to show differences 
between the two states. It is appropriate to use the 
information produced by the two techniques in conjunction 
in order to obtain a more complete representation of mole- 
cular structure. The X-ray data produces reasonable values 
for bond lengths and bond angles, whereas the NMR data yields 
molecular conformations which are preferred for the solution 
phase. Both give an averaged description of molecular geometry 
and it is advisable to be aware of the limitations of each 
method and treat the information with a degree of suspicion. 
A notable error in X-ray work, for instance, lies in the 
measurement of bond lengths which tend to be underestimated 
due to molecular vibrations distorting the structure. ý10 
calculations can be executed for molecules in any conformation 
one desires and the main advantage of a method such as PCILO 
is that a conformational energy contour map can be obtained 
by running a large number of MO calculations for differing 
conformations in a short time. The size and shape of the 
energy minima determine the relative contributions of these 
conformations to the total structure. However, MO calcu- 
I 
I-lations 
usually refer to gas phase species so that incorpo- 
ration of solvent interactions are likely to yield more 
significant results. Even so, it is the essential confor- 
, mation 
that is important and one has to inspect SARs for, 
series of molecules of similar structure, and deduce whether 
there are changes of rigidity, or conformation, with 
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concomitant changes in activity before relevant information 
can be obtained about the drug-receptor interaction. 
Causality of QSARs 
A priori, a causal relationship must exist between a 
derivable molecular property and biological activity. The 
aim of MO-QSARs is to reveal causal relationships between 
theoretical parameters and drug activity. It is difficult 
to estimate the causality of a, particular relationship 
arrived at through regression analysis. One can only assess 
its statistical significance by specific tests such as the 
t- and F-tests, and by determination of the percentage-of 
the data points which lie outside the limits of the F-dis- 
tribution. Other ways of assessment are provided by the 
regression and correlation coefficients, standard error, 
and degrees of freedom. Inspection of the correlation matrix 
facilitatesthe elimination of cross correlations, or auto- 
correlations, from the determination. Thus it is possible 
to reject those relationships which have arisen by chance 
and retain those which are causal with a high degree of 
certainty. A summary of regression analysis is given in 
appendix 
The usefulness of a quantitative structure-activity relation- 
ship - is in its predictive power, i. e. to estimate the biolo- 
gical activity of an untested compound. The value of an SAR 
is , in providing an insight into the biological mode of action 
of a drug at the molecular and sub-molecular level. 
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To summarise the molecular electronic parameters employed in 
QSARs for the assessment of the relative priority of events 
in a drug's I action it is appropriate to write 
-log A= alf, + a2f2 + a3: E3 + ... anf n'+ constant 
for the general equation of a QSAR where: A is the measured 
drug activity, whether it be LD50, EDSO, % increase in life 
span (ILS), etc; a-*an are numerical constants obtained by 
multiple regression analysis - their relative magnitude will 
provide an assessment of the importance of each term f, fn 
to the biological activity. The theoretically-derived para- 
meter f, -* fn are reactivity indices determined by MO calcu- 
lations. One would expect that the following quantities 
estimate the ease of transport across cellular barriers: - 
ESE, QT 1 112 -1 01 MOL 
and to a lesser extent ES N* The hydrophobic parameter and 
log P are, therefore, redundant, since ZS E and EQT correlate 
with these and also -correlatý! better with drug activity. 
If the drug molecules are ionized at the pH of the medium 
under scrutiny then MO calculations for these ionized species 
need to be carried out in order to give greater validity to 
the QSARs. The square of the dipole moment is included as it 
is a component of the total molar polarizability. It is 
thought that calculation of amol is unnecessary because atom 
polarizability (from which it is constructed) can be related 
to SB and S N' 
Inclusion of the following parameters show that metabolism, 
whether it be activating or de-toxifying in nature, is of 
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importance: 
Ionization energy, E(HOMO)and protonation energy, E (PROT) , 
which often correlate well-with rate constant of in vitro 
reactions designed to mimic cellular processes such as 
alkylation, oxidation, protonation, etc. These parameters 
can also be related to Hammett a constants and Taft a* con- 
stants. 
Interaction with the receptor site as being the predominant 
feature of drug activity will be indicated by the presence 
of the following reactivity indices in the expression: - 
E(HOMO), E(LEMO), QN(ýOMO)' QN. (LEMO) for. frontier- 
controlled processes involving CT interactions, 
QN for lst order interactions, that are indicated by the position 
and size of the potential energy minima calculated from 
molecular electrostatic potential maps, 
SE (N) and SN (N) for charge transfer interactions and also 
(possibly) for ease of covalent binding, 
11P. 11 2, and 11 4 for the various types of weak intermolecular 
forces which are respectively dipole, dipole-induced dipole, 
and dipole-dipole. 
Finally, a flow-chart for the process of mathematical (MO) 
analysis of drug activity utilizing MO QSARs is shown as 
follows 
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I 
Biological Biochemistry Chemistry MO calcn L* Electronic Activity Pharmacology (molecu- structure 
(membrane transport, lar str. ) 
metabolism, etc. ) 
Regression 
analysis 
I 
Molecular Orbital-Structure-Activity Relationships Mathematical 
MO-QSARs level 
CHAPTER 3 
MODIFIED INTERMEDIATE NEGLECT 
OF DIFFERENTIAL OVERLAP METHODOLOGY 
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The MINDO/3 Method 
7he MINDO/3 technique, representing the third version of the 
,, Modified Intermediate 
Neglect of Differential Overlap method, 
is a semi-empirical self-consistent field (SCF) method of 
calculating electronic structures of molecules. It has certain 
advantages over othermolecular orbital (MO) calculations, 
including ab initio methods. The strength of MINDO/3 lies in 
its ability to provide accurate values of molecular properties 
from relatively fast calculations on medium to large molecules 
Cof up to 80 atoms) at about a fifth of the cost of ab initio 
methods. In fact, it has been stated that MINDO/3 is more 
108 
accurate than the Roothaan-Hall (RH) ab initio method irf 
obtaining agreement with experimental, data and, additionally, 
, 
MINDO/3 can execute MO-calculations for larger molecules. 
Comparisons between MINDO/3 results and experimental data 
are shown later on in connection with criticisms of the method. 
MINDO/3 is a versatile method in that routines are included 
in the program for MO calculations of positively and negative- 
ly charged molecules and on radical and biradical species of 
varying multiplicity where configuration interaction (CI) is 
'employed. There is also a facility for performing reaction 
calculations using the reaction coordinate routine. These 
useful inclusions in addition to several modifications made 
to the original program in the course of this work, and coupled 
with the fact that input data is in terms of bond lengths 
and bond angles make this program very attractive to the 
o. rganic and medicinal chemist. 
75 
4INDO/3 has been shown to be very successfiil in the estimation 
of bond lengths, bond angles, heats of formation, and 
ionization energies of a substantial range of organic mole- 
MINDO/3 is an all-variance electron method, i. e. it includes 
cules (see tables of results at end of chapter). 
a and Tr electrons and is essentially simpler to Pople's NDO 
procedures 
109 in that an approximation for the core Hamiltonian 
is retained and the valence electrons are assigned a minimum 
basis set of atomic orbital (AO) wave functions (ýi). There 
is some equivalence to the INDO method since certain electronic 
repulsion integrals are'neglected, but the modifications come 
in the way some of the remaining integrals are parametrized. 
The following table summarises the energy terms and their 
derivation as referred to in Appendix 2. 
Energy term 
I- 
Centre 
Coulombic attractions (n-e) 
Interelectronic repulsions 
Exchange terms 
lectron-core attractions 
Resonance integrals 
UPP 
=j 
Derivation 
V2 
ZS 
M (i) dT psp 
i (j )dT 
JfMý 
(i) L 
pp rij pppi 
dTj = <ppipp> 
Kpp ` ip p 
dTi vpa, =fPs rs i cr 
R =f 0 *(i) 
[_IV2 z 
pa p9r si 
2- Interelctronic repulsions j Pa = 
if 
ý *(i) 0 (i) 10 *0 0 
Centre 
PPr ij cr cr 
dTi dTj =< pploo > 
Exchange integrals 
,, Core-core repulsions 
Kpcr (j)Pcr(j' 
p ij P 
dTj ` <PaIPCr> 
zszt N Rst 
S>t 
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Evaluation of the expectation value for the energy of the. 
molecule involves derivation of the expression <ýJHJý> 
where ýP (i) is the determinantal wave function. The total 
Hamiltonian can be separated into l-electron and 2-electron 
parts 
H=H1+H2 
where H, HC (P) HC -1 
V2P rp 2 ZA A 
p ore ore(p) A 
and H2= lp<q I rpq 
In the MINDO/3 scheme, certain adjustments and simplifying 
approximations are made in the treatment of the various 
and 2-centre integrals. These are as follows: - 
(a) So that the calculations. are invariant to rotation, all 
repulsion integrals (ii, jj) between ao i on atom m and 
ao j on atom n are made equal to a common value y mn* 
(b) The 1-centre repulsion integrals gik are left unchanged. 
(c) Using the Goepert-Meyer-Sklar potential function"O 
wh 
, ich neglects penetration int 
- egrals 
( fý, (i) 
zS 
ý (i) dT 
r si P 
for electron-nuclear attractions, the attraction between 
an electron in ao i of atom m and core of atom n is given 
by: - 
where c is the core 
Vin 'ý -cn Ymn ... charge 
n of atom n in 
units of -electronic 
charge 
The expression for the element of the Fock 
III 
matrix in 
t, 
,,, MINDO is as 
follows: - 
(n) (n) 
F+0.5qigii + 0.5h U111 
jýi ij -7y 
(c -I qj) 
ným mn ni 
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where: - F are the diagonal elements of the Fock matrix. 
Uii is the sum of the KE of an electron in ao i of 
atom m and its PE due to attraction to the 
core of atom m 
qi is, the electron population (density) of ao i 
gij,, h ij are the 1-centre coulomb and exchange integrals 
for ao's i and 
ijcmm) ý-- 0.1pij (3h ij - 9ij) (3) 
F 
3. j (mn) -0c ij - 
O. Spjj - O. Spjj yij 
Fij(MM) are the off- 
diagonal elements 
between ao's ij on 
atom m; 
p ij is the bond order 
between ao's i and j. 
. .. 
where F ij(mn) are the-off-diagonal elements between ao s ij 
of different atoms m, n; 
ecý. is the 2-centre. l-electron exchange integral 13 
(core-resonance integral). 
The total energy of the molecule can be expressed as the 
sum of electronic and inter-core repulsion energies as 
shown: - 
E total = Eel + Ec = Eel +II CR mn 
(5) 
m>n 
where CR is the P. E. of repulsion between the cores of 
. mn 
atoms m and n. 
The energy of atomization (-heat of'formation) of any molecule 
is the difference in energy between that molecule and that 
of, its constituent atoms. Atomic epergies are calculated 
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from single configuration wave-functions using the same 
assumptions and integral valu6sýas in the MO calculation. 
Thus atomization energies can be equated with experimental 
heats of formation values, where KE terms in Hf are taken 
into account by the parametrization. 
The parametrization in MINDO/3 takes into account and deals 
with the following major sources of error inherent in semi- 
empirical NDO procedures: 
1. Neglect of coulombic electron correlation 
2. Errors brought about by virtue of the simplifying 
assumptions made in the derivation. 
3. Errors due to equating calculated atomization energies 
with measured heats of atomization. 
In the original versions of MINDO (1 and 2) the 1-centre 
integrals gij and hij were found from Slater-Condon para- 
, meters 
by Pople's method, as employed in INDO. MINDO/3, 
however, utilizes Oleari's 
112 
method whereby all the gij 
and hij integrals can be evaluated independently. 
Optimization of Molecular Geometries 
The geometry of a molecule is found by optimizing its total 
energy with respect to the corresponding geometric variables. 
Input parameters are in the form of bond lengths, bond angles, 
and dihedral or torsional angles. Any number of these para- 
neters nay be optimized independently or grouped, if desired, 
using the symmetry option whereby a parameter to be optimized 
can be linked (or tied) to one or ruore other geometry para- 
79 
meters. This greatly facilitates convergence of the SCF 
equations tlýus decreasing combutation time. There is also 
a facility' for parameter dependence which involves linking 
one optimizable parameter with another while including a 
transform such as rotation through 1800 relative to the 
*0 optimizable parameter. For example, an -Nko group can be 
rotated relative to a benzene ring by optimizing the dihedral 
angle of one of the oxygens and at the same time stipulating 
that the other oxygen must remain in the same plane of rotation. 
Obviously, the larger the molecule, the more difficult it is 
to optimize a large number of parameters, though it is possible 
for small molecules (about 10 atoms) to optimize everything 
and obtain a relatively fast rate of convergence. 
With large molecules of about 40 atoms, it is advisable to 
optimize up to about 5 parameters simultaneously, otherwise 
a tedious iterative procedure ensues which can be misleading 
or even erroneous in the final result. 
Generally, it is best to start with reliable X-ray crystal 
data, microwave data, or at the worst, tabulated values of 
standard bond length and angles, and optimize any geometry 
parameters which are either not available, or not known to 
any great degree of certainty. 
A Critique of MINDO/3 
MIND013 has been criticized for having certain short-comings 
brought about by the parametrization methods employed. 
It is true that for bonds containing a substantial amount of 
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d orbital. character, such as sulphur and phosphorus, dis-. 
crepancies occur in the calcuiation which are inevitable. 
In fact, no parametrization exists in MINDO/3 for S =0 and 
P= 0 bonds, although amendments to the prograp could be 
made to include them. 
MINDQJ3 has a propensity for overestimating torsional (dihedral) 
angles between singly bonded SP2 atom centres. This is 
because the Davidon-Fletcher-Powell (DFP) minimization 
procedurel13 does not have an adequate weighting to allow for 
the stability of co-planar 7-systems. However, other semi- 
empirical, methods suffer from the same shortcomings and, if 
accurate molecular geometries are known from X-ray or micro- 
wave data, little or no optimization is necessary. It has 
been found that chunges in Vorsional angles have the least 
effect on electron densitiesp whereas these and other derived 
molecular properties are more susceptible to changes in 
bond lengths and bond angles. 
MINDOJ3 correctly predicts that the position of a hydrogen 
0H 
atom of a carboxylic acid ýýC _ 0/ 
group as lying co- 
planar with the carbonyl C =0 moiety. The rotation of a 
methyl -CH 3 group adjacent to an aromatic ring is correctly 
optimized as 60 0 to the plane of the ring and the preferred 
conformations of biomolecules such as histamine and sero- 
_, 
tonin are in agreement with accepted conformational studies 
by_other., techniques. Also the C-I' 
0%% 
C bond angles in ethers 
, and esters as estimated 
by MINDO/3 are close to the tabulated 
, values. 
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A slight overestimation of C-H, O-H, and N-H bond lengths. 
I has been found using this method but this problem can'. be 
nullified if literature values are employed and no optimi- 
zation is necessary. 
It has been said that MINDO/3 gives inaccurate orbital ener- 
gies which nay be true, but it is difficult to verify or 
disprove because of a lack of experimental data. The orbital 
energies of--th-e highest occupied Msý (HOM01s) are equivalent 
to first ionization energies and these have been compared 
with experimental values for DNA bases, showing clearly that 
MINDOJ3 gives-good estimates of these values. A recent 
publication entitled "the organic chemist-§' book of orbitals" 
by Jorgensen and Salem lists values of orbital energies for 
a large number of organic molecules and it is interesting 
to note that the two methods used to calculate these quantities 
are ab initio and MINDOJ2. 
MIND013 can exaggerate dipole moments if the molecular geo- 
netries used in the calculation are inaccurate, but if recent 
X-. rayror microwave data are input very good agreement is 
achieved as shown in the list of values at the end of this 
chapter. 
Clearly MINDO/3 is as good a method for, elec, tronic structure 
calculation as any other available. It would seem to fill 
the-, gap between CNDO, INDO, and ab initio methods and has 
several advantages over all of these. After a fairly quiet 
period of critical assessment, MINDO/3 is at present occupying 
a certain degree of vogue in the sphere of quantum chemical 
calculations. 
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Dil)ole moments for monosub's*tittit6d b'enz*en'es (Debyes) 
Compound Calcd. 
1 Exptt. 
Ph F 1.62 1.60 
Ph Cl 1.69 1.69 
Ph NH 2 1.00 1.13 
Ph NO 2 4.88 4.29 
Ph OH 1.41 1.45 
Ph OMe 1.31 1.30 
Ph COMe 3.26 3.02 
Heats of iormation (kcal. mole-') for parent structures of 
anti-tumour agents 
Molecule Calcd. 
1 Exptz- 
Phenyl- +59.48 +56.61 
aziridine 
1-methyl-17 -49.31 -42.06 
nitrosourea 
1-ethyl-l- -54.22 -57.84 
nitrosourea 
Ionization energies for DNA bases (eV) 
Expt. L MINDO/3 CNDO SCF 
Adenine 8.00 7.60 10.08 7.92 
Cytosine 8.90 8.70 10.78 8.16 
Thymine 9.43 9.31 - 8.80 
-Guanine 7.80 7.66 9.06 7.59 
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MINDO calculations in Biological and Chemical Research (A Survey) 
The literatu 
, re relating 
to MO correlations with drug activity 
has been adequately reviewed by Blair 
91 
who has also cited 
references pertaining to the rationale of s. tructure-activity 
work. It remains to mention briefly some areas of recent 
research where MINDO calculations have been usefully employed. 
Since its inception by Dewar and co-workers 
92 
, MINDO has been 
successfully applied in structural studies of many molecules. 
The early litgrature concerning the utilization of MINDO 
methods has been reviewed by Murrell and Harget 
93 
. Klopman 
and Evans94 , and by FernAndez-Alonso95 who stress the useful- 
ness of MINDO to a wide range of studies in theoretical 
chemistry and biochemistry, e. g. excited states, photochemical 
reactions, insertion reactions, catalysis and enzyme reactions. 
The advantage of MINDO above other methods is due to the 
fact that it is able to produce fast, accurate results in 
good agreement with experimental findings combined with its 
applicability to -many areas of research. 
D6war 96 used an up-dated version of MINDO/3 to perform MO 
calculations on some non-benzenoid aromat'ic systems, such- 
as benzyne, cyclobutadiene and other polymethines, and 
achieved comparable accuracy to ab initio SCF procedures. 
In-1977, Boyd97 published the results of structure optimi- 
zation of N-substituted monocyclic s-lactams using MINDO/3, 
whereas 1978 witnessed a plethora of MINDO studies, parti- 
cularly involving geometry optimization and conformational 
98 
work. Olah investigated protonation of hydroxylamines, 
axines and DNISO using MINDO/3 calculations in support of 
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NMR data. Garvey and Hashmall 
99 
performed similar calcu- 
lations to. ascertain the mechanism of acid-catalysed ring 
100 
opening of 6xaziridines, and Bischof et al. ,, utilized 
MINDO/3 to correlate electronic structure parameters of 
tricyclic compounds with electrophilic and steric inter- 
actions. The MINDO/3 results were in agreement with photo- 
electron spectral data for these compounds. Trindle and 
Halevilol used MINDO/3 in geometry optimization of the 
postulated jioXetene formed by the reaction between ethyne 
and oxygen, whilst Zielenski 
102 
made use of MINDO/2 in 
I 
conformational studies of guanine and adenine tautomers. 
Shinagowa and Shinagawa 
103 
studied meta and para methylation 
of catechols with MINDO/3 in the same year. 
A newer method, abbreviated MNDO, has been conceived by 
Dewar et al. 
104, 
which has been parametrized for the inclu- 
sion of second row elements utilizing d orbitals (i. e. P, S 
and Cl). It is essentially similar to MINDO/3 in many 
respects, containing the same facilities for the electronic 
calculations and geometry optimizations of ions and radicals 
ii! addition to neutral species. Apparently, the results 
achieved by MNDO are comparable to MINDO/3 but with improved 
accuracy to experimental data. The evaluation of MINDO/3 
and MNDO calculations for alkanes, cycloalkames, carbonium 
ions, and hetero-alicyclics has been reported in two papers 
105 by McManus et al. 
In 1979, Czerminski et al. 
106, 
published work on geometry 
optimization of pyrimidines by IMINDO/3, and in 1980 Defina 
and Andrews 
107 showed that MINDO/3 calculations on amides, 
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uI reas, and simple heterocycles gave better agreement with. 
I 
experimental dipole moments than did ab initio calculations. 
Therefore, . it would appear that MINDOJ3 and MNDO methods 
can be confidently applied to a large number and variety 
of inolecules of biological interest to achieve precise 
descriptions of-molecular structure and electron distribution. 
CHAPTER 4 
PHENYL AZIRIDINES 
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Introduction 
The phenyl qziridines are a group of activated aziridines 
which exhibit biological activity due to their ability to 
114 
act as alkylating agents In the sphere*of anti-tumour 
chemotherapy, phenyl aziridines resemble the nitrogen mustards 
in inhibiting DNA replication and consequently effecting 
115 
tumour regression The azacyclopropane ring is susceptible 
to cleavage by-weak acids to form a linear carbonium ion (via 
an aziridinium ion intermediate) which is strongly electro- 
philic in nature. 
H 
He al R-<R-N RNH-CH2-CH20 
jl\J 
aziridine aziridinium carbonium 
ion ion 
Electron-withdrawing groups adjacent to the aziridine nitrogen 
facilitate ring fission by withdrawing charge away from the 
nitrogen atom and thus weakening the carbon-nitrogen bonds 
of the 3-membered ring system. Some examples of aziridines 
which are activated by electron-withdrawal are shown below. 
0 
II 
R 
carbonyl aziridines 
0 
it 
R -', 
S/ --NJ NJ 
0 
0 
sulphonyl aziridinýs 2-niV-rC& phenyl 
aziridines 
The third compound forms the basis of the tumour-inhibitory 
phenyl aziridines studied in this work. Although inactive 
itself, substitution of a second nitro group in the 4-position 
gives rise to CB1937, a compound which displays activity 
against the Walker 256 carcinoma. Substitution by an 
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amido moiety in the 5-position results in the highly active 
116 
anti-tumour drug CB1954 The molecular structures of these 
I compounds are shown below. 
0, N 
CB 19L37- 
N02 
CONH2 
OýNJEC 
CB 1954 
Phenyl aziridines are, in general, highly toxic compounds. 
The lethal dosage in the rat varies from 4 to 1600mg/kg of 
body weight. The cytotoxic action is due to the aziridine 
ring because of its propensity to react with cellular 
nucleophils The mode of biological action toward cancerous 
tissue is likely to be alkylation of one or more of the 
purine or pyrimidine bases in DNA. However, other sites on 
DNA, e. g. the phosphate and deoxyribose groups, are also 
susceptible to attack. Also inhibition of RNA synthesis 
can occur, though studies on CB1954117 show that the pre- 
vantion of DNA synthesis is the major effect (87% inhibition) 
relative to RNA synthesis (34% inhibition). CB1954 shows 
the highest therapeutic activity yet-known against Walker 
256. Its chemotherapeutic index (CI) hag been found to be 
as high as 70. 
C, = 
LD50 For CB1954 LD50 = 0.4mg/kg 
ED90 ED90 = 28 mg/kg 
However, CB1954 is relatively inactive against other carcino- 
mae, whereas other anti-tumour agents, such as BCNU and 
bis-ethylenene diamine dichloro platinum, have little effect 
88 
on the Walker tumour. These findings suggest that there is. 
a specificity of binding to CB1954 in Walker 256. Metabolic 
118 
studies on CB1937 have shown that reduction of the 2-nitro 
group to an amino function occurs by the action of nitro- 
reductase., and it is thought that this may be the active 
species. However, 2-amino 4-nitro phenyl aziridine shows 
little therapeutic activity itself (CI =1.8). An alternative 
suggestion has been given that CB1937 is partially reduced to 
an azoxy compound which would then, presumably, act as a 
bifunctional al-kylating agent. Although this has an LD50 
value in excess of 1500mg/kg, it is therapeutically inactive. 
'Ij, 
ýý <ý 
U 02 
2,2L-diaziridinyl-5,5Ldinitro azoxy benzene 
Substitution of a second aziridine in the 5-position of CB1937 
produces a compound of low effective dose and an identical 
lethal dose, resulting in a chemotherapeutic index of unity. 
This suggests that, if cross-linking of DNA does occur, the 
effect is not specific for tumour cells and that other 
mechanisms are operative in the anti-tumour activity of 2.4- 
dinitro phenyl aziridines. It appears that both nitro groups 
O-N 
'-plane of reflection 
/N symmetry 
2,4-dinitro-5-aziridino phenyl aziridine 
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are necessary for activity, the aziridine ring imparts 
cytotoxicity to the compound, and the nature of the'S-sub- 
stituent enhances (positively or negatively) the therapeutic 
effectiveness. The equal-proclivity for inhibition of tumour 
and normal tissue displayed by 5-aziridino CB1937 could be 
due to its unusual symmetry. This and other known facts 
about phenyl aziridine biochemistry point to an involvement 
of the 2-nitro group in cell-arresting mechanisms. 
Studies on the mechanism of action of CB1954 
119 
point to 
three cellular processes taking part. These are: - 
(a) that the amide moiety is hydrolysed in vivo to the 
corresponding carboxylic acid (or its anion) which is then 
unable to diffuse extracellularly as it is no longer lipo- 
philic. 
(b) that the 4-nitro group (ortho to. the amide) is reduced 
by nitro reductase to the corresponding amine, which then 
participates in the binding to some cellular receptor. 
This postulate is strengthened by the fact that ortho amino- 
amides such as 4-amino imidazole 5-carboxamide (AIC) and 
anthranilamide reverse the cytoxic effect of CB1954 by 
competing with its reduced form for the receptor site. I 
H2N CONH 
N 
0"; 
ýH 
AIC 
and (c) that a specific binding site exists for 2,4-dinitro 
phenyl compounds, of which CB 1937 and CB 1954 are homo- 
90 
120 121 logues . It is known that 2.4-dinitro phenyl aziridines 
bind reversibly to bovine serum albumin (BSA) protein and a 
similar mode of action may occur'in Walker 256 carcinoma, cells. 
Also it has been noted elsewhere that 2.4-dinitro phenol is 
an inhibitor of mitochondrial phosphorylation. It is there- 
fore possible that other molecules containing 2,4-dinitro 
groups placed relative to electron-pair donating species like 
amino groups-, or even aziridino groups, may interact in the 
same way. It is interesting that one of the metabolites of 
CB1954 is 2.4-dinitro 5-amido phenylamine. 
Therapeutic activity is shown for 2,4-dinitro phenyl aziridines 
where the 5-substituents are potential carboxylic acid groups 
122 For example, amido and cyano groups can hydrolyse to 
the carboxylic acid, and a methyl group can undergo oxidation 
and hydrolysis to give the acid. The fact that the latter 
might not occur readily in vivo may explain the low activity 
of the 5-methyl derivative of CB1937. Ester groups are more 
resistant to hydrolysis under cellular conditions which would 
explain the low activity of methyl and ethyl esters of 5- 
carboxyl CB1937. Lower activity (relative to CB1954) is 
found when the amide nitrogen is substituted by alkyl. groups 
since amide hydrolysis becomes sterically hindered. However, 
the relative lipophilicity of these species is an important 
factor in their overall measured anti-tumour activity. 
There are a number of reactions that aziridines undergo 
which may be relevant to their node of cytotoxic action. 
The attack by nucleophilic agents and protonation of the 
91 
k 
je 
aziridine nitrogen has been-mentioned earlier and will not 
be pursued at this juncture. Another interesting rearrange- 
ment involving ring opening is the isomerism of aziridines 
to afford 5-membered ring compoun s 
123 This also occurs 
in the presence of a nucleophil and is only given by activated 
aziridines. The reaction can be expressed in the general 
form by: - 
-7.7 N E) N 1 Nu 
, (; =x 
so that for carbonyl aziridines, oxazolines are formed: - 
IN Nu 
eN0 
=O ---- > C1 %"( 
RR 
Biological data for the compounds where R0 ON 
0 NJ 2 
N02 
are available 
122 
and both exhibit anti-tumour activity. 
R6sults given below suggest that this might be a de-toxi- 
fication reaction. 
2,4-dinitro phenyl aziridine 
0 
5 
N 
II 
5 -C0 
A 5W ED 90 ci 
30 4 7.5 
90 15 
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Also, the phenyl aziridine itself can Tearrange as follows:. - 
N 02 
R 
Nu . 
60- 
to form a purine-type structure. This gives support to the 
hypothesis that 2,, 4-dinitro phenyl aziridines have anti meta- 
bolite properties of relevance to their activity. 
It is known that 2-amino benzophenones react with aziridines 
to form benzodiazepines: - 
NHR N= 
+ 
'ýN 
10 
ICOAr 
Rl 
cN 
Ar 
The mechanism for this is likely to proceed as follows: - 
R 
H 
)o 
-N 
elp"-l I rHAO -N H4'90; 
\Ar "ý\R 
N 
Ar 
I 
One can propose that anthranilamide, a known inhibitor of 
CB1954p could react in a similar way with an aziridine. 
Mel 07 , -NH :CN 20 
:N 
, C, -NH 
11 
C-N 
lo: 
2R 
Rl 
ýNH 
'(HO-H (d2 
N- 
NH 
2 
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The other inhibitors, AIC and Ph-AIC, might react in an 
analogous manner, thus providing a rationalization for their 
unusual properties toward CB1954 as a result of their 
structural similarity in possession of amido groups ortho 
to amino groups. 
Amide hydrolysis seems to play a r6le in the cellular function 
of CB1954 and its derivatives. The mechanism of aromatic 
amide, hydrol-ysis in acid solution 
124 is likely to proceed 
via protonation of the nitrogen atom, as shown: - 
0 
11 
eq cH E) 
Ar H Fý A 
00 op 
I 
ED 
11 
Ar----'-C 
0H -RNH 
Ar-""'C-, ýE) 
-H 
Ar-, "',., 
c *ýýOH F'o P OH 2 
G OH 2 Acid-catalysed Amide Hydrolysis 
Studies on amide hydrolysis indicate that steric and hyper- 
conjugative effects are more important than polar or 
inductive interactions. It is found that increased electron 
density on the carbonyl carbon atom assists protonation 
by inhibiting nucleophilic attack by water. The maximum 
rate of hydrolysis prevails in acid solutions, whereas in 
alkaline solution, electron-withdrawing substituents favour 
the second order mechanism. Also the rate of amide hydro- 
lysis decreases in the order: 
R=H> Me > Et > Pri > But 
where R is the amide substituent. The activity of N-substituted 
94 
CB1954 analogues decreases in the same order, and corresponds 
to the increase of steric hindrance of the amide nitrogen to 
protonation. Amide hydrolysis in vivo is effected by the 
enzyme w-amidase, present in the-liver, which is responsible 
for the hydrolysis of glutamine and asparagine. 
The fact that amide hydrolysis increases with decrease in 
solution pH indicates that the specificity of CB1954 for 
tumour cells-might be due to its relative ease of conversion 
to the carboxylic acid species. AIC and Phenyl-AIC act as 
competitive inhibitor s of CB1954 as they have amido groups 
capable of similar type of hydrolysis, as does another 
inhibitor, anthranilamide. 
It can be seen that CB1954 successfully exploits the diffe- 
rences between Walker 256 cells and normal tissue cells. I 
The three electron-withdrawing substituents lower the aziri- 
dine nitrogen electron density, thus prolonging its trans- 
port before initiation of its cytoxic effect. This cellular 
transport is assisted by its nearly equivalent solubility 
in-both aqueous and lipid phases. The acid catalysed amide 
hydrolysis of CB1954 in Walker 256 cells prevents extra- 
cellular diffusion and enables the carboxylic acid form to 
react irreversibly with the DNA of the tufnour. There are 
indications that CB1954 or one of its metabolites inter- 
acts with guanine or the guanine-cytosine pair and this 
possibility is pursued elsewhere in this work. 
The mechanism of action of phenyl aziridines is important 
to their cytotoxidity and it is believed that aziridine 
ring opening occurs when nucleophilic species are present. 
gs 
The acid catalysed ring opening of aziridine probably takes 
place via a rdte determining step involving protonation of 
the aziridinb nitrogen atom, as shown below: - 
H 
I 
,,,., 
-N H 
Ar- Ar me 
slow 
Ar.. 'ýH ""ýCH 
CH2 
Ar 
H,, 
".., CH 2ý H 21 2 
About fifty biologically active phenyl aziridines have been 
investigated by Khan and Ross 
122 
and these provide the data 
for a quantitative structure-activity study based on MO 
calculations. Although not used clinically, phenyl 
aziridines are of interest because the most active compound 
is highly selective and specific for one tumour type. An 
unjierstanding of the mode of action of these species can 
provide a basis for anti-tumour drug design based on precise 
differences between various types of cancer cells. 
I 
Molecular Geometry Optimization 
It was necessary to investigate and optimize the aziridine 
ring geometry and preferred molecular conformations of 
phenyl aziridines. Aziridine (ethylenimine) itself is a 
highly strained molecule consisting of a three-membered 
ring of two methylene (CH2) groups bonded to an N-H group 
96 
to form an isosceles triangle as shown. The angle between 
the planes of the CH 2 group and the aziridine ring is twisted 
Figure 4.1 Optimized aziridine ring geometry 
H 
\1. OLý 
0N 
1.475A / \1.475A 
1.084AQ 
1.4 
H 
109.31ý 
N 
. 15.720 
i 
0ý 
slightly out of perpendicular at 87 These results of micro- 
2 
wave spectra indicate a partial sp character of the aziridine 
nitrogen which increases when the hydrogen atom is substituted 
for an aromatic ring. A preliminary MO calculation on phenyl 
aziridine was executed in order to optimize the aziridine 
ring geometry and its conformation relative to the aromatic 
ring. The phenyl ring was assumed to be a regular hexagon of 
carbon atoms of bond length 1.397A and C-H bond length 1.084X 
as standard geometry. The optimization produced a molecular 
geometry of close agreement to the experimental values for 
125 
aziridine with variations as anticipated by the act of 
phenyl substitution. The only constraint on the optimization 
of the aziridine ring was that a perpendicular plane of 
symmetry bisects the plane of the ring. 
ihe 
results are 
. 
collected below as shown (Figure 4.2) and the interplanar 
dihedral angle between CH and aziridine planes optimized at 2 
88.50 was close to the perpendicular. It was of interest to 
ascertain the change in geometry and conformation of the 
aziridine ring when a nitro group is substituted in the ortho 
97 
Figure 4.2 Optimized phenyl aziridine ring geometry 
Ph 
\1 
- 3766R 
N 
1.436 
.. 
8V \1.4368X 
1.114L9/--l. -46-97 -CH2 -1 
Ph 
l. '2356V 
N Ph N 
149.3 
06.20 
position of the, benzene ring as found in all tumour-inhibiting 
phenyl aziridines. The nitro group was assumed to have the 
standard geometry of C-NO 2 1.40X. and NO, geometry as: - 
NO-distance 
0 
- N, 
) 1200 1.24A 
The two adjacent ring constituents were found to be rotated 
out of the plane of the phenyl ring as shown in Figure 4.3 
otherwise the geometry of the aziridine ring remained virtually 
unchanged. 
/ 
-n 
wo"- 14ý7 >c 
\H 
Fi, Rure 4.3 
Ph= N 
153. W'4 
A second nitro group in the 4-position remains in the coplanar 
position relative to the benzene ring and has little or no 
effect on the aziridine ring. However, further ring sub- 
stitution to give the 5-amide as in CB1954, the 4-nitro and 
5-amido moieties prefer to align themselves out of the plane 
98 
of the phenyl ring as shown in Figure4.4. 
I 
0 
I 
Figure 4.4 
A comparison-with the X-ray crystal structure of CB1954 
126 is 
made in the following table. 
I 
Table 4.1 
Bond length X Optimized value X-ray structural value 
N(Az) - C(Ph) 1.377 1.391 
C(Az) - C(Az) 1.470 1.477 
C(Az) - N(Az) 1.437 1.474 
Bond angle 0 Optimized value X-ray structural value 
C(Az) - N(Az) - C(Az) 61.5 60.1 
C(Az) - N(Az) - Ph 123.6 122.6 
Dihedra l angle 0 Optimized value X-ray structural value' 
Az(ring) - Ph(ring) 113.9 133.4 
2-NO2 - Ph(ring) 79.3 26.3 
4-NO2 - Ph(ring) 68.9 13.6 
S-CONH 2 - Ph(ring) 84.7 
64.7 
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The MINDO/3 optimized geometry for CB1954 agrees reasonably 
well with the experimental geometry. The greatest discrepancy 
is in the twist-angles of the two nitro groups and this may 
be due to the fact that MINDO/3 overestimates the rotation 
2 
about two sp centres. It is possible, however, that steric 
interactions in the solid state are rather different from 
those encountered in the'gas phase-(since MO calculations 
assume no intermolecular interactions). The results of the 
optimized molecular geometry-of CB1954 were taken as bases 
for the remaining compounds in the series where amide sub- 
stitution occurs. Molecular orbital calculations were carried 
out on neutral and protonated phenyl aziridines. The proton- 
ated aziridine ring geometry was optimized to the minimum 
,. energy configuration and results showed the expected changes 
-, in geometry for a trend towards a tetrahedral environement 
of the aziridine nitrogen atom, i. e. a change in hybridization 
-j, from sp 
2 to SP3. The optimized geometric parameters are given 
-in 
Table 4.2 and Figure 
Protonated Aziridine Ring 
Tible 4.2 
Bond Bond length X 
N(Az) - C(Ph) 1.453 
C (Az) -C (Az) 1.459 
C (Az) - N(Az) 1.493 ? 
-H 1.04 
Figure 4.5 H 
10 
V1.04AQ 
Ph _1 . 
4.5.3- N 
459R 
Bond Bond angle 
C(Azý - N(Az) - Ph 126.2 
H- N(Az) - C(Ph) 107.8 
Planes Dihedral angle 
/11ý 
r ing 
288.5 
Az6ring) - Ph(ring)111.5 
H-N(., kz) - ph(ring) 288.5 
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Phenyl aziridines for which biological and physico-chemical data 
were available were divided into four series of compounds of 
similar general structure. On the whole structure-activity 
relationships have been formulated for each series, though it 
was found that some relationships were valid for two or more 
series of compounds. Molecular orbital calculations were 
executed on these compounds, and on their protonated counter- 
parts, using the MINDO/3 method. The electronic parameters 
obtained were correlated with the biological parameters, LD501 
ED 90, and CI, obtained 
by Khan and Ross 
122 
a It was also of 
interest to subject the physico-chemical parameters, partition 
coefficients and rate constants, to regression analysis. 
The ether/water partition coefficients (P) were used to obtain 
the log P hydrophobic parameters and the rate constants (k) 
for a nucleophilic reaction with iodide ionsinacid medium were 
employed to obtain log k values as estimates of the alkylating 
reactivities. Details of the compounds used in this study 
are given below in Table 4-3-A number of inactive compounds 
were omitted. as their inclusion would give an undesirable bias 
to the correlations produced. 
In addition, two molecules were analysed for which biologi- 
cal and chemical data were not known in an, attempt to predict 
their biological activity on the basis of existing relationships 
between electronic structure and activity. 
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Table 4.3 
teries 
6eneral 
RI 
2 
N 
1ýbmula 0'%ýN 
--, 0, 
CýýN 
-- 
I 
0zN 
I 
N-alkyl 2,4-dinitro 5-amido phenyl 
kame 2-nitro phenyl aziridines aziridines or N-alkyl CB1954 
derivatives 
40. 
of Members 12 8 
R, H CN N02 N02, N02 N02 N02 N02 Rl H Me Et Pr n Pr 
i 
Pr'y Bu 
i 
Bu t 
. 
R2 HHH CONH2 CN CH3 NJ C02H 
ents 
ýdstitu 
R, N02 N02 N02 N02 
1ý C02Me C02Et NHC02Et C"O: l 
terles IV 
0 0 x 
eneral 
N 
c "ýýNHX 
N02 
00ý-CONHO 
t*Ormula .0 02N 
0N N 
N-pbenyl 2,4-dinitro 5-amido phenyl 
laze N-methylene, derivatives of CB1954 aziridine or N-phenyl CB1954 
derivatives 
io. of Members 12ý 14 
X-(CH2)- Pecy (CH2)2Ph (CH2)2Cl CH2Ph X' H 2-Me 3-Me 4-Me 2,5-diMe 3-OMe 
5 
-(CH2)- CH2CN (CH2)20H CH2CH(OMe)2 4-OMe 4-COMe 4-OH 4-r 4-Cl 
UbStituents 
2 
CH2CH(014)CII2014 CH2CH=CH, Cl12C=-'CH 2-CONH2 4-CONH2 4-NMe2 
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Results of MO calculations and Regression Analyses 
Discussion of Conformational Results 
One of the interesting results of MINDO/3 calculations is 
that of the optimized conformation of the most active com- 
pound in the series, CB1954. It appears that the stereo- 
chemistry of the minimum energy conformation of CB1954 is 
such that, if it were to enter into a receptor complex with 
some biologi-cal macromolecule, the oxygen atoms of the nitro 
and amido groups would be expected to participate in the 
interaction. Binding studies suggest that the planar face 
of the molecule is presented to the receptor when complex 
formation occurs, and this would lead one to postulate a 
receptor-substrate complex as shown in Figure 4.6. 
Figure 4.6 
Hypothetical alignment of 
CB1954 with a receptor 
molecule (showing the 
nitrogen non-bonding 
electrons) 
The aromatic 7r-electron molecular orbital would also penetrate 
the receptor site and therefore, one might expect that the 
a- romatic ring carbon electron density, as well as those of 
the nitro and amido group oxygen atoms, to be a measure of 
the strength of binding between substrate and receptor. It 
will be seen later that this view is substantiated by corre- 
lations of these electron densities with therapeutic activity. 
An' alternative mode of binding may involve N-0-0 triangulation. 
This structural feature, consisting of a triangle made by two 
oxy I gen atoms and one nitrogen, is a well-known molecular 
fragment in many anti-tumour compounds. It is thought that 
N-0-0 triang ulation is responsible for binding to a critical 
receptor involved in tumour cell multiplication. The inter- 
atomic distances of the N-0-0 triangle in anti. -tumour agents 
127 lie in the following range: 
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Atoms Range (X) CB1954 values (X) 
0 1- 02 
N- 01 
3.35 -+ 0.65 
7.08 -+ 0.56 
3.74 0(4-NO 2) - O(CONH 2) 
5.62 N(Az) - O(CONH 2) 
N- 02 '8.62 
-+ 
0.58 6.28 N(Az) - 0(4-NO2) 
It can be seen that the 0 1-0 2 distance in CB1954 lies within 
the range, whereas the N-0 distances are slightly shorter 
than for most other anti-tumour drugs. However, in CB1954, 
a 4-point attachment may occur if the 2-nitro group is in- 
corporated into the scheme, and assuming that protonation 
of the aziridine nitrogen is established in tumour tissue, 
the altered geometry would bring about a different mode of 
interaction. 
The molecular electrostatic potential energy contour map (p. 177) 
abovethe plane of the benzene ring for CB1954 indicates a 
4-point attachment to a cellular receptor site,, and it is 
thought that a DNA interaction is important to the action 
of this anti-tumour drug. There is evidence to suggest that 
guanine or adenine is involved in this interaction, and 
ýCB1954, or one of its metabolites, may bind to one or two 
. of 
the base pairs present in DNA. Molecular modelling of 
-CB19S4 and DNA shows that the most likely state of affairs 
is as shown in Figure 4.7. 
104 
H 
Figure4.7Possible mode of interaction between guanine and 
CB 1954. 
Results for Series I Compounds 
For the group of substituted 2-nitro phenyl aziridines of 
general formula shown in Figure 4.8 , seven members'were 
found to have chemotherapeutic acitivity. In addition, the 
parent compound 2-nitro phenyl aziridine has been included 
for toxicity and rate constant correlations. A further 
four inactive species have been included to provide a base 
line for zero activity. 
FiRure 4.8 
General-7-ormula for 
Series I members 
(showing numbering 
system adopted in 
the text) 
Molecular geometries were optimized, where necessary, 
during the MINDO/3 procedure and MO parameters have been 
tabulated from the respective output of results. It is 
105 1 
convenient to show, at this stage, chemical and biochemical 
parameters for Series I compounds in Table 4.4. 
Table 4.4 Series I Chemical and Biochemical Parameters 
Compound log 1/LDSO log 1/ED90 log CI log k6.5 log PE 
2NO2 -2.6021 3.3618 1.46 
2NO 2 4CN 
2,4 N02 
it SCONH 2 
it SCN 
-2.6021 -1.9031 0.699 2.2742 1.88 
- -2.3541 -1.3424 1.000 2.143 1.48 
-1.4472 
-1.7782 
0.4 1.845 1.9085 -0.28 
-1.4771 0.301 2.2305 0.91 
SMe -2.3979 -2.3 0.06 2.2601 1.81 
SNI - 0.6021 -0.6021 0.00 2.4698 1.00 
5_ CIý, IN '0 -1.9542 -0.7782 
1.176 - 1.06 
SC02H <-3.1761 - 2.1139 
5CO 2Me -2.861 - 2.0792 inactive 
5C02Et <-3.2041 - 2.0294 species 
SNHCO Et 2 -1.0531 - 2.1987 
Key: k 6.5 refers to the rate constant 
for reaction with 
Iodide at pli 6.5 
PE refers to the ether/water partition coefficient 
LDSO, ED 90, and CI 
have been previously defined on page 20. 
1 
Of primary interest, for the purpose of obtaining correlations 
with chemical and biochemical parameters, are the net atomic 
charge densities as shown in Table 4.5. General trends 
shown in these results are that the aziridine ring atoms 
(1,8 and 9) are relatively unaffected by changes in the 
aromatic ring substituents, whereas the'aromatic ring carbons 
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(2 to 7) exhibit. -s-ome. differences (especially 5,6 and 7). 
with substitution in the ring. The results for the 2-nitro 
group (atoms 14,15 and 16) show a greater dependency on 
biological parameters than those of the 4-nitro group 
(atoms 19,20 and 21). The orbital energies of the so-called 
frontier orbitals, that is the highest occupied MO(HOMO) and 
lowest empty MO(LEMO), are also of interest. These are tabula- 
ted below in Table 4.. 6. 
Table 4. -6 Se 
I 
ries I Frontier Orbital Energies (eV) 
Compound E(HOMO) E(LEMO) 
2NO 2 -8.4059 0.2101 
2NO 2 4CN -8.4539 0.0045 
2p4 N02 -9.1952 -0.9185 
it 5CONH2 -9-2346 -0.8740 
it 50 -9.1528 -0.8848 
it SMe -9.0475 -0.5362 
it 5N 8.9673 -0.4400 
it 5 CýN 
N 
0] -9.1298 -0.7560 
Frontier orbital energies correlate well (in conjunction 
with other electronic parameters) with log CI and, to a 
le 
1. 
sser extent, with log l/LD Soo By inspection, it can be 
I 
seen that the 5-amido compound (CB1954) has the most nega- 
tive HOMO energy and it is also the most active thera- 
peutically. It-is of interest to note that Mo calculations 
of DNA bases show that both adenine and guanine have frontier 
orbital energies close to -9.2eV. 
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Frontier orbital electron population densities have been 
successfully applied in correlation expressions with log k, 
log CI and, in particular, to log l/LD. The latter is found 
to be closely related to the frontier electron densities of 
carbon atoms 6 and S. Tables 4.7 and 4.8 show values for 
HOMO and LEMO electron densities. Table 4.9 shows the 
energetics terms (including dipole moments) of which heats 
of formation CHf), electron energy (E. E. ) and core repulsion 
energy, correlate with log k and log l/LD. 
The bond energies of the molecular skeleton hair-e been in- 
vestigated for possible correlations and log k has been found 
to be dependent on the bond energy between aromatic carbon 
atoms 5 and 6. The results are shown in Table 4.10. Perhaps 
the most striking feature of Table4 . 10is the constancy of 
the aziridine C8-C9 bond energy which remains about 14.219eV 
throughout the series. The bond energies stay fairly constant 
in the aziridine ring, but a change in the aromatic ring sub- 
stituents brings about variations in bond energy for carbons 
5, 
,6 
and 7. The changes in bond energy between C6 and C 22 for 
the 5-cyano and 5-methyl derivatives show the differehces in 
the effects for an electron-withdrawing group (CN) and an elec- 
tron-donating one (CH 3 ). There is a 7% d, ifference in the 
bond energies, whereas inspection of the atomic charges on 
C6 exhibit a 12% increase in electron density in going from 
-CN to -CHY It can also be seen that the methyl group acts 
ortho/para in the aromatic nucleus., whilst the cyano group 
shows a meta effect. 
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Table 4-. 7 Series I. Frontier Electron Densities 
Highest Occupied MOs 
Compound N(l) C(8) C(9) C(2) C(3) C(4) C(5) C(6) C(7) 
, 
2N02 0.8337 0.0410 0.0202 0.1115 0.2072 0.0469 0.3048 0.0145 0.2471 
2NO24CN 0.7468 0.0385 0.0173 0.1149 0.2001 0.0562 0.3153 0.0205 0.2277 
2,4NO2 0.8601 0.0391 0.0248 0.0634 0.2115 0.0149 0.2420 0.0048 0.2586 
5CONH2 0.8533 0.0365 0.0239 0.0707 0.2199 0.0208 0.2916 0.0128 0.2378 
11 5CN 0.8606 0.0373 0.0238 0.0713 0.2202 0.0211 0.2926 0.0107 0.2397 
5Me 0.8658 0.0384 0.0235 0.0741 0.2211 0.0226 0.2990 0.0087 0.2424 
0.7986 0.0389 0.0232 0.0633 0.2911 0.0106 0.3567 0.0107 0.1640 
5CO2H 0.4320 0.0189 0.0120 0.0342 0.1095 0.0105 0.1446 0.0062 0.1195 
5C02Me 0.4303 0.0188 0.0121 0.0353 0.1113 0.0105 0.1466 0.0058 0.1173 
1151C02Et 0.4283 0.0184 -0.0119 0.0361 0.1108 0.0111 0.1471 0.0061 0.1173 
5NHC02Et 0.4355 0.0196 0.0123 0.0328 0.1069 0.0095 0.1439 0.0035 0.1270 
5_CN 
1 0] . 
0.8652 0.0382 0.0240 0.0729 0.2095 0.0232 0.2842 0.0093 0.2529 
-. Table . 4.3 Series I. Frontier Electron Densities LEMOs 
Compound N(l) C(S) c(9) C(2) C(3) C(4) C(5) C(. 6) C(7) 
2NO2 0.0355 0.0384 0.0070 0.1901 0.4702 0.2942, 0.0454 0.5495 0.1395 
211024CN 0.0716 0.0751 0.0142 0.3961 0.3911 0.0683 0.1641 0.5584 0.0403 
294NO2 0.0829 0.0638 0.0089 0.5017 0.0361 0.1959 0.2504 0.2952 0.0238 
" 5c ONH2 ý 
0. 
- 
0575 0.0435 0.0065 0.3513 0.3512 0.0395 0.1965 0.6224 0.0760 
- 
5CN 0.0389 0.0301 0.0039 0.2365 0.3969 0.0990 0.1457 0.6027 0.0289 
5me 0.0582 0.0543 0.0093 0.3347 0.3999 0.0929 0.1435 0.6235 0.0807 
5N: 
1, 0.0924 0.0978 0.0233' 0.3449 0.2193 0.0505 0.1437 0.4723 0.0358 
SC02H 224 0.0 0.0162 0.0027. 0.1354 0.2123 0.0463 0.0791 0.3296 0.0741 
SC02Me _ 0.0193 0.0013 0.0065 0.1194 0.2051 0.0502 0.0740 0.3233 0.0798 
SC02Et 0.0199 0.0115 0.0015 0.1248 0.2051 0.0513 0.0722 0.3214 0.0747 
51THQQ2Et 0.0264 0.0232 0.0033 0.1596 0.1930 0.0463 0.0666 0.3221 0.0425 
O. OS38 0.0502 0.0082 0.2994 0.3992 0.0879 n-l; po 0.6142 OJO 4 
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Table 4.9 Series I. Energy Terms and Dipole Mome ts 
Compound Hf(kcal. mol-1) 
. 
E. E. (eV) Core replý(eV) T. E. (eV) I. P. (eV) 11 (D) 
2NO2 44.035- -10501.17 8365.80 -2135.37 8.4509 5.4025 
2NO24CN 66.962 -12420.32 9981.42 -2438.91 8.4539 5.2863 
2,4NO2 34.005 -15055.77 12123.01 -2932.76 9.1952 7.3259 
5CONH2 -20.836 -20251.07 16672.22 -3578.84 9.2346 8.3746 
5CN 54.376 -17440.62 14204.22 -3236.40 9.1528 6.5980 
5Me 32.414 -16859.79 13770.55 -3089.24 9.0475 6.9982 
5NI 61.512 -20053.68 16631.65 -3422.03 8.9673 7.4249 
5CO2H -54.006 -20368.30 16685.54 -3682.76 9.3344 8.0511 
" 5CO2Me, -45.575 -22200.80 18361.99 -3838.80 9.2669 7.3762 
" 5CO2Et 27.146 -24001.72 20009.66 -3992.06 9.1701 7.5225 
" 5NHC02Et -67.917 -25991.83 21788.47 -4203.36 9.1118 7.0458 
to 5N 0.967 -23SO3.67 19642.49 -3861.19 9.1298 
Table 4.. I, )Series I. Bond Energies (eV) 
Aziridine ring bonds Aromatic ring bonds R subst. 
d 1' 1-2 1-8 1-9 8-9 1 2-3 ý3-4 
4-5 5-6 6-7 2-7 6-22 
16.999 13.234 13.338 14.219 19.692 19.944 20.502 20.120 20.504 19.793 
17.072 13.216 13.322 14.219 19.658 19.986 19-991 19.623 20.560 19.743 
17.429 13.147 13.254 14.221 19.565 20.430 20.137 19.720 20.827 19.662 
17.330 13.153 13.261 14.219 19.573 20.250 20.193 19.322 20.306 19.594 14.895 
17.312 13.159 13.268- 14.219 19.571 20.241 20.257 19.446 20.248 19.679 16.529 
17; 297 '13.169 13.279 14.219 19.594 20.270 20.272 19.553 20.462 19.723 15.318 
17. , i5'3 13.180 13.288 14.219 19.575 20.448 20.456 19.519 20-166 20.208 17.202 
17.364 13.140 13.248 14.216 19.566 20.224 20.185 19.259 20.274 19.540 14.962 
17.336 13.147 13.253 14.219 19.571 20.219 20.200 19.348 20.310 19.553 14.868 
17.316 13.154 13.259 14.219 19.574 20.214 20.206 19.342 20.308 19.563 14.826 
17.400 13.151 13.257 14.218 19.596 20.354 20.290 19.864 20.653 19.787 15.722 
17.305 13.160 13.269 14.218,19.582 20.239 20.217 19.4SO 20.371 19.626'14.694 
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Multiple-Regression Analysis on Series 1 
The MO parame 
, 
ters which display the best correlations with 
biological and chemical data are shown in Tables 4.11 to 4.13. 
Table 4 11 Series I. Log k correlations 
ýSet Independent Variables Parameters R F P D. r. Data Points 
HOMO Q6 Q9 
LEMO Q99 Q4 0.910 14.457 >0.005 2 and 6 8 
Q4 LEMO ý B. E. 
(5,6) Q4 LEMO 0.859 19.728 >0.0025 1 and 7 8 
-B. E. (5,6) 0.869 21.537 =0.0025 1 and 7 8 
r2- 
E Prot (= Hfprot-Hf) E Prot 0.77489 12.02288 <0.01 I and 8 10 
E Prot- 0.77605 13.62725 =0.005 1 and 9 11 
Table 4.12 Series I. Log CI correlations 
Independent Variables Parameters R F P D. F. Data Points 
Q7 LEMO Q6 Q7 
LEMO 
, Q6 0.992 46.260 =0.005 4 and 3 8 1, 
Q99 Q6 HOMO Q99, Q6 
HOMO 
Q7 LEMO 3, Q6t Q9 0.983 37.378 <0.0025 3 and 4 8 
Q3* Q69 Q7 Q35 Q9 0.99474 23.55939 >0.1 4 and 1 6 
Q99 Q7 LEMO Q62 Q7 
LEMO 
Q149 Q159 Q39 Q6 Q159 Q7 0.99997 3596.88978 <<0.025 4 and 1 6 
LEMO Q79 Q9, Q7 
LEMO Q6ý Q7 
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Table 4; 13 Series I. Log 1/LD correlations 
0 
Set Independent Variables 'Parameters RPD. F. Data Points 
Q6 HOMO Q8 HOMO Q8 HOMO 0.94739 43.80589 <0.0025 1 and 5 7 
Q1 HOMO E. E. 
From the results of log k regressions(Table 4.11) it is evident 
that log k is dependent on the bond energy between carbons 5 
and 6. and tcr a- lesser extent, on the Q (4) LEMO value and Q (9)in 
the aziridine ring. As the reaction (described by k) involves 
attack on the aziridine ring, the presence of a correlation 
with electron density of its atoms is not surprising. However, 
the significance of Q(4)and the C S-C6 bond energy is less 
obvious. It can be seen that the inclusion of Q(3), Q(6) and Q(7) 
into the regressions gives no improvement in the correlation. 
The relationship between log k and E(prot) are discussed in 
more detail in the section dealing with reaction kinetics and 
protonation studies on phenyl aziridines. 
With the log CI correlations (Table 4.12) the effects of in- 
cluding more MO parameters can be seen. In the first set, the 
more statistically significant regression is that involving 
Q(7)LEMO, Q(6) and Q(9) -Introduction of Q(3) into the regression 
gives a better correlation coefficient, být the F and p values 
are less favourqble. When Q(14)dndQ(15)are included (Set 3) a 
good resul t is obtained. This indicates that the 2-nitro group 
(ortho to aziridine) has some bearing on the therapeutic 
action of this series, possibly by participating in the inter- 
action with a specific bio-receptor. The presence of the 
electron density of an empty frontier orbital (Q(7)LEMO)suggests 
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that charge transfer-occurs in the binding, where charge is 
donated from the receptor into the empty MO on the substrate 
molecule. 
Table 4.13 shows the correlation between t6x'-city, measured 
by log l/LD and the frontier electron density (HOMO) of C8 
in the aziridine ring. This is a very encouraging result 
since it shows the importance of HOMO frontier orbitals in 
the toxicity-of-phenyl aziridines and should lead to a means 
of predicting toxieities of unknown derivatives. As HOMO 
frontier orbitals do not figure very highly in regressions 
of chemotherapeutic index (which appear to be dependent on 
LEMO and total charge densities), it is reasonable to assume 
that there is a marked difference in the bio-mechanism of 
phenyl aziridines toward normal cells and Walker carcinoma 
cells. 
Results of MO calculations for Series II molecules 
Series II consists of a group of alkyl N-substituted 2,4- 
dinitro 5-amido phenyl aziridines of general formula shown in 
Figure 4.9. 
I Figure 4.9 
General formula 
for Series II 
(showing numbe- 
ring system) 
/\ 89 
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MINDO/3 calculations were run for this series using the 
optimized geometry of 2,4-dinitro 5-amido phenyl aziridine 
and substituting the various alkyl groups for one of the 
amide hydrogens, then optimizing the orientation of each 
substituent. Chemical and biochemical data are shown in 
Table 4.14. 
Table 4.14 Series II. Chemical and Biochemical Parameters 
Compound log'E-Dso log EDqo log CI log k6.5 log PE 
R' H -1.4472 0.4 1.845 1.9085 -0.28 
Me -1.4771 0.1 1.60 1.9542 -0.06 
Et -1.4472 0.0 1.48 2.0453 0.301 
Pr n -1.4771 -1.0 0.48 1.8451 0.73 
Pr -1.2041 -0.2 1.00 2.1106 0.65 
Prcy -1.4771 0.0 1.48 2.0934 0.23 
Bu 
i 
-1.6532 -0.95 0.70 2.0170 1.15 
Bu t -1.8451 -1.3 0.54 2.2095 1.48 
115 
Previously, it has been found that log CI and log I/ED are 
related to log k and log P. Therefore, it has been of inter- 
est to equate electronic terms with these parameters. In a 
similar manner to series I, MO calculated data for Series II 
is presented. Electronic parameters for the amido group are 
included because of their importance to correlations with the 
activity of this series. Tables A. Jý to 4.20 show similar 
parameter sets to Series I, whereas Table4.21shows electronic 
polarizabilities, PE, electrophilic superdelocalizabilitiest 
Is 
El and total-atomic charges, QT* 
Table 4.21 
RI I PE I QT I ISE 
H 0.0171 7.6711 5.7695 
Me 0.0569 7.6985 6.1795 
Et 0.0930 7.7358 6.5733 
Prn 0.1316 7.9373 6.9675 
Prl 0.1168 7.7681 6.9604 
Prc" 0.1355 7.6455 6.8591 
Bui 0.1452 7.9224 7.3583 
But 0.188T 7.8700 7.9883 
I 
The PE values were obtained by summation of the HOMO frontier 
orbital coefficients over the atoms of the amide substituent 
group RI. This can be expressed as: - 
k HOMO where i refers to atoms and k PE Ci is the set of atoms 
comprising RI 
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Table 4.16 Series II. Atomic charges 
N(14) 0(15) 0(. 16) N(19) 0(20) 0(21) 
If 1.0977 -0.5677 -0.5774 1.0895 -0.5853 -0.5499 
Jýe 1.0982 -0.5686 -0.5783 1.0906 -0.5875 -0.5514 
7zt 1.0983 -0.5690 -0.5787 1.0911 -0.5882 -0.5519 
prlý 1.0984 -0.5693 -0.5789 1.0913 -0.5884 -0.5523 
1.0985 -0.5693 -0.5789 1.0915 -0.5887 -0.5525 
Prc 1.0982 -0.5687 -0.5783 1.0906 -0.5870 -0.5515 
13U 1.0985 -0.5693 -0.5790 1.0914 -0.5886 -0.5523 
P, ut 1.0985 -0.5696 -0.5789 1.0915 -0.5883 -0.5536 
Table . 4.17 Frontier Orbital Energies 
Rl E(HOMO)eV E(LEMO)eV 
H -9.234618 -0.874019 
Me -9.183049 -0.814160 
Et -9.159630 -0.785611 
pr n -9.146493 -0.769707 
Pr 
i 
- 9.145635 -0.770213 
Pr c -9.176722 -0.811446 
Bu 
i 
- 9.144840 -0.768063 
Bu t - 9.133257 1 -0.760074 
Table 4.1E, Series II. Energetics data and Dipole Moments 
Rl Hf (kcal mol-1) E. E. (eV) Core repP(eV) T. E. (eV) I. P. (eV) 11 (D) 
H -20.836 -20251.07 16672.22 -3578.84 9.2346 8.3746 
Me -7.676 -22111.25 18376.57 -3734.57 9.1830 8.3824 
Et -16.670 -23913.72 20022.28 -3891.44 9.1596 8.4739 
Pr n -19.194 -25641.31 21593.31 -4048.00 9.1465 8.4895 
Pr i -15.074 -25944.54 21896.72 -4047.82 9.1456 8.4199 
Pr c tl. 840 -25205.74 21188.18 -4017.56 9.1767 8.4572 
Bu -13.479 -27690.88 23486.72 -4204.16 9.1448 8.4704 
Bu t -0.031 -28219.24 24015.66 -4203.66 9.1333 8.3052 
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QT values are the totals of the net'atomic charges for the 
whole molecule andISE are the total electrophilic super- 
delocalizabilities. These parameters have been defined 
elsewhere in this work since they have been employed in 
other structure-activity relationships with the hydrophobic 
parameter, log P, for other series of compounds. 
Multiple Regression Analysis on Series II 
By an analogous procedure to Series 1, multiple regressions 
were carried out using MO data and log k, log P and log l/LD 
values as measures of alkylating reactivity, therapeutic 
activity, partitioning capability and toxicity, respectively. 
MO calculations were also done on protonated molecules where 
a proton is bonded to the aziridine nitrogen atom and the 
computation re-run with this inclusion into the molecular 
geometry. Tables 4.22 to 4.28 show the correlations for log k, 
log CI, log 1/LD and log P. Series I and II have been 
combined for the log k and log 1/LD correlations. 
Table 4.22 Series I and II log k regressions (Table 4.29 for data) 
Pariameters RFPD. F. Data 
points 
Series I E(Prot)=Hfprot-Hf 0.935 49.06 <0.001 1+7 9 
Series I E(Prot) 
and II 
0.930 82.90 <<0.001 1+13 15 
I 
Table 4.23 Series II log P -regressions 
Parameters R F p D. F. 
F'E(electronic 0.984 149.56 <<0.001 1+ 5 7 
polarizability) 0.910 28.73 <0.0025 1+ 6 8 
SE 0.969 92.21 <0.001 1+ 6 8 
SE QT 0.992 149.35 <0.001 2+ 5 8 
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The graphs shown in Figures -4.10 to 4.13 show the linear depen-. 
, 
dence of log k upon E(prot), log P against PEP log P against 
Is 
El and log CI against 
IQT, respectively. For protonated 
molecules, the following regression against log. I/ED appeared. 
-Table 4.24 Series II log 1/ED regressions 
Parameters RFPD. F Data 
points 
I 
Q(16), Q(5) Q(23) 0.998 90.25 2! 0.0 1 5, Z. 8 
Q(O)E(LEMO) 
Table A-. -ZS 
Series II. Log k correlation 
Parameter R D. F. Data 
I 
Points 
a-, 'C 0.9621 124.4776 0.001 1 and 10 12 
including 
I 
Series I 
Data used for this correlation was obtained from values for the Taft 
substituent parameter, 0*. These are shown below: - 
Substituent 0* Substituent (I* 
5-CONH2 0.27 2,4 N02 0.0350 
N-Me 0.22 5CN -0.1275 
N-Et 0.17 5N -0.6002 
N-Pr n 0.15 2NO24CN -0.0825 
i 0.08 N-Pr 
N-Pr c 0.17 
N-Bul 0.14 
N-Bu t -0.03 
r. 
0 
.H 
41 
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94 
0 
I-1 
0 
1-; D 
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Figure 4.10 
DEPENDENCE OF LOG K ON PROTONATION ENERGY 
FOR SERIES I AND 11 PHENYL AZIRIDINES. 
E(PROT) 
12 ý 
I 
Table 4.29 Heats of Formation. Series I, II (kcal mol-1) 
Protonation Energies (E pr2t) and log k values 
Compound Hf Hf Prot 
E Prot log k (kcal mol-1) 
Series I 2NO2 44.035 200.023 155.988 3.3618 
2NO24CN 66.962 224.367 157.405 2.2742 
2s4NO2 34.005 200.942 166.937 2.1430 
it 5CONH2 -20.836 150,021 170.957 1.9085 
5CN 54.500 223.369 168.869 2.2305 
it 5Me 32.414 199.543 167.129 2.2601 
511 61.512 225.267 163.755 2.4698 
5CO2H -54.006 118.769 172.775 2.1139 
5CO2Me 45.575 125.531 171.106 2.0792 
5CO2Et 27.146 195.969 168.823 2.0294 
5NHC02Et -67.917 98.978 166.895 2.1987 
-N 5-C 0.967 168.532 167.565 (2.0792)* 
Series I Me -7.676 161.743 169.419 
Et -15.670 153.087 168.757 2.0453 
j Pr n -19.194 149.162 168.356 1.8451 
prl- -15.074 153.244 168.318 2.1106 
c Pr 1.840 170.786 168.946 2.0934 
i 
Bu -13.479 154.761 168.240 2.0170 
t Bu -0.031 167.891 167.922 2.2095 
*estimated 
Figure 4.11 
IIEPENDENCE OF LOG P ON ELE. CTRONIC POLARIZABILITY OF 
ATAIDE SUBSTITUENT FOR SERIES 11 PHENYL AZIREDINES 
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Figure 4.12 
Relationship between log partition coefficient and the sum of 
electrophilic superdelocalizabilities for substituent groups 
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ýRegression Equations 
The following equations, derived from correlation analysis, 
'de a good explanation of the data for Series I and II provl 
, compounds. These can 
be used as a basis for predicting anti- 
tumour, activity and toxicity of untested phenyl aziridines. 
Series I 
Eqn. Relationship nSRF 
4.1 log k= 3.67Q(4)LEMO-159.2Q(9)+22.18 8 0.2187 0.910 14.457 
4.2 log k= 4.21Q(4)LEMO+1.848 8 0.2307 0.859 19.728 
4.3 log k= -1.40 BE(5,6)-25.04 8 0.2233 0.869 21.537 
4.4 log k= -0.055 E(PROT)+11.49 11 0.2578 0.776 13.627 
4.5 log k= 1.658 E(HOMO)+17.31 8 0.0737. 0.988 254.989 
4.6 lo7g CI 163.36Q(9)-16.31Q(7)LEMO 8 0.1256 0.992 46.260 
-3. OSQ (6)+5.24Q (6) HOMO- 20.46 
4.7 169 C, 161.22Q (9)-20.07Q (7)LEMO 8 0.1598 0.983 37.378 
-2.91Q(6) - 20.07' 
4.8 l6g -ýCI 56.74Q(9)-14.40Q(7)LEMO 6 0.1604 0.9947 23.559 
-18. SOQ(6)+51.77Q(3)-82.58 
4.9 log CI -70.27Q(15)-16.87Q(7)LEMO 6 0.01304 0.99997 3596.9 
-23. OOQ(6)+36.39Q(7)+40.57 
4.10 J? gýl/LD -254.97Q. (8)HOMO+7.61 7 0.2604 0.947 43.806 
L" ýnd II 
Eqn. ' 
- 4.11 log,,, l/LD = -256.83Q(8)HOMO-136.40Q(6) 15 0.4531 5 0.8178 5.5 
HOMO+3.94B(HOI. 10)+7.29Q(1)HOý10442.51 
4.12 10 
1gk= 
-0.0855 E(PROT)+1.6.54 15 0.1327 0.9298 82.90 
4.13 169 L/LD = -177.74Q(S)HOMO+21.06Q(3) 15 0.2237 0.9342 41.14 
HOMO+0.1476 
4.1"4-1 log 1/LD = 139.85Q(8)HOMO-125.42Q(l) 15 0.1669 0.9731 32.07 
(protonated) 
HOMO+19.68Q(7)BOMO-12.49Q(3)HOMO 
-11.33 0.7 6E (HOMO) 
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Discussion on the Regression Equations 
, 
portune to derive some conclusions from the It is now op 
results of the preceding correlations, while taking stock of 
the significance of some, and discarding those which might 
have arisen by pure chance. The emerging pattern shows 
that different areas of the phenyl aziridine moleculeare 
responsible for toxic and therapeutic effects. Log l/LD is 
found to be negatively dependEFht on Q(8)HOM'O fQr Series I, (Fig. 4.14) so 
low toxicity is favoured by a relatively high electron 
density in the highest occupied MO on theaziridine ring 
carbon, C(8). The other aziridine carbon atom, C(9) does 
not appear in the log 1/LD regressions and it is not imme- 
diately obvious how this can be explained. The only major 
difference between the. two caybqns is in their relative 
orientation in space. Due to the dihedral angle of 25 0 
between the aziridine and aromatic rings, C(S) lies further 
below the ring than C(9) and perhaps the lower C(S) atom is 
attacked preferentially by cellular nucleophils. It is 
also interesting to note that HOMO electron densities are 
markedly higher for C(8) relative to C(9). When Series II 
members are included, toxicity becomes dependent upon other 
HOMO parameters viz... Q(6) HOMOO Q(3)HOMO, Q(1)HOMO, and 
E(HOMO). High electron density on the aziridine nitrogen, 
N(l), favours high toxicity and this would be expected since 
the postulated reaction mechanism involves protonation of 
that nitrogen. Likewise, a relatively high energy (less 
negative) of the HOMO brings about high toxicity. When 
protonated species are employed for correlations with log l/LD, 
HOMO coefficients still appear in thd regressions which 
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Figure 4.14 
Relationship between log 1/LDSO and Q(8)HOMO Series I 
(S) HCr, 40 
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involve az 
. 
iridine atoms N(l) and C(8), together with phenyl 
ring atoms C(3) and C(7). This indicates the prime importance 
of the aziridine ring in the toxic effect of phenyl aziridinel- 
together with other ring carbons. In particular, the regression 
involving Q(3) and QCS) for unprotonated molecules shows the 
grea - test statistical significance which suggests that aziridines 
are probably neutral species when exerting their toxic action. 
The dependence of log k on E(HOMO) indicates that the rate 
of nucleophilic reaction varies with the position of the highest 
occupied MO, such that the less negative the value of E(HOMO) 
the faster the reaction. Since the HOMO frontier orbital 
involves electron donation to an electrophilic species, the 
evidence suggests that protonation of the aziridine nitrogen 
is the rate-determining step. Also log k is negatively 
dependent upon protonation energy: that is, a slow reaction 
corresponds to a high E(PROT) value. This is to be expected 
as the overcoming of a large energy barrier will lead to a 
slow reaction. For Series I compounds it has been found 
that log CI is highly dependent upon log k, whereas in 
Series II, terms in log P figure also in regressions with 109 
CI and log l/ED shown in Table 4.30. 
Table 4.30 
Eqn. Series Relationship nSRF 
4.27 1 log CI = -3.315log k+8.802 6 0.2212 0.951 38.13 
4.28 
4.29 
log CI = -0.99log P+1.732logk 8 0.1521 0.970 39.79 
- 1.844 
log l/ED =-1.159 log P80.1428 0.981 64.09 
+ 1.712 log k-3.224 
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It was-useful therefore to obtain expressions for log P in 
terms of MO parameters which mýy, in, turn, assist in bio- 
lodical activity correlations. The agreement between log P 
and electronic polarizability as measured by summation of 
the HOMO coefficients of the amide substituent is excellent 
if the cyclo propyl derivative is excluded from the regression 
as shown in the regression data below. for Series II compounds. 
The reason for this is probably due to the approximation for 
Eqn. Regression equation n 
4.31 log P = 10.85 PE- 0.594 
4.32 log P = 10.06 PE- 0.587 
7 0.1243 0.983 149.6 
8 0.2676 0.910 28.73 
polarizability which was obtained from the expression for 
self-atom polarizability as follows: 
occ unocc C. Ck where Ej, k refer to 
pI -j- energy evels of orbitals IE -E jkkj and k, with coefficient: 
Cj and Ck* 
Assuming that the difference in energy between frontier orbitals 
is roughly constant for a structurally similar series of 
molecules, then the expression reduces to 
HOMO 
(P E )gAeonstant Cj 
group 
It-, has been found that electrophilic superdelocalizability SE 
relates better with log P, and an inspection of the derivation 
of SE shows a comparability to polarizability, thus: 
occ C-2 
2 -E 
Such good correlations imply that MO parameters could super- 
ced'e. Hansch's w values in structure activity relationships. 
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Other work has indicated that some electronic parameters can 
achieve better correlations wiih rate constants for aromatic 
reactivity than Hammett's a values, and so these findings 
could revise linear free energy relationships and provide 
new scales of substituent parameters. 
The results of the regressions for log CI are in support of 
the model for receptor site interaction outlined previously. 
It must be remembered that CI depends upon LD as well as ED, 
such that log CI =log 1/ED- log l/LD. However, in Series II 
compounds the LD values remain virtually constant, and one can 
assume that regressions involving CI also apply to ED. 
In Series I, Q(6) and Q(7) LEMO terms are present in the 
significant-log CI correlations and Q(9) is also a prominent 
factor. The best relationship is obtained when Q(15) is 
incorporated into the regression equation. The Q(6) and 
Q( 7) factors point to an interaction involving the aromatic 
ring, which is sensitive to 5-substitution, whereas the 
presence of 0(15) suggests that there is some participation 
by the 2-nitro group. The appearance of Q(9) shows that the 
aziridine ring takes part in the therapeutic effect, which 
may differ from the toxic effect as Q(8) figures in LD 
regressions. 
Series II regressions show several differences from Series I 
in that data for protonated species give more significant 
relationships and that electron densities of the amido group 
are important. The similarities between Series I and II 
regressions for log CI are that aromatic ring carbon and 
2-nitro group electron densities appýar as factors in both 
13'6 
sets of r. esults, though the influence changes from C(6) in 
Series I to C(5) in Series II, This suggests that a change 
in the amide substituent displays an ortho effect. It is 
"'interesting to note that atomic charges on. oxygen atoms 16, 
21 and 23 appear in Series II relationships., with log CI. 
These atoms, belonging to the 2-nitro, 4-nitro, and 5-amido 
groups respectively, all lie above the plane of the aromatic 
'ring. Values of Q(3), Q(5), and Q(6) also arise in these 
regressions and these ring carbon atoms are the points of 
attachment for the 2-. 4 4-, and 5-substituents, respectively. 
The appearance of ECLEMO) suggests that electron donation 
from some nucleophilic species into empty orbitals on the 
phenyl aziridine is favourable. 
The log CI correlations with*S, 'and QT for Series II compounds 
show that it is possible, albeit navively, to explain activity 
of these compounds as being attributable to an alkylating 
- ability or rate factor 
(QT), and a hydrophobic factor measu- 
rable by SEI which relates with log P. There are, therefore, 
at least two levels on which to base structure-activity 
relationships of phenyl aziridines. 
Series III and IV Calculations 
'In 
general, Series III compounds would be expected to show 
similar characteristics to Series II and therefore provide 
equivalent correlations with activity. This has been found 
to be fairly true and it has been possible to obtain regression 
equations from a combination of Series II and Series III data. 
In fact, in the case of E(PPDT) regressions with log kj Series 
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II and III provide a statistically significant correlation. 
MINDO/3 calcuiations on neutral and protonated members of 
Series III carried out in the conventional manner provide 
the raw data for electronic structure- biological activity 
relationships. It is likely that the substituent on the amide 
nitrogen atom in Series III and Series IV brings about a steric 
effect and an electronic effect on the phenyl aziridine 
activity. This was shown by initial structure-activity re- 
gressions using log k and w values (where Tr is the Hansch 
substituent parameter). The resulting equations and statis- 
tical significance terms are shown below. 
Eqn. Series nS 
4.34 111 log Ci = -4.9223 log k+0.09271T 
+10.9793 
4.35 IV log CI = 0.934 Sa - 0.05947r 
+0.6181 
cr is the Hammett substituent parameter 
15 0.1542 0.9513 57.1548 
16 0.1444 0.9353 45.4491 
Although such equations are useful, they do not indicate which 
areas in the molecule are responsible for the variations in 
activity of the series. More valuable correlations for the 
point of view of drug design and comprehension of the biologi- 
cal interaction of these compounds are obtained by relation- 
ships involving theoretically-derived MO electronic parameters. 
The results of MINDO/3 calculations for Series III and IV 
molecules are given in Tables A. -zl to 4.. y, and derived regression 
equations with biological and chemical activity are given in 
Table 4.35. 
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Table 4.31 
Phenyl_ Aziridines Series III (Protonated) 
MO parameters log CI regression (with Series 
R" Q(4) Q (5) Q (8) Q(21) Q(23) 
CH2CN 0.1314 -0.1182 0.0971 -0.4956 -0.5219 
CH2CH2Cl 0.1315 -0-1184 0.0971 -0.4945 -0-5189 
CH2 CH 20H 0.1313 -0-1185 0.0969 -0.4951 -0-5187 
CH2CH=CH2 0.1315 -0.1193 0.0964 -0.4975 -0.5258 
CH2 C=-CH 0.1313 -0-1185 0.0967 -0.4966 -0.5251 
Table 4.32 
Series III (unprotonated) log CI regression 
R" Q(14) Q(15) Q (9) 
CH2CN 1.0979 -0.5681 0.1283 
CH2CH2Cl 1.0987 -0.5826 0.1262 
CH2CH20H 1.0980 -0.5682 0.1283 
CH2 CH=CH2 1.0984 -0.5692 0.1282 
CH2C=-CH 1.0981 -0.5687 0.1283 
CH2 CHCOMe)2 1.0982 -0.5687 0.1283 
Table 4.33 
Series III (unprotonated) log l/LD regressions 
R" Q(7)HOMO Q(8)HOMO Q(9)HOMO Q(24)HOMO E (HOMO) 
CH2 CN 0.2408 0.0353 0.0236 0.0027 -9.2177 
CH2 CH2C1 0.2408 0.0358 0.0233 0.0025 -9.2403 
CH 2 CH 2 OH 
0.2399 0.0355 0.0236 0.0023 -9.2039 
CH2 CH=CH2 0.2405 0.0348 0.0233 0.0029 -9.1506 
CH2 C=-CH 0.2407 0.0351 0.0234 0.0028 -9.1819 
CH2 CH(C)ý"9)2 0.2402 0.0351 0.0233 0.0026 -9.1793 
Pe cy 0.2415 0.0340 0.0299 0.0040 -9.1141 AH 
CH 2 CHCH 2 
OH 0.2399 0.0348 0.0230 0.0027 -9.1247 
-(CH2)2- 0.2388 0.0353 
0.0234 0.0033 -9.1873 
-(CH2)20 (CH2)2 0.2366 0.0340 0.0232 0.0048 -9.1680 
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Table - 4.34 
'Phenyl Aziridines Series IV MO parameters for biological 
activity -regressions 
RSE (5) SE (22) Q (8) LEMO Q (9) LEMO E (LEMO) ISE 
H 0.2597 0.1843 0.0440 0.0067 -0.7857 7.7440 
4rCl 0.2580 0.1827 0.0419 0.0062 -0-8786 7.9779 
4-F 0.2580 0.1828 0.0415 0.0062 -0.8810 7.9984 
4-OH, 0.2595 0.1845 0.0442 0.0067 - 0.7954 8.0525 
3-Me 0.2596 0.1841 0.0443 0.0067 -0.7884 8.1102 
4-Me 0.2596 0.1841 0.0442 0.0067 -0.7892 8.0966 
4-COMe 0.2574 0.1815 0.0410 0.0061 -0-9088 8.6665 
4-OMe 0.2599 0.1849 0.0447 0.0068 -0.7726 8.4813 
4-CONH2 0.2575 0.1816 0.0441 0.0061 -0-9047 8.6907 
4- NIM e 2 0.2602 0.1851 0.0451 0.0069 -0-7564 8.9576 
2-CONH2 0.2624 0.1855 0.0446 0.0067 -0.6360 8.7537 
3-OMe 0.2591 0.1834 0.0429 0.0064 -0.8169 8.4565 
2,5-diMe 0.2604 0.1848 0.0453 0.0069 -0.7439 8.4899 
2-Me 0.2602 0.1846 0.0450 0.0069 -0.7537 8.0869 
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Eqn. Sdries Regression equation SR 
4.36 1,11,111 log k 10.097E(PROT)+18.4238 20.0.0975 0.9553 187.8534 <ý(). 001 
4.37 1 log k 1.0789E(HOW)-0.0348 8 0.0658 0.9924 161.5426 <<0.001 
(for comparison) E(PROT) + 17.8587 
4.38 111 log l/LD = 1648.59Q7 (HOND)ý 6 0.2140 0.953 39.65 -0.0025 
-398.04 
4.39 111 log I/LD 25.0SE(HCHO)+2154.87 6 0.0312 0.999 682.49 
Q7 (HOW)+l984.87OQ8(HOND) 
-359.48 
4.40 111 log l/LD = 939.3Q7(HOMD)+ 
1335. lQ8(HOMO)-415.9Q9 
(HOMO) +2157.3Q24 (HCM) 
-270.5 
<0.0025 
10 0.1440 0.1440 18.73 0.005 
4.41 111 log CI = -5695.76Q(14)-2515.67 6 0.0525 0.995 66.69 <0.025 
Q(15)-4028.92Q(9)+5342.16 
4.42 11,111 log CI = 6883.8Q(4)+3650.2Q(5) 13 0.1201 0.9784 31.42 <0.025 
6378.9Q(8)+691.5Q(2l)- 
87.88Q(23)+444.3 
4.43 IIj, III log k = -0.0944E (PROT) +17.9864 27 0.2779 0.934 170.933 <<0.001 
4.44 111,111, log k = -0.0901E(PFDT)+17.2537 32 0.1020 0.919 162.279 <<0.001 
IV 
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Essentially, the results of regression analyses show that the 
general trend is for Series III and Series II molecules to 
operate . bythe same mechanism toward cellular receptors in 
normal and tumour tissue. It is intrinsically interesting to 
note the relative significance Of ISE regressions with log CI 
to justify the overall acceptability of this parameter in 
view of its dependency with log P, the hydrophobic parameter, 
in other activity correlations. The inclusion of log k values 
for Series IV in the regression with E(PROT) compounds the 
highly significant equation found with Series I, II and III. 
Electronic parameters of Series IV molecules were found to 
correlate with toxicity and anti-tumour activity, though the 
significance of the regressions is not high. As therapeutic 
activity (log CI) was found to-be related to a linear combi- 
nation of the hydrophobic parameter, Tr, and the Hammett sub- 
stituent constant, a, it was of interest to equate calculated 
parameters with w. Due to the close relationship between w 
and log P, it was thought that IS E would be expected to relate 
to 7r. Equation 4.45 shows that the relationship between these 
parameters is of low significance. 
Eqn. RelationshiD nsRF 
4.45 Tr = -1.50 IS B+ 12.58 14 0.7959' 0.5779 6.0171 
In view of the large standard error, S., relative to the low 
correlation coefficient, R, this equation could not be employed 
with any confidence in predicting 7T values of N-phenyl CB1954 
derivatives. 
correlations with toxicity and therapeutic activity both 
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show the importance of the lowest empty molecular orbitals 
and electrophilic superdelocalizability in explaining the 
activity of Series IV phenyl aziridines. 
Toxicity, as measured by log l/LD, relates*wi*th two combi- 
nations of occupied and unoccupied orbital parameters, as 
shown iri equations 4.46 and 4.47. The second of these 
equationslis the more significant and shows that it is likely 
Eqn. Relationship nSRF 
4.46 log l/LD = 11860 S E(5) -217.1 14 0.3615 0.7452 6.870 E (LEMO) -3252 
4.47 log l/LD = 747.4 SE (22) 14 0.3489 0.7651 7.763. 
-7.48.2 Q(8)LEMO - 106.98 
that at least two areas of the molecule are relevant to its 
mode of action: the aziridine group and the amide function. 
Anti-tumour activity, measured by log I/ED, relates with 
similar parameters as toxicity which may explain why the 
overall therapeutic activity of these compounds is not great. 
The regressions are shown below in equations 4.48 and 4.49. Due 
to the unusual occurrence of toxicity and anti-tumour activity 
Eqn. 
4.48 log l/ED = 10327 SEM-190.13 
E(LEMO) - 2833 
14 0.3721 0.7330 6.3865 
4.49 log l/ED =-953 Q(9)LEMO + 4.76 14 0.4272 0.5779 6.0173 
being related by the same set of parameters in equations A. 49 
and 4.46, it would be prudent to employ the second of the log 
I/ED equations preferentially in activity predictions. A 
143 
possible reason for the fact that only the aziridine moi6ty 
appears to be responsible for anti-turour activity is that 
the N-pheny*l substituent of the amide group is sterically 
hindering'its interaction at the cellular rec'eptor site, 
hence bringing about a. drop in therapeutic activity 
The relationship between log k and E(PROT) is shown graphically 
in Figures 4.15 and 4.16. The data for series I to IV phenyl 
aziridines is given in Table 4.35, and a comparison between 
observed and calculated values is shown in Table 4 . 36. 
Further comparisons between observed and calculated para- 
meters are given in Tables 4.37 and 4.38. These show that 
the. predictive power of these regressions is fairly strong 
and agreement between experimental and estimated values is 
often excellent. The data used to generate the structure- 
activity relationships of equations 4.1 to 4.49 is reproduced 
in Tables 4.39 to 4.42 on pages 150 and 151. - 
. r, 
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2.51 Figure 4.15 
Dependency of log k on E(PROT) for Phenyl Aziridines 
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Table 4. '35 log k -vs. E (PROT) regressions (Series I, II, I-II 
and IV) 
Sub'st ituent E (PROT) 
Series IV 40Me 167.511 
2,5Me 167.155 
2Me 167.424 
30Me 171.208 
3Me 167.874 
4Me 167.838 
Series III CH -2 CH 2 
Ph 167.394 
-CH 2 CH 2- 169.394 
N ýýO 168.553 
CH 2 CH(OMe 
)2 
, 
168.942 
Pec 167.474 
-(CH 2)5- 169.619 
CH 2 CH 2 cjý 169.877 
CH 2 CH =CH2 168.345 
CH 2 C=-CH 169.026 
CH 2 CH 2 OH 169.652 
CH 2 CN 169.869 
CH 2 Ph 167.855 
Series II Me 169.419 
Et 168.757 
Pr n 168.456 
Pr' 168.318 
Prc 168.946 
Bu' 168.240 
BU t 167.922 
Series I 2NO2 155.988 
2p4NO 2 166.937 
SCONH 2 170.957 
50 168.869 
SMe 167.129 
SNJ 163.755 
5C02 Et 168.823 
5NH C02 Et 166.895 
Eqn. Relation 
log k 
2.0128 
2.0682 
2.0294 
1.9777 
1.9867 
2.053 
1.960 
2.085 
2.1173 
2.042 
2.1703 
2.1043 
1.950 
1.970 
1.990 
2.032 
2.045 
2.2253 
1.9543 
2.0453 
1.8451 
2.1106 
2.0934 
2.0170 
2.2095 
3.3618ý 
2.1430 
1.9085 
2.2305 
2.2601 
2.4698 
2.0294 
2.1987 
nSRF 
4.44 log k= -0-0901 E(PROT)+17.2537 32 0.1020 0.9187 162-279 
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Figure 4.16- 
The relationshiD between Rate of NucleoDhilic rine oDenin 
reactions and protonation energies for Phenyl Aziridines 
RegressiOn'Equation nsRF 
log k= -0.09 E(PROT) + 17.25 32 0.102 0.92 162.3 
02-NO2 
0 
0 Pecy 
02ý, 4 02 
1 
N, oz)-uYiNin 2 
156 158 160 162 164 166 168 170 172 
E(PROT) 
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Table 4.36 
Coinparison of observed and calculated values for log k 
Series 'I ý II-; III and IV molecules 
log k (obs. ) log k (ca1c. ) 
2.0128 2.1643 
2.0682 2.1964 
2.0294 2.1721 
1.9777 1.8313 
1.9867 2.1316 
2.6530 2.1348 
1.9600 2.1748 
2.0880 1.9947 
2.1173 2.0704 
2.0420 2.0354 
2.1703 2.1676 
2.1043 1.9744 
1.9500 1.9512 
1.9700 2.0892 
1.9900 2.0278 
2.0320 1.9714 
2.0450 1.9519 
2.2253 2.1333 
1.9543 1.9924 
2.0453 2.0521 
2.1106 2.0916 
2.0934 2.0350 
2.0170 2.0986 
2.2095' 2.1273 
3.3618 3.2073 
2.1430 2.2160 
1.9085 1.8539 
2.2305 2.0420 
2.2601 2.1987 
2.4698 2.5026 
2.0294 2.0461 
2.1987 2.2198 
Table 4.37 
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Observed and calculated value's: a comparison 
Series II 7protonated molecules. Regression of log CI against 
Q(21) Q(3)' Q(5) Q(6) Q(16) E(LEMO) for 8 members 
log CI (obs. ) log CI (calc. ) 
1.845 
1.60 
1.48 
0.48 
1.00 
1.48 
0.70 
0.54 
1.844 
1.588 
1.458 
0.512 
1.015 
1.513 
0.670 
0.525 
Series III molecules. Regression of log l/LD against E(HOMO) 
Q(7)HOMO Q(8)HOMO for 6 members 
log 1/LD (obs. ) 
-1.3979 
-0.9542 
-2.6021 
-1.3617 
-1.0969 
-2.0792 
log l/LD (calc. ) 
-1.3867 
-0.9607 
-2.584 
-1.3455 
-1.1014 
-2.1135 
Series II, III protonated molecules. Regression of log CI 
against Q(4) Q(5) Q(8) Q(21) Q(23) for 13 members 
log CI (obs. ) 
1.845 
1.600 
1.480 
0.48 
1.00 
1.48 
0.70 
0.54 
1.00 
1.519 
0.756 
1.362 
1.398 
log CI (calc. ) 
1.851 
1.385 
1.539 
0.568 
0.933 
1.457 
0.720 
0.545 
1.123 
1.578 
0.680 
1.290 
1.490 
14,9 
Table 4.39 
Series II predicted against observed values of activity 
log CI against S,, E(PROT)* QT 
log CI jobs. ) 
1.845 
1.60 
1.48 
0.48 
1.00 
1.48 
0.70 
0.54 
log CI. (calc. ) 
1.862 
1.578 log CI= -0.238 S +0.0697E(PROT) - 
1.330 2.964QT+14. OY8 
0.613 nsRF 
1.111 8 0.1377 0.9803 32.912 
1.529 
0.558 
0.544 
log CI against SE QT E(HOMO) 
log CI (obs. ) 
1.845 
1.60 
I. 48 
0.48 
1.00 
1.48 
0.70 
0.54 
log CI (calc. ) 
1.854 
1.579 
1.330 
0.618 n 
1.111 8 
1.538 
0.561 
0.536 
sR 
0.1389 0.980 
F 
32.335 
loj 1/LD against Q(7) Q(8) Q(9) Q(24) HOMO electron densities 
log 1/LD (obs. ) 
-1.3979 
-0.9542 
-2,. 6021 
, -1. '3617 
-1.0969 
-2: 0792 
'-2.0792 
-2.6021 
-1.4771 
-2.2553 
lot OLD (calc. ) 
-1.1806 
-0-9197 
-2.6219 
-1.5738 n 
-1.2427 8 
-2.1022 
-2.0743 
-2.4440 
-1.6817 
-2.1648 
log CI =-0.250S - 1.786 E(HOMO) 
-2.927QT +9. 
ý56 
log I/LD =939.31Q(7) +1335. IQ(8) 
-415.87Q(9) +2157.3Q(24) -270.5 
sRF 
0.2037 0.9682 18.731 
Table 4.39 
'Series III ... BibI*ogýi'c: a*l' *a: rfd thetiI61' Pataffetets 
R log k Tr (i f log l/LD log CI 
-CH CH 22 2.085 1.1239- -1.4771 0.875 
CH 2 CN 2.045 0.1139 -1.3979 1.000 
CH CH OH 22 2.032 -0.5528 -2.6021 0.756 
CH 2CH(OMe )2 2.042 0.1139 -2.0792 0.778 
CH CH 2 2C1 1.950 0.8976 -0.9542 1.519 
CH2CH2Ph 1.960 1.7993 -2.1523 1.447 
CH2CH=CH 2 1.970 0.6721 -1.3617 1.362 
CH2C=-CH 1.990 0.5682 -1.0969 1.398 
CH2CHOHCH 20H - -2.000 -2.6021 0.6435 
Pe c 2.1703 - -2.0792 0.480 
-(CH2)5" 2.1043 0.95 -1.9777 0.420 
CH2Ph 2.2253 - -1.6532 0.480 
-(CH2)20(CH2ý 2.1173 0.08 -2.2553 0.477 
Series IV Biological and Chemical Parameters 
R log k fT 
.R 
7T log 1/LD log 1/ED log CI 
-R 2.1004 0.21 1.896 -1.954 -1.176 0.78 
4-Cl - 0.70 0.71 -2.176 -1.000 1.176 
4-F - -0.35 0.14 -1.204 -0.903 0.301 
2-Me 2.0294 -0.23 0.55 -1.633 -1.342 0.30 
3-Me 1.9867 -0.18 0.56 -2.079 -1.903 0.18 
, 
4-Me 2.0530 -0.12 0.57 -2.857 -2.301 0.56 
2,5-diMe 2.0682 -0.24 1.12 -2.176 -1.699 0.48 
, 3-OMe 1.9777 
0.06 -0.01 -2.602 -2.000 0.602 
4-OMe 2.0128 0.56 -0.02 -2.000 -0.699 1.30 
4-COMe 
' 
1.9912 0.46 -0-55 -2.176 -1.176 1.00 
'ý 
-OH - -0.36 -0.67 -2.025 -1.602 0.398 
2-CONH 2 - -0.21 -1.49 -1.699 -1.301 
0.398 
4-CONH2 1.9031 0.59 -1.50 -2.978 -1.653 1.322 
4- NMe2 - -0.39 0.18 -2.778 -2.301 0.477 
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Table 4.41 
Series II Protonated molecul*es Electronic Par. ameters 
Q (3) Q (4) Q (6) Q (16) Q(21) Q (23) E(HOMO) E(LEM 
H -0.1534 0.1270 1, -0.1098 
Me -0.1593 0.1313 -0.1181 
Et -0.1605 0.1315 -0.1191 
Pr -0.1610 0.1315 -0.1195 
Prl -0.1612 0.1316 -0.1197 
Prc -0.1602 0.1313 -0.1186 
Bui -0.1612 0.1315 --0.1196 
But -0.1617 0.1317 -0.1201 
0.0200 -0.5187 -0.4882 -0.5040 
0.0262 -0.5199 -0.4956 -0.5213 
0.0268 -0.5206 -0.4966 - -0.5236 
0.0271 -0.5211 -0.4974 -0.5251 
0.0281 -0.5212 -0.4976 -0.5313 
0.0271 -0.5206 -0.4968 -0.5233 
0.0274 -0.5213 -0.4976 -0.5253 
0.0292 -0.5218 -0.4992 -0.5410 
-13.7629 -5.562: 
-13.0484 -5.489, 
-12.9633 -5.451( 
-12.9149 -5.427S 
-12.6204 -5.425S 
-12.8450 -5.4521 
-12.8020 -5.4192 
-12.5130 -5.4021 
Table 4.42 
Series I'and II neutral molecules HOMO Electronic Parameters 
R Q (1) Q (3) Q (6) Q (8) E (110MO) 
H 0.8533 0.2199 0.0128 0.0365 -9.2346 
Me 0.8529 0.2170 0.0143 0.0355 -9.1830 
Et 0.8511 0.2155 0.0152 0.0350 -9.1596 
Pr 0.8476 0.2143 0.0159 0.0346 -9.1465 
Prl 0.8497 0.2149 0.0157 0.0347 -9.1456 
Prc 0.8506 0.2149 0.0153 0.0349 -9.1767 
Bu' 0.8476 0.2139 0.0160 0.0345 -9.1448 
Bu t 0.8473 0.2136 0.0169 0.0340 -9.1333 
2- N0 0.8337 0.2072 0.0145 0.0410 -8.4059 
, - 2 
4-CN 0.7468 0.2001 0.0205 0.0385 -8.4539 
2p'4-NO 2 
0.8601 0 . 2115 0.0048 0.0391 -9.1952 
5-CN 0.8606 0.2202 0.0107 0.0373 -9.1528 
5-Me 0.8658 0.2211 0.0087 0.0384 -9.0475 
SN(CH 2) 
0.7986 0.2911 0.0107 0.0389 -8.9673 2 
5NHC02Et 0.4355 0.1069 0.0035 0.0196 -9.1118 
Predicted activities of untested molecules 
Two phenyl a.. ziridine molecules were employed in activity 
prediction. These are the 5-trifluoro methyl and 5-trichloro- 
methyl derivatives of 2., 4-dinitro phenyl aziridine. It was 
thought that the electron-withdrawing influence of the 
halogen atoms would give rise to highly active species that 
might . display advantages over CB 1954. MO calculations on 
the neutral and protonated molecules were executed using 
MINDO/3 and the electronic parameters fitted into a number 
of the established equations; The electronic parameters 
are given below for the two molecules. 
R E(PRDT) E(HOMO) Q(8)HOMO Q(3)HOMO) Q (6) Q(9) Q(7)LaiO 
CCL 3 171.49 -9.3139 0.0416 0.1809 0.1003 0.1285 0.0229 
CF3 175.77 -9.4552 0.0423 0.2057 0.0196 0.1286 0.0294 
Pred icted values of log k, log l/LD, and log CI were obtained 
from regression equations and the following results showed 
that the two compounds should exhibit low toxicity. However, 
the therapeutic activity was f ound to be lower than might 
have been expected. 
log k log 1/LD log CI 
CCL 3 1.9221 -2.9968 -0.1047 
CF 3 1.5690 -3-1752 
0.0158 
Although instructive, these predictions indicate that it 
appears unlikely that a more active congener of CB 1954 
can be found to inhibit the Walker 256 tumour. 
15; 
Reaction Kinetics 'and Protoiiati: on Enerzi: e's* in 'Phenyl Aziridines 
I 
The relationship between nucleophilic reaction rates in acidic 
media and protonation energies for phenyl aziridines has been 
found to be highly significant. It is therefore possible to 
estimate the value of the entropy of activation (ASý) of, 
and postulate the mechanism for the reaction. It is generally 
thought that the reaction for the ring-opening of aziridin6s 
in acidic aqueousl solution is second order, S N', with perhaps 
a small SNI contribution 
ý28,129 
. Assuming second order 
kinetics, transition state theory requires us to write for 
,, 
the rate constant, k, 
e2( 
'ZT )e -AGý/RT E- 
where:, e is the exponential' c7onstant 
IZ is the Boltzmann constant 
R is the gas constant 
h is the Planck constant 
AGý is the free energy change for the formation of 
the transition state (TS) 
Taking logarithms, we get: 
ET AGO lnk =2+ ln 
1F)-= 
and conversion to common logarithms gives: 
log k=2+ log 
RT &Gý 
2.30258 
( 
7) - 2.30258R7- 
From the Third Law of Thermodynamics (AG = AH - TAS) this 
can be rewritten 
log k= -2 + log 
'FT AHý 
_+ 
Asi 
2.30258 2.30258RT T. 30258R 
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where AHýAs the enthalpy change for the formation of the TS 
I 
,, 
and ASý is. the entropy change for the formation of the TS. 
Evaluation of constantsgives: 
log k= 13.662 + 
Asý 60 
-19.144 5.705 
where ASý is in Joules and AHý is in kJoules, T= 298K. 
It is thought that AH is related to E(PROT) and, if this 
is so, then the intercept of the log k versus E(PROT) graph 
should provide a value for the entropy change, ASý. ' This is 
found to be a small positive'value, i. e.: 
ASý = +0.356J 
The positive value indicates an-increase in entropy and, 
thus a decrease in the order of the transition state. 
iss 
Corollary 
Mode of Action of CB1954 IncludinQ DNA Interaction 
It is possible at this juncture to suggest cellular pathways 
in the bio-mechanism of phenyl aziridine activity. As, CB1954 
exhibits the highest known chemotherapeutic index against 
Walker 256, this molecule is used as an example. A likely 
sequence of events is as follows: - 
The CB1954 molecule enters the cell by diffusing easily through 
the cell membrane due to its high lipophilicity. Because of 
the relatively low pH encountered in most cancer cells, 
protonation of the aziridine nitrogen occurs and it is likely 
that hydrolysis of the amide function is effected by enzyme 
action. Formation of the carboxylic acid moiety prevents the 
molecule from extracellular transport. The active species 
becomes attached to a specific bio-receptor via its nitro and 
carboxylic acid groups (oxygen atom attachment) and binding 
is assisted by charge transfer (CT) interaction with the 
aromatic ring. DNA synthesis is retarded by alkylation of 
either the heterocyclic bases or phosphate groups (or both) 
on DNA itself, and alkylation of RNA is also likely to take 
place. Normal cells are not going to be affected by CB1954 
to the same extent as Walker 256 tumour cells since the 
cellular environment possesses certain differences in pH and 
in bio molecules in the nucleus and cytoplasm. 
Another possible mode of action is for the phenyl aziridine 
molecule to intercalate with DNA, forming a CT complex with 
one or more of the base pairs - whicb it may alkylate also. 
15 6, *- 
This could occur since the width of the CB1954 molecul'e 
(about 3X) is small enough to ýit between two adjacent 
complementary pairs of heterocyclic bases (3.4A apart), and 
covalent bonding may also be possible via the oxygen atoms 
of the substrate CB1954. It is known that phenyl aziridines 
bind reversibly to BSA protein, which is facilitated by 
nitro groups in the 2 and 4 positions. Reversible binding 
suggests a weak interaction such as charge transfer or van 
dýr Waals interaction or a combination of both. Protein 
binding is often related to log P, the hydrophobic parameter, 
and this probably explains the good correlation between 
activity and total superdelocalizability. The reason that 
this is not the complete picture is due to the fact that a 
strong interaction with DNA is expected on the basis of the 
likely mode of action. 
The involvement of CB1954 with, and'its 
nucleotide levels is of interest and is 
relevance to its anti-tumour activity. 
is not certain but it may be a cause of 
similarity or complementarity between C 
arrangement) and cAMP and cGMP. 
effect on, cyclic 
likely to be of some 
The reason for this 
some structural 
B1954 (after re- 
Molecular models of CB1954 and part of DNA, G-C and A-T 
connected by the appropriate ribophosphate, show that 
a number of possible orientations between substrate and 
receptor are possible. It can be demonstrated that 
alkylation of guanine at (0)6 or N(7) is likely in con- 
junction with CT/van der Waals interaction between aromatic 
rings and substituent groups. Also,, it appears that hydr ogen 
15 7 1, -------l-l- -- 1--- 1 -111-1-11-1-1 
bonding can be visualised between CB1954 nitro and amido 
groups and deoxyribose moietieý in DNA while the drug 
I 
molecule is intercalated between base pairs. The orienta- 
tion that produces the strongest interaction energy is 
probably the most likely in the respect of cytotoxic and 
tumour-inhibitory activity. 
Some of these orient4tions are outlined and discussed in 
the chapter connected with DNA bases and drug interactions 
where the frontier orbital energies of CB1954 (protonated 
and unprotonated) are compared with those of DNA bases and 
base-pairs. Figure 4.17 shows how CB1954 might intercalate 
DNA base-pairs in part of a polynucleotide double helix. 
Figure 4.17 Base pair 
CB1 954 
ribophosphat 
"---ribophosphate 
Base-pair 
CHAPTER 5 
DNA BASES 
Introduction 
It is genera-lly believed that alkylating agents are able to 
bind irreversibly to DNA and RNA, and thus exert their 
cytotoxic action by interfering with the molec'ular processes 
involved in cell division. It is not only the purine and 
pyrimidine bases of nucleic acids, however, which are suscep- 
tible to alkylation; other nucleophilic moieties are present 
130 in protein sub--units, as shown in the following Table 
Table 5.1 
Nucleophilic Groups in Proteins and Nucleic Acids 
Group Location Structure 
-S: 
-S : 
methionine 
cysteine 
CH 3S CH 2 CH 2 CH CO 2H 
NH 2 
S CH 2 CH CO 2H I 
NH 2 
N: histidin e (Nl, N 3) HN-'ýýCI-12ýHC02 0H I LQ 
I N3 ýIH2 
guanine (N7) HN- 
06 
N7 
0>8 
to adenine (Nl, N3) 
, ýN N NH 
NN 
N I L 0ý 
c 
'N' NH 3 
to cytidine (N3) zzý: 
NI-12 
H, N, ýN3 
0 
CS-aromatic tyrosine (C3) 1-10-4ýCF! ýýHC02H 
NH2 
guanine (C8) see above 
\c 
-0 guanine (06) see above 
P6 1-01,0 - OH ribophosphate -0". ' H 2" "' 
P'ý'* 
0 
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Alkylation of DNA base pairs has particular relevance to 
I carcinogenesis as well as to cancer chemotherapy as the 
sites of reactivity are closely linked. The following dia- 
gram shows more completely possible reaction sites in the 
guanine-cytosine and adenine-thymine pairs. The numbers 
indicate the number of modifications caused by carcinogenic 
7 
chemicals at those positions 
Li 
Figure 5.1 
1 
6 
L., 
D14A chain 
Cytosine 
DNA chain 
Adenine 
/I 
3pi ---- /ý2 
S 
12 
-4 
D14A chain 
Thymine 
There is special interest in the 06 and N7 atoms of guanine 
as it is thought that 06 methylation gives rise to a cancer, 
whereas N7 methylation does not necessarily bring about this 
'' 131 effect . It is clear that alkylating agents will attack 
chain 
1 Guanine 
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other cellular sites before they reach DNA, but nucleohistones 
are depleted. in tumour cells. which enables cytostatic agents 
to enjoy eas e of access to DNA. Though there is a possibility 
of phosphate alkylation, guanine is the most s. usceptible 
moiety to alkylation and this is almost certainly due to 
electronic factors. Also, the imidazole ring of guanine can 
open out during covalent interaction by some cytoxic agents, 
the reason for this is not generally understood. Some results 
of methylation of DNA bases by MeNU are given in Table 5.2 
below, and it 'is thought MO calculations can provide an - 
electronic explanation for these findings as well as giving an 
insight into the interactions of DNA with anti-cancer drugs. 
Table S-2 Methylation of DNA by N-methyl-N-nitrosoureal32 
Base Site % Total identified methylation of 
bases 
Guanine N7 75.5 
06 7.3 
N3 1.1 
Adenine N3 11.2 
Nl 1.4 
N7 2.5 
Thymine N3 0.3 
04 0.1 
Cytosine N3 0.6 
Full MINDO/3 calculations were executed on the base-pairs 
guanine-cytosine and adenine-thymine as well as on the 
constituent bases. 
61 
Molecular 
geometric parameters were obtained from crystallographic 
datal33 . and optimization of the hydrogen-bonding 
distances 
in the guanine-cytosine and adenine-thymine pairs was carried 
Out. Results show that the hydrogen atoms prefer to remain 
associated with their original bases at distances close to 
134 
the experimentally determined values 
Details of el-ectronic parameters are given in Tables 5.4 to 5.6 
and the results of regression analyses for correlations with 
I 
base methylation as a measure of activity are given in 
Table 5.3. 
The results of these calculations provide a comparison between 
MINDO/3 and other MO methods in agreement with experimental 
135 
.,, 
values of ionization energies These data are given in 
Table 5.3 
Ionization 
Enern-ies Mass. Spec. 
136 CTC(exptl) 137 MINDO/3 CNDO SCF 
Adenin e 8.91 8.0 7.60 10.08 7.92 
Cytosine 8.90 8.1 8.70 10.78 8.16 
'Thymine 9.43 - 9.31 8.80 
Uracil 9.82 - 9.59 11.88 9.15 
Guanine - 7.8 7.66 9.06 7.59 
,,, In7general, it can be seen that MINDO/3 gives better agreement 
experimental data than other MO methods. There is 
interest 138 in the phenomenon of proton-tunnelling in DNA 
base-pairs and also in the interaction energies between com- 
162 
Purines 
Guanine Adenine 
Table 5.4 
Results of MO calculations 
1, 
Atomic 
Parameter N(2) C (3) -N (5) C (6) C(7) C(8) 0, N(9) N(10,12) C(11,13) N(15) 
e. d 
(Gua 5.0574 3.8977 5.0966 3.7672 4.2398 3.3444 6.5886 5.3576 3.5906 5.2486 
de 5.0794 3.8503 5.1860 
. 
3.7710 4.1509 3.6510 5.182- 5.3050 3.6946 5.3571 Ad 
ý Net(Gua, --0.0574 
0.1023 -0.0966 0.2328 -0.2398 0.6556 -0.5886 -0.3576 0.4094 -0.2486 
charge(Ade ý-0.0794 0.1497 -0.1860 0.2290 -9.1509 0.3490 -0.1829 -0.3050 0.3054 -0.3571 
ia 'ýO. 0192 0.3267 0.1549 0.2111 0.4958 0.0301 0. lS25 0.3606 0.0959 0.0116 
e. d. de (0.0690.0.2062 0.2006 0.0906 0.3144 0.1343 0.4004 0.3541 0.1219 0.1086 
H%I0 
-, 0.1429 0.0772 0.0290 0.1367 0.0485 0.1164 0.0579 0.2757 0.2807 0.1639 
e. d. 
(Zde 
1.0., 0198,0.3050 0.1356 0.0585 0.0425 0.7102 *0.1290 0.3048 0.2488 0.0458 
Gua 0.2606 0.4092 0.2472 0.3164 0.1905 0.4881 0.4256 0.2065 0.3672 
Ade de 0.: ý628 0.2560 0.4228 0.2525 0.3087 0.2287 0.3693 0.4411 0.2407 0.4490 
sý - 
9614 1.2812 0.8758 1.3573 0.9759 1.3377 0.4340 0.9891 1.7319 0.9255 MAde 
-000,7950 1.2161 0.7768 1.1092 0.9032 1.2716 0.7384 0.7484 1.1810 0.7077 
En ergies E (HOMO) E (LEMO) E (Electronic) E (Total) 
Guanine -7.6579 0.8165 -9125.22 -1982.54 
Adenine* -7.6034 1.6014- -7611.31 -1669.36 
Nomenclature 
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Pyrimidines 
Nomenclature 
Table 5.5 
Results of MO calculations 
Atomic 
Parameter N(2) C 0(4) N(S) C(6,7) O(S), N(7) C(9,10) C(11,12) 
E: D'fcyt 5.1667 3.3216 
6.5987 5.4084 3.6104 5.1553 3.7728 4.2750 
IThy 5.1736 3.3283 6.5749 5.2781 3.3612.6.5685 3.8171 4.2365 
, 
Net (Cyt -0.1667 0.6784 -0.5987 -0.4084 0.3896 -0.1553 0.2272 -0.2750 
Charge[Thy -0.1736 0.6717 -0.5749 -0.2781 0.6388 -0.5685 0.1829 -0.2365 
',, HOW (Cyt 0.2734 0.0667 0.1210 1.0610 0.0800 0.0300 0.0331 0.1365 
e. d. [Thy 0.5923 0.0152 0.1389 0.0001 0.0066 0.1694 0.2167 0.7198 
JEW (Cyt 0.2268 0.0079 0.0032 0.2256 0.4675 0.1100 0.8144 0.1445 
e. d. [Thy 0.1137 0.0205 0.0075 0.0945 0.2623 0.1199 0.9500 0.3808 
(Cyt 0.3542 0.1862 0.4920 0.4375 0.2104 0.3454 0.2301 0.2974 SB' [Thy 0.3333 0.1722 0.4500 0.3523 0.1826 0.4592 0.2277 0.2836 
' 
(Cvt 1.0366 1.2650 0.4245 0.9589 1.6921 0.9578 2.0468 1.2509 C N [ýffly 1.7773 2.2002 0.7617 1.3826 2.0670 0.7724 3.7270 2.0099 
Energies E (HOMO) E (LEMO) E (Electronic) E (Total) 
Cytosine -8.6976 0.8396 -5765.74 -1470.86 
Thymine -9.3119 0.4185 -7150.58 -1731.91 
Thymine Cytosine 
164 
Base-pairs 
Optimised 
H-bmd (R) 
a. 2.002 
b. 1.878 
c. 1.646 
d. 1.913 
e. 1.747 
Cytosine-Guanine Adenine-Thymine 
Table 5.6 
Results of MO calculations 
Atomic 
Parameter N(2) C(3) N(S) C(6) C (7) C (8) 0, N(9) N(10,12) C(11,13) N(15) 
e. d. 
(G-JC 5.0632 3.8962 5.1050 3.7538 4.2506 3.3322 6.63SO 5.3709 3.5773 5.2687 
JA-T 5.0790 3.8558 S. 1808 3.7711 4.1574 3.6414 5.2054 5.3089 3.6907 5.3782 
Net(G-c -0.0632 0.1038 -0.1050 0.2462 -0.2506 0.6678 -0.6330 -0.3709 0.4227 -0.2687 
: arge(A-T -0.0790 0.1442 -0.1808 0.2289 -0.1574 0.3586 -0.2054 -0.3089 0.3093 -0.3782 
'3094 0.1595 0.1783 0.4858 0.0404 0.1247 0.3968 0.0845 0.0029 10, j)(G-C 0.0284 0. 
e. d. JA-T 0.0562 0.2079 0.1776 0.0951 0.3314 0.1097 0.4406 0.3497 0.1156 0.1161 
(C'-C 0.3586 0.2634 0.4155 0.2488 0.3223 0.1916 0.4866 0.4388 0.2098 0.3789 SE 
JA-T 0.3681 0.2604 0.4296 0.2565 0.3157 0.2308 0.3848 0.4495 0.2436 0.4556 
(G-C 0.8700 1.2022 0.8268 1.2397 0.9112 1.2885 0.3950 0.8295 1.4428 0.8186 
JA-T 0.7495 1.1381 0.7349 1.0444 0.8519 1.1731 0.6574 0.6983 1.1173 0.6728 
Atomic 
Parameter N(19,22) C(18,20) 0(17,21) N(16,21) C(18,22)0(19), N(23)C(24,, 26)C(26.. 28) 
C-G 5.1679 3.3172 6.6406 5.4391 3.3172 5.1786 3.7769 4.2748 e. d 
(T-A 
5.1747 3.3249 6.5739 5.2982 3.3516 6.5897 3.8120 4.2422 
Net (C-G -0.1679 0.6828 -0.6416 -0.4391 0.4069 -0.1786 0.2231 -0.2748 
chargL T-A -0.1747 0.6751 -0.5739 -0.2982 0.6484 -0.589,7 0.1879 -0.2422 
IZO C-G 0.2122 0.0042 0.0014 0.1900 0.4314 0.1279 0.8510 0.1819 
e. d. 
[ 
T-A 0.1216 0.0158 0.0059 0.0999 0.2780 0.1164 0.9497 0.3637 
( C-G 0.3553 0.1856 0.4876 0.4405 0.2111 0.3626 0.2320 0.3006 SE I T-A o. 3352 0.1732 0.4534 0.3601 0.1825 0.4582 0.2278 0.2853 
( C-G 0.9899 1.2822 0.4128 0.8785 1.5302 0.8335 1.9145 1.1972 Sý t T-A 1.6348 2.0262 0.6971 1.2841 2.0169 0.7175 3.4519 1.8708 
Energies E(HOMO) E(LEMO) E (Electronic) E(Total) 
G-C 
A- T' 
-7.4609 
-7.3591 
0.9562 
0.4574 
-20946.37 
-20542.35 
-3452.54 
-3400.45 
Nomenclature 
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plementary bases as a result of their hydrogen-bonding. If 
proton-tunnelling does occur in, DNA base-pairs, then the 
tautomeric bases produced might give rise to mis-coding which 
would lead to mutation and possibly spontaneous tumours. 
G* --C* pair 
Figure S. 2 
Proton-tunnelling in 
the Guanine-Cytosine Pair 
G-C pair 
The hydrogen atom in a hydrogen bond should move toward the 
more electronegative atom (as shown in Fig. 5.2) and this 
simultaneous movement of hydrogen bonds, known as proton 
tunnelling, should give rise to double minima in the inter- 
molecular hydrogen bond distance - molecular energy profile. 
In fact, only one minimum and a shoulder is obtained'39 and 
optimization of the hydrogen bond distance indicatesthat 
the, protons prefer to remain associated with their original 
bases. These findings do not preclude the formation of 
tautomeric base-pairs, however, because the input of energy 
from e. g. ionizing radiations could induce proton-transfer, 
and molecular electrostatic potential maps of DNA base-pairs 
(se_ýe later) show some interesting minima between hydrogen- 
bonded atoms. 
ý 4. 
Calculations of the interaction energies between DNA base- 
pairs produce values which, in the case of the guanine- 
166 
cytosine pair, are in agree . ment with Pullman's results 
140 
However, the adenine-thymine calculated interaction energy is 
at a'variance with the EHT'calculation of Pullman. Inter- 
action energy is obtained by subtracting the. hpat of 
formation of the base-pair from the sum of the constituent 
base heats of formation, i. e. 
Interaction Energy = Hf base-pair - 
jHf 
bases 
The results are shown in Tables 5.4,5.5 below. 
Table 5.4 
1 Molecule Heat of Formation (kcal mol-1) 
AT 
C 
Table S. 5- 
Ba! ý'e Pair 
-101.212801 
- 70.62182 
, 21.11173 jHf = -89.45822 
-110.569915 
- 60.32437 
- 60.69007 
jHf = -121.01444 
Interaction nergy 
kcal mole-1 
I 
eV 
Interaction Energy 
140) k cal mole-1 (Pullman 
A-T- 18.8364 -0.8168 - 7.0 
G-C- 19.8016 -0.8588 -19.2 
The discrepancy between the adenine-thymine results indicates 
that the interactioh may be stronger than predicted by the 
earlier Huckel MO calculations, and it could be due to pseudo- 
hydrogen bond formation to the second carbonyl oxygen atom 
on'" ine as shown below in Figure 5.3. thymi 
167 
Figure 5.3 
Adenine-Thymine 
pseudo hydrogen 
bonded Dair 
There is evidence that, in certain instances, hydrogen bonds 
can be formed b. etween carbon and more electronegative atoms, 
and such a configuration does show symmetry with the guanine- 
cytosine triply hydrogen-bonded pair. 
The results of the frontier orbital energy calculations indicate 
I 
the relative propensity of DNA bases to participate in charge 
transfer (CT) interactions. The values of frontier orbital 
energies in eV for DNA bases and base-pairs are as follows: - 
Table 5.6 
Base or Base-pair ECHOMO) E(LEMO) 
G-C -7.461 0.956 
A-T -7.359 0.457 
Adenine -7.603 1.601 
Thymine -9.312 0.418 
Guanine -7.658 0.817 
Cytosine -8.698 0.840 
For an alkylating agent such as CB 1954 , for instance, the 
frontier orbitals of the neutral and protonated species are 
168 
shown. 
Table S. 7 
Alkylaýll-ng Agent 
Alkylating Agent E(HOMO) E(LEMO) 
CB 1954 - 9.235 -0.874 
CB 1954 +H -13.755 -5.569 
E(LEMO) for protonated CB 1954 is fairly close to E(HOMO) for 
G-C and A-T,, - indicating that there is a possibility of charge 
transfer from, DNA base-pair -* protonated CB 1954 . This type 
of interaction, involving mutual orbital overlap, can only 
occur when there is a juxtapositioning of interacting species. 
In order for CT interaction then, intercalation of the alky- 
lating species has to occur. The indication is, therefore, 
that a combination of inter-base intercalation and alkylation 
is a likely mode of interaction. A way of depicting this is 
sI hown in Figure 5.4 below, and in the following Figure 5.5 
the example of CB 1954 is made. 
Figure S. 4 
substrate molecule 
site of CT interaction 
site of DNA base or base-pair 
alkylation 
Schematic model of Alkylation and Intercalation of an 
: 'Anti-tumour drug with DNA 
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guanine-cytosine or 
Figure 5.5 
adenine-thymine pair 
000 
intercalation of CB195. 
ýON 
in DNA (CT complexatioi 
0 NH2 0 
alkylation guanine-cytosine Dair 
site 
Possible mode of interaction of CB1954 with DNA bases 
(see also Figureý 4.17). 
It is possible that alkylation of the phosphate groups from 
the ribophosphate helices occurs, but molecular models of 
intercalation complexes with DNA show that, for the anti- 
cancer drugs under investigation in this work, the phosphate 
groups are too far away for alkylation and intercalation to 
occur simultaneously. It is thought that this type of inter- 
action occurs in aniline mustards and nitrosoureas as well as 
for phenyl azirdines, and is discussed in the relevant chapters 
relating to these agents. The importance of frontier orbitals. 
to CT interactions is reflected in the appearance of HOMO 
coefficients in toxicity correlations for phenyl azirdines. 
Also LEMO coefficients figure in the QSARs for therapeutic 
I 
activity in these compounds which suggests that., although a 
CT interaction is weak and reversible, it may play a vital 
role in the way in which these agents bind to DNA. For 
example, CT might assist in the orientation of the drug to the 
relevant DNA base-pair to alkylation at the most propitious 
site. 
I 
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One way of investigating DNA interactions with electrophilic 
agents, whether they be free radicals, positive ions, or 
alkylating species, involves electrostatic molecular potential 
calculations. These are very readily achieved. and conveniently 
displayed as contour maps of equipotentials as an adjunct to 
MO calculations. The routine POTENT computes the potential 
energy experienced by a proton at a specified and variable 
distance from the molecule under scrutiny. Details of these 
calculations are given in the appendices, and will not be 
ý,, pursued here. 'Results of molecular electrostatic potential 
calculations for DNA bases and base pairs display some inter- 
esting features. The equipotential contour maps for relevant 
molecules in the molecular plane are shown-as follows: -,,, 
Guanine-cytosine pair 
Adenine-thymine pair 
Guanine 
Cytosine 
Adenine 
Thymine 
CB 1954 
Figure 5.6 
if 5.7 
it 5.8 
it 5.9 
5.10 
5.11 
5.12 
The results for DNA bases and base-pairs show the following 
potential minima (Table 5.8). 
The change in pattern of the potential maps'from thymine to 
cytosine is brought about by the differences irý structure, 
notably the effect of changing a carbonyl moiety on thymine 
to give an amino moiety on cytosine. The resultant redistri- 
bution of electron density produces the overlap of potential 
171 
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Table S. 8 
Molecule Atom Number Potential min. energy 
(kcalmol-1) 
Guanine-cytosin 
base-pair 
Guanine N5 (N7) 
09 (06) 
N10 (N3) 
Cytosine 017 (02) 
Adenine-thymine Adenine NS (N7) 
base-pair 
N12 (N3) 
Thymine 019 (04) 
021 (02) 
Guanine NS (N7) 
09 (06) 
N10 (N3) 
Cytosine 
Adenine 
Thymine 
04 (02) 
NS (N3) 
NS (N7) 
N12 (N3) 
N15 (N1) 
04 (04) 
08 (02) 
- 89 
-122 
- 90 
- ill 
- 82 
- 94 
-100 
-99/-98 
- 85 
-119/-123 
- 79 
-115/-127 
-102 
- 77 
- 90 
- 98 
-94/-94 
-105/-101 
Note: The notation in brackets refers to the standard nomen- 
clature as in Figure S. lat the beginning of the chapter. 
Otherwise the notation is as used in Mo calculations and 
as shown on the potential energy maps. 
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wells which is apparent in the cytosine contour map. It is 
this feature which gives rise to the very low value of the 
potential minimum of cytosine. A similar arrangement pro- 
duces the observed differences in the contou. r maps of the 
purine bases, adenine and guanine. Once again, an overlap of 
potential wells produces the marked minimum of the guanine 
molecule. Merger of the contour diagrams when the relevant 
bases are pai-red as in DNA shows a disappearance of some 
minima due to hydrogen bonding. This produces further minor 
minima along tfie line of hydrogen bond attraction and the 
details are summarized in TableS. 9 which supports known 
evidence for proton tunnelling. In fact, closer inspection 
of the electrostatic potential energy maps for A-T and G-C in 
the hydrogen-bonded region show that a potential valley runs 
through this area. This probably has some relevance to 
cytotoxicity because agents which break this association by 
attack in this region will lead to increased cell proliferation. 
Table S. 9 
Bas. e-pair Hydrogen bond 
Potential ener inima 
(kcal mole 
Adenine-thymine N9 - Hll ... 019 -61 
N15 ... H17 - N16 -57 
C13 - H14 ... 021 -62 (pseudo hydro- 
gen bond) 
Guanine-cytosine 09 ... H24 - N23 -51 
N15 - H14 ... 017 -53 
N12 - H14 ... 017 -80 
ISO 
Agents which are able to strengthen this binding in some 
degree will be cyto-arresting agents. 
It is now possible to rationalise the structure of DNA on 
the basis of base-pair interactions. The tiýist angle in 
0 the pitch of the double helix is about 36 . The reason for 
this is due to the method of stacking of base-pairs so as 
to ensure maximum charge-transfer interactions with minimum 
steric interactions. This can be visualised by supra-posi- 
tion of potent. ial energy contour maps for G-C and A-T which 
shows maximum complementarity of potential maxima and minima 
if the two structures are aligned at an angle of 360 to each 
other. 
The preferred orientation of intercalating/alkylating agents 
with DNA base-pairs can also be investigated using molecular 
electrostatic potential energy contour diagrams via this su - 
perposition principle. For example, using molecular modelling 
in conjunction with the elctrostatic potential maps possible 
modes of interaction between CB 1954 and guanine can be 
outlined as shown below 
available for 
alkylation of 
base pairs above 
1 
0%% 
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0 N, N- 
011N N02 
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N::::: j 
N7 alkylation AC-- 
region of high 
electron density 
Possible orientation 
of CB1954 and Guanine 
Mode 2 
Possible orientation 
of CB1954 and Guanine 
Mode 3 
Guanine has been chosen because it should be the most 
susceptible of the DNA bases to alkylation on the basis of 
its electronic structure, which has been established 
experimentally by studies involving methylating agents 
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such as DMN Also it is likely that a transformation of 
gtianine is responsible for the high levels of the amino 
acid lysine in the histone fraction of Walker 256 which 
CB 1954 inhibits so effectively. Of the three likely 
modes of orientation with guanine, the lower potential 
minimum near the 06 oxygen favours mode 3 rather than mode 2. 
However, interaction with bases above the drug molecule in 
addition to below, as shown in mode 1. cannot be ruled out. 
Additionally, one should not assume that the interacting 
species is the same as the original drug. It is very 
likely that the 4-nitro group will be reduced to an amino 
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function., the amido group will have been hydrolysed to the 
carboxylic acid, and the aziridine nitrogen will have become 
protonated. Finally, there is the fact that phenyl aziridines 
are capable of rearrangement to a purine-like structure, (Fig. 5.13) 
resembling guanine or adenine, which could result in another 
mode of interaction. The occurrence of this rearrangement 
is discussed in the phenyl aziridines chapter together with 
related reac_tions of relevance to cellular interactions. 
r*LKj ON NO ZN -Z 02 21 0 
Figure S. 13 
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Structure-activity relationships 
The relative propensity for specific sites on the DNA bases 
to be methylated by MeNU has been shown in the results dis- 
played in Table 5.2. The percentage methylation of basic 
atoms (N or 0) can be utilized as an expression of activity 
for correlation with electronic structure parameters. 
Multiple regression analysis of atomic charge, Q(N), HOMO 
electron density, Q(HOMO), LEMO electron density, Q(LEMO), 
nucleophilic and electrophilic superdelocalizabilities, SN(N) 
and SE (N), and potential energy minima, E(POT), against the 
logarithm of the percentage methylation, log A, at the speci- 
fied atoms, (N), was executed. 
The data sets and results are shown below in Tables 5.9,5.10 
below. 
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Atom Q (N) Q (HOMO) SE (N) Q (LEMO) SN (N) E (POT) LOG A 
G(N)7 -0.097 0.155 0.409 0.029 0.876 - 85.0 1.879 
G(0)6 -0.589 0.152 0.488 0.058 0.434 -119.0 0.863 
G(N)3 -0.358 0.361 0.426 0.276 0.989 - 79.0 0.041 
A(N)3 -0.305 0.354 0.441 0.30S 0.748 - 90.0 1.049 
A(N)l -0.357 0.109 0.449 0.046 0.708 - 98.0 0.146 
A(N)7 -0.186 0.201 0.423 0.136 0.777 - 77.0 0.398 
T(N)3 -0.278 0.001 0.352 0.096 1.383 - 5.0 -0.523 
T(0)4 -0.568 0.169 0.459 0.120 0.772 -105.0 -1.000 
C(N)3 -0.408 1.061 0.437 0.226 0.959 -102.0 -0.222 
The most significant correlations with activity are as follows: - 
Table S. 10 
Parameters D. F. R F 
Q(N) 1,7 0.5098 2.458 
Q(N), SE -(N) 
2,6 0.7889 4.945 
. Q(N), SN (N) 2,6 0.8287 6.576 
Q(N), E(POT) 2,6 0.7472 3.791 
It was found from the correlation matrix-that Q(N) and SE (N) 
are covariant, that is to say, they cross-correlate. 
Therefore the best relationship, i. e. the most significant, 
is that between Q(N), SN (N) and logA . It is also interesting 
to note that SE (N) and E(POT) correlate remarkably well with 
each other. The regression equations are given below: 
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Table 5.11 
Eq. Relationship n D. F S R F 
5.1 log A = 4.412 Q(N) - 2.440 SN (N) + 3.907 9 2,6 0.5649 0.8287 6.576 
5.2 E(POT) = -822.8 SE (N) + 270.6 9 lp7 11.23650.946560.60f 
Overleaf is a graph of the relationship generated by equation 
5.2. Relationship 5.2 shows that there is a strong tendency 
for the electrophilic superdelocalizability of the stated 
atoms to affect the magnitude of the electrostatic potential 
well. Since a proton is an electrophilic reagent, this is 
perhaps not very surprising. However, it is interesting that 
this correlation is better than between atomic charge, Q-(N), 
and the potential minima. 
Equation 5.1 indicates that methylation depends upon the two 
factors, net atomic charge and nucleophilic superdelocaliza- 
bility. This relationship supports the hypothesis that 
methylation of these bases occurs via a carbene intermediate, 
CH 2 :, as this would 
be expected to display nucleophilic and 
electrophilic characteristics. 
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CHAPTER 6 
ANILINE MUSTARDS 
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Introduction 
Aniline mustards, or N-phenyl nitrogen mustards, have been used 
clinically in cancer chemotherapy for 
141 
many years Particular 
success in a number of treatment regimens ha-s been achieved by 
chlorambucil and melphalan under their proprietary names 
Leukeran and Alkeran, respectively. Chlorambucil is used in 
the treatment of chronic lymphocytic leukemia, Hodgkin's 
disease and other lymphomas, multiple myeloma and reticulum 
cell sarcoma, choriocarcinoma, and cancers of the breast and 
ovary. Its slow activation coupled with very low toxicity has 
made chlorambucil one of the most successful anti-tumour drugs 
in recent years. Melphalan is effective against chronic 
granulocytic leukemia, Waldenstrom's macroglobulinemia, mul- 
tiple myeloma, breast and ovarian cancers, testicular cancer 
and malignant melanoma. It is often employed in combination 
with prednisone, vincristine, or cyclophosphamide and is 
particularly useful in adjuvant therapy following mastectomy. 
The transport capabilities of the amino acid carrier moiety 
contribute to melphalan's mode of action by enabling it to 
attack cycling cell populations. 
The structuresbelow show these compounds to be para-substituted 
aniline mustards, and extensive studies b)ý Ross 
142 
and co-workers 
0 CH CH C) 
\\ C (CH N 
HOý' 23 
-CO l-- \CFýchýCI 
C02H 
, 
CFýCH CL 
2 
CHCH -CC -N 20 
CH20tCl NH2 
i 
Chlorambucil ? le 1T)h al an 
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indicate that para-substitution produces the most efficacious 
drugs. This is probably due to a possible mesomeric effect on 
nitrogen electron density, which is likely to affect the way 
that these molecules alkylate DNA. It is important at this 
stage to mention the role of alkylating agents in chemotherapy 
as the aniline mustards are classic examples of potentially 
bi-functional alkylating species capable of cross-linking DNA 
143 
strands 
Table 6.1 
Biochemical Function pAso(-log A 
for 50%inhibition' 
Template activity of DNA in RNA synthesis 5.3 
Template activity of DNA in DNA synthesis 5.0 
Coding ability of synthetic mRNAs (poly U&C) 3.0 
Ribsomal function 3.0 
Soluble enzymes involved in peptide formation 3.0 
Soluble enzymes involved in aminoacyl-tRNA synthesis 2.3 
DNA polymerase activity <3.0 
RNA polymerase activity <3.0 
Table 6.2 
Informational Content of Methylated Bases 
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Alkylated base Genetic function 
N-7-methyl guanine 
0-6-. methyl guanine 
3-methyl cytosine 
Pairs normally 
Miscodes 
Miscodes 
0-4-methyl thymine Miscodes 
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The postulated mechanism for alkylation of DNA by aniline 
mustards is shown below, using guanine as an example for 
cross-linkage. 
,,, 
CH 2 CH 2 ci 
- CL 
0/ CH 2 CH 2 C-1 /CH 2 CH 2 ci Ar-N :0 Ar-N -CH 2 Ar-N,,, " @ CH 2 CH 2 Cl alkaline or ED\ 
/ CH 2 CH 2 
neutral pH CH 2 
aromatic nitrogen mustard aziridinium ion carbonium ion 
g anine 
e 
Us 
idue 
OH CH2CH2 '- N,.. -CH2CFýCl 
Ed I 
N Ar N 
H2N N 
I 
N-7 alkylation R 
aziridinium ion 
I 
carbonium ion 
attack on 2nd guanine 
OH Cý2CH ' 0ý CH OH 
e. / 2 
"- N 1,10,2N,., (D 
NN 
4ýNý-ý 
N 
Ar 
HNN 
[t-11 
NH NNN2 
21 
RR 
The carbonium ion intermediate formed by cleavage of the 
unstable aziridinium ion is highly reactive and non-specific 
so that it is able to alkylate other bases on DNA + RNA and 
can also be attached to nucleophilic sites on protein and 
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nucleic acids such as the ribose or phosphate moieties. 
Table6.1 shows the relative inhibition of various nucleic 
acid functions resulting from nitrogen mustard attack on 
strains of E. coli. Table 6.2 indicates that the outcome of 
DNA base alkylation does not always result in mutation because 
N-7 methylation of guanine does not interfere with hydrogen 
bonding and, thus, bases can pair normally. Attack of a water 
molecule on the carbonium ion intermediate will give rise to 
a route of elimination of the nitrogen mustard via glucuronide 
formation and-is therefore a detoxification mechanism brought 
about by inactivation of the N mustard. 
CH CH C1O., CH 2 CH 2C1 -H 
0 
_*, 
CH 2 CH 2C1 
Ar_N, l 22 
r6H ) Ar-N 9 _. -w % Ar-N 
**% CH 2 CH 202 
\CH 
2 CH 2 OH 2\ CH 2 CH 2 OH /UDP-glucuronic 
acid 
Ar-N" 
CH 2 CH 2 OGA 
further 
Ar-N ., 
CH 2 CH 2 Cl 
+ UDP 
**'CH 
2 CH 2 OGA metabolism 
\CH 
2 CH 2 OGA 
di-glucuronide aniline mustard glucuronide 
Th. e metabolism of chlorambucil has been studied by McLean et 
al. 
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, who postulated an active metabolite as 
dehydro- 
chlorambucil formed by ý-oxidation of the butanoic acid side 
chain to a butenoic acid moiety. This process may result 
in activation of the mustard at the tumour site and explain 
the effectiveness of its therapeutic action. 
(CH 2)3 Co 2H cii 2 Cli = CHCO 2 11 Cll=CHCII 2 Co 2H 
P, -oxidaticn, isoniersm-> 
N (CH 2 CH 2C1) 2N (CH 2 CH 2 Ci) 2N (CH 2 CH 2 Ci) 2 
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1460147 In this work, a series of 4-substituted aniline mustards 
were subjected to structure-activity analysis following MO 
calculations. The preferred conformation of the parent 
compound, aniline mustard, was investigated using the MINDO/3 
geometry optimization procedure. Standard bond lengths and 
angles of the aromatic ring were used, and this was assumed 
to be planar. The final geometry of the nitrogen bis (2- 
chloroethyl) group was ascertained to be as follows: - 
Table 6.3 
cl 
c \ 
CH 2 
1.46 2'ýý N 
H2c 
CH 2 
. 766 
cl 
Bond Calcd. Expt. (Chloramb) 
N-Ar 1.445 1.458 x 
N-C 1.462 1.469 0 A 
C-Cl 1.766 1.787 
These findings compare favourably with the results of Berges 
and Peradejordi 
148 in indicating that the two chloroethyl 
grOups prefer to lie above and below the plane of the aromatic 
ring. Optimized bond lengths are in close agreement with 
structural data obtained for crystalline chlorambuci, 
149 
as 
shown in Table6.3 where the nitrogen is on a trigonal planar 
(sp 2) rather than tetrahedral (sp3) environment. The three 
minimum energy conformers of aniline mustard are shown below, 
together with their calculated heats of formation. It is 
convenient to view the molecule from the position indicated 
by the arrow as in the diagram below. 
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Conformer III 
The distance between the two chlorine atoms for the three 
conformers indicates the preference for the molecule to 
adopt conformer III supported by its crystal structure, which 
has been taken as the parent structure for MO calculations 
of this series of para-substituted aniline mustards. 
Two groups of workers have attempted to formulate QSARs for 
aniline mustards. Berges and Peradejordil48 performed CNDO/2 
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calculations on a small number (9) of p-substituted aniline 
mustards, which did not include the highly active species 
chlorambucil and melphalan, and only obtained correlations 
between rates of hydrolysis, alkylating activity, and MO para- 
meters. The Hansch group have studied a larger number of 
mmebers (22) and have obtained some correlations between 
therapeutic activity, toxicity and Hammett (a) and Hansch (7) 
150 
substituent parameters A number of compounds were not 
included in the regressions and also it was difficult to 
explain the high activity of chlorambucil using Hansch's 
equations. 
In this work 23 para-substituted aniline mustards were in- 
vestigated to obtain correlations between electronic structure 
and biological activity so that predictions could be made 
about the activity and therapeutic usefulness of hitherto 
untested species. Biological and chemical data for the 
series was obtained from the work of Bardos et al. 
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and MINDO/3 calculations executed for these molecules together 
with those of melphalan (phenyl alanine mustard) and the 
dehydro metabolite of chlorambucil. The series may be sub- 
divided into smaller sized groups of similar molecular 
structure as shown below: - 
N(CH2CH2C')2 
0 
R 
R=H, OH, CHO, CO 2H 
CONH 2' NH 2' 
(CH 2)3C02 H 
CH=CHCH 2C02 
Hb 
11 
N (C H2C H2C1 )2 
le. 
ocow 
RI=Me, Ph, 2-MePh, 
2,6-diMe, 
NHPh 4 CO 2H 
CH 2 CHNHCO 2 H- a=chlorambucil b=chlorambucil metabolite 
c=meiptiaian 
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N (CH 2CýýC1)2 
NHCOW1 
R"=Me,. CH 2FI CH 2 NH 2 
0 Prl 
p CH 2 NHCOMe, 
CH 2 NHCOCH 2 cl 
N(CH2CH2C1)2 
0 
R! " NHCC)2PW- 
R"'=H, 4-CO 2 Hp 2-CO 2 Me, 
3-CO 2 Hp 4-CO 2 Me 
The results of MO calculations are shown in Table 6.1 
and chemical and biological data are shown in Table 6.5. 
The nomenclature for the atomic framework used in this work 
is shown below. 9C_. " I ý, _C8 N 
7-"ý- --, 3 
5ý-Oý-4 
First of all it was found that a linear relationship exists 
between therapeutic activity, as measured by logl/ED, and 
frontier electron density (HOMO) on the mustardnitrogen (1) 
for a number of members in the series. The following data 
set was used to generate the regression equations shown 
below. The second equation is for data forced through the 
origin to provide a highly significant correlation, summarised 
in the graph shown as Figure 6.1 . This equation indicates 
that a high activity against the Walker 2S6 carcinoma is 
favoured by a low electron density in the HONIO of the nitrogen 
atom. 
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Table 6.5 Chemical and Biological Parameters for Aniline Mustards 
Compound log k log l/LD log l/ED log CI 
1. H 1.1139 -2.5647 -2.6021 -1.0000 
2. OH 1.6866 -1.8692 -1.5051 0.3617 
3. CHO -0.4815 -3.2122 -3.0607 - - 0.1461 
4. CO 2H 
0.6628 -2.9614 -2.7076 0.25S3 
S. CONH 2 -0.3001 -3.0792 -3.0792 
0.0000 
6. NH 2 
1.6232 -1.1761 -1.3010 -1.0000 
7. NHCO'lMe 1.4713 -2.0086 -1.5315 0.4771 
8. NHCOH 2F 
1.2148 -1.4314 -1.4314 -1.0000 
9. NHCO 2 CHMe 2 1.5051 -2.7284 -2.1614 0.5682 
10. NHCOCH 2 NH 2 1.0374 -1.5315 -1.5315 0.0000 
11. (CH 2)3 
CO 2H 1.6191 -1.9638 -0.8751 1.0864 
12. NHCOCHZNHCOMe 1.0899 -1.8260 -1.2041 0.6533 
13. OCOMe 1.1761 -1.7404 -1.4150 0.3223 
14. OCOPh 1.1761 -1.9731 -1.1761 0.7994 
15. NHCOCH 2 NHCO 2 Me 1.0899 -2.3010 -2.1461 0.2305 
16. NHCOCH 2 NHCO 2 Ph 1.4771 -2.7536 -1.9243 0.8261 
17., OCOPh-2Me 1.1761 -2.3222 -1.4914 0.8326 
18. NHC02 Ph-4CO 2H 1.3490 -2.1644 -0.4771 1.6628 
19. OCOPh-2,6Me 1.1761 -2.9330 -2.7259 0.2042 
20. NHCO 2 Oh-2CO 2 Me 1.4264 -2.4441 -0.3428 
2.1003 
21. NH C02 Ph-4CO 2 Me 1.4472 -2.4281 -0.2901 2.1367 
22. OCOPh-4. CO2 H 1.1461 -2.1523 -0.9031 1.2304 
23. NHCO 2 Ph-3CO 2H 1.3802 -2.2330 -0.3010 1.9294 
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Eqn Relationship nSRF 
6.1 log l/ED = -5.0536 Q(1)HOMO + 1.6312 11 0.3535 0.8878 33.474 
6.2 log l/ED = -2.8531 Q(1)HOMO 11 0.4643 0.9803 221.859 
Data set for Equations 6.1 and 6.2 
R Q(1)HOMO log 1/ED 
H 0.8567 -2.6021 
OH 0.7062 -1.5051 
CHO 0.8723 -3.0607 
CO 2H 0.8846 -2.7076 
CONH 2 0.8613 -3.0792 
NH 2 0.4971 -1.3010 
NHCOMe 0.6419 -1.5315 
NHCOCH 2F 0.6611 -1.4314 
NHCO 2Pr' 0.6537 -2.1614 
NHCOCH 2 NH2 0.6434 -1.5315 
NHCOCH 2 NHCOMe 0.6484 -1.2041 
Figure 6.1 
0.4 0.5 0.6 0.7 
-1. 
log 1/ED2. 
-3. 
0.8 0.9 Q(1)HOMO 
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When further data is included, the majority of compounds fit 
the equation with a few exceptions. In particular, 
chlorambucil gives a point far removed from the regression 
line. However, if the N(l)HOMO electron density for the 
chlorambucil metabolite is substituted, the point moves 
considerably nearer to the line. This does indicate that 
the relationship obtained above partially explains the 
activity of aniline mustards, though it is likely that there 
are other effects in operation which need to be revealed. 
It would appear that electron-withdrawing groups tend to 
increase nitrogen electron density, whereas electron-donating 
groups conversely reduce nitrogen electron density. To a 
certain extent this effect is allied to the alkylating ability 
of the aniline mustards, since reduction of electron density 
on the nitrogen in the HOMO will (enable and) facilitate the 
formation of an aziridinium ion intermediate. 
When the total number of aniline mustards are considered, the 
above relationship loses its predictive power, but it still 
retains some significance as it is featured in a number of 
regression equations. Of the data available, it was decided 
that it would be useful to obtain correlations with alkylating 
activity (log k), therapeutic activity (log CI), anti-tumour 
activity (log l/ED), and toxicity (log 1/LD). Regression 
analysis of the data sets for 23 active compounds yielded a 
number of statistically significant correlation equations 
which have been listed below. One compound which is inactive 
was omitted because it undergoes metabolic inactivation by 
hydroxylation of a -CH 20 moiety to -CH 2 OH which can then 
conjugate feadily and be eliminated. The alkylating activity 
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of aniline mustards was obtained by measuring the rate of 
reaction with the nucleophile y-(4-nitrobenzyl)-pyridine 
(NBP). The logarithm of the rate constant, k, for this 
reaction was used to generate SARs. The best correlations 
are shown in Table6.6below. 
Contrary to expectation, the nitrogen(l) electron density 
does not appear very frequently in the correlations with lok k. 
The ring carbon(2)adjacent to the nitrogen, however, seems 
to be related to log k with reasonable significance. This 
shows that a para electromeric effect is in operation which 
shows a comcomitant variation in the degree of stabilization 
of the aziridinium ion intermediate by charge delocalization. 
In other words, e1 ectron- donating substituents in the para 
position will stabilize the positive charge on the aziridinium 
nitrogen which would effectively lengthen the reaction time 
for alkylation, thus prolonging the biological activity. 
In a similar manner, the appearance of the Q(7)term indicates 
that the carbon atom ortho to (2) is sensitive to changes in 
the electron-density power of the para substituent. 
Very few good correlations with toxicity were obtained for 
this series of compounds, though carbon (2) shows a fair 
relationship with this parameter. Superdelocalizability (SE) 
on the nitrogen (1) has a small degree of significance, but 
total superdelocalizability (ISE) for the whole molecule is 
clearly not related to toxicity as the results in Table 6.6 
show. Somewhat better relationships between structure and 
activity are displayed by the regressions with anti-tumour 
activity, (log 1/ED). Table6.7shows the most significant 
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Table 6.6 Regression Equations for Aniline Mustards (log k+ 
log l/LD) 
Eq. Relation n s R F 
6.3 log k=16.46Q(7) + 2.07 23 0.3437 0.7807 32.7821 
6.4 log k=S4.85Q(7)-39.72Q(3)+2.056 23 0.3279 0.8134 19.5485 
6.5 log k=67.08Q(7)-5l. 57Q(3)-0.047QT 23 0.3279 0.8237 13.3619 
+ 2.33 
6.6 log k=-256.4lQ(l)+22.93Q(7)-47.94 23 0.3049 0.8411 24.1778 
6.7 log k=65.41SE(2) -15.23 23 P. 3534 0.7664 29.8895 
6.8 log k=47.75SB(6) -11.71 23 0.3540 0.7654 29.6981 
6.9 log k=-14.75Q(2) + 31.4 23 0.3449 0.779.0 32.4237 
6.10 log 1/LD=-11. SSQ(2) - 0.73 23 0.4113 0.6323 13.9907 
6.11 log 1/LD=51.17SE(2) - 15.10 23 0.4160 0.6212 13.1978 
6.12 log 1/LD=8.90Q(2)HOMO - 3.93 23 0.4079 0.6399 14.5643 
6.13 log 1/LD=35-01SE(4) - 11.76 23 0.4168 0.6194 13.0739 
Table 6.7 Regression Equations for Aniline Mustards (log l/ED 
log CI) 
Eq. Relation n s R F 
6.14 log 1/ED=149.57Q(7)-132.64Q(3)- 23 0.551S 0.7916 16.7877 
0.42 
6.15 log 1/ED=107.92Q(7)-92.28Q(3)- 23 0.5048 0.8384 14.9853 
0.16QT 
6.16 log 1/ED=0.261SE+0.81logk -4.38 23 0.5758 0.7702 14.5798 
6.17 log 1/ED=52.48SE (6)+0.25QT-16.93 23 O. S494 0.793S 16.9955 
6.18 log 1/ED=-15.27Q(2)+0.26QT-0.80 23 O. S622 0.7824 15.7833 
6.19 log 1/ED=69.23SE(2)+0.28QT-20.30 23 0.5557 0.7881 16.3897 
6.20 log 1/ED=11.97Q(2)HOMO+0.26QT - 23 0.5514 0.7918 16.8046 
5.05 
6.21 log CI=0.471SE - 2.80 23 0.4924 0.8163 41.9400 
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Table 6.7 continued 
Eq. Relation n R F 
6.22 log CI=0.42 QT - 1*51 23 0.4134 0.8745 68.2820 
6.23 log CI=58.28Q(l) + 0.42QT 23 0.4200 0.8768 32.2497 
+9 . 97 
6.24 log CI=1.49Q(7) + 0.42 QT - 1.40 23 0.4218 0.8756 32.8730 
6.25 log CI=0.40QT + 0.014ji2- 1.58 23 0.4169 0.8787 33.8932 
6.26 log CI=-403.80Q(8)+0.51iSE 23 0.4550 0.8536 26.8531 
+ 50.15 
6.27 109 CI=-511-SSSE(2)+388.87SE(6) 23 0.4054 0.8918 24.6189 
+ 0.060p 2 +23.11 
6.28 log CI=12.88SE(l)-527.85SE(2) 23 0.4163 0.8920 17.5145 
+394.03SE(6)+0.06p 2 +20.86 
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correlations which include QT, the total net atomic charges 
summed over the whole molecule. It is interesting to note 
that the best single parameter regression is with Q(8)FIOMO, 
which also figured in the log k analyses, and suggests that 
there may be a connection between the two mechanisms. In 
fact, log k itself can be related to log 1/ED, but the para- 
llelism is not very great. The inclusion of a second para- 
meter can give rise to an improved correlation in some cases, 
particularly those involving QT. Electron density on the 
ring carbon adjacent to the nitrogen, C(2), figures in a number 
of regressions with QT, as does C(6) - which is adjacent to the 
para substituent. This suggests that the aromatic ring 
may interact with a cellular receptor site during the course 
of biological alkylation and probably plays a r6le in the 
activity of aniline mustards. Total superdelocalizability 
is moderately well related to log 1/ED when log k values are 
included. The energy of the highest occupied MO correlates 
fairly well, in combination with QT) with anti-tumour activity 
indicating that electron-donation from the aniline mustard 
participates in the attack of cellular nucleophiles. 
The most encouraging results are achieved when the chemo- 
therapeutic indices (CI) are considered. These are given 
in Table 6.7and show that total molecular effects prevail 
over single atomic parameters. In the regressions with log 
CI it can be seen that ISEP the total superdelocalizability, 
QT, the total net atomic charge, and to a lesser extent jj2' 
the square of the dipole moment, all correlate well. These 
findings suggest that the chemotherapeutic activity is 
governed by: (i) a transport factor 6ased approximately on 
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molecular size and can be related to the balance between lipid 
and aqueous s olubility. Thus IS E is roughly equivalent to the 
Hansch hydrophobic parameter, 7r, and expresses the ease with 
which the drug molecule reaches the site of action, and (ii) 
an electronic factor dependent on the way in which electron 
density is distributed in the molecule as a whole, i. e. not 
necessarily allied to particular atom centres. QT therefore 
represents a molecular parameter that is related to the 
Hammett or Taft substituent electronic parameters, a and a*. 
Inclusion of a second parameter into the regression can im- 
prove the correlation coefficient R, but lower the signifi- 
cance F of the relationship. The best of these double re- 
gressions is that involving QT and V2, which indicates a 
receptor interaction of the second order type depending on 
the molecular polarizability. Also Q(8) and ISE correlate 
well with log CI showing that alkylation involving an 
aziridinium ion participates in the biological activity of 
aniline mustards. 
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Prediction of Values for Untested Molecules 
Two aniline mustards, melphalan and dehydro-chlorambucil, 
were selected for activity prediction. The former because 
it is of high activity and of therapeutic use-fulness, and 
the latter because it may be the active species responsible 
for the effects of chlorambucil. MINDO/3 calculated electronic 
parameters for these molecules are as follows: 
Q (1) Q (2) Q (3) Q (7) Q (2) HOMO QT ISE 
Mel. -0.1974 
De C. -0.1971 
0.1666 
0.1646 
-0-0816 
-0.0821 
-0.0785 
-0.0822 
0.1504 
0.1647 
4.8605 
4.3646 
7.0498 
6.8701 
Values for log k were predicted for these compounds using 
equations 6.3,6.5 and 6.8. The results were as follows: 
log k (eqn) 6.3 6.5 6.8 average 
Mel. 
DeC. 
0.7779 
0.7170 
0.8753 
0.7136 
0.6827 
0.7122 
0.7786 
0.7143 
It can be seen that the melphalan figure fluctuates with 
the regression equation used, whereas the dehydro chloram- 
bucil value is remarkably constant. Both values are rela- 
tively low compared with those of other aniline mustards. 
Toxicities were predicted using equation 6.11 and these 
were found to be quite low. Anti-tumour activity predic- 
tions using equation 6.14 also showed lower than expected 
values. Chemotherapeutic indices were also predicted using 
equations 6.20 and 6.21 and the results are given below: 
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log I/LD log l/ED log CI (6-20) log CI(6.21) 
Mel. -2.5914 -3.0694 0.5134 0.5314 
DeC. -2.4642 -3-3432 0.4289 0.3231 
These findings predict activities for these compounds to 
be higher than most of the other aniline mustards though 
not as high as chlorambucil. 
CHAPTER 7 
POLY-AROMATIC HYDROCARBONS 
20S 
Introduction 
It has been-known for some years that certain poly-aromatic 
151 hydrocarbons (PAHs) are potent environmental carcinogens 
PAHs have been isolated from industrial effluent gases, 
cigarette smoke, automobile exhausts, and smoked/cooked meats. 
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They are probably formed in all instances where incomplete 
combustion of carbon-based matter occurs. The metabolism of 
many PAHs has been studied and pathways to activation and de- 
toxification outlinedl53. The ultimate carcinogens have been 
identified as being epoxy-diols, and their adducts with DNA 
154 bases have been isolated 
As a result of a series of elegant experiments, Jerina and 
co-workers'55 formulated the so-called Bay-region theory which 
is now generally accepted as an explanation for the carcino- 
genicity of many PAHs. Thus, for a PAH to be carcinogenic it 
must possess a bay-region in order to form the active epoxy- 
diol metabolite. The active metabolism of benzo(a)pyrene (BP) 
by hepatic enzymes can be shown as follows: - 
12 1 
Bayp 02 cytochrome 
P-45F Epoxide hydras& 
regitai or -448 H20 MFO I -) 3 NADPH 
9 00090 02 0 
4 am H 
650VH 
BP BP-7.8-epoxide <N 
11 
1, 
NH 
BP-7,8 dihydrodic 
a U, N NIrkN,, H NADPH 
0H 
0 
0H 
DNA 0 00 
HHH 
HHH 
BP-7,8-dihydrodiol-9,10-epoxide BP-triol-carbonium ion Guanine-BP-triol-adduct 
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The general scheme for activation and detoxification are 
given below: - 
le-toxification 
Phenols Diol phenols Tetrol 
T '11ý T "'ýDistal bay- Bay region 4 Bay region Carbonium - DNA Activation PAH "tegion epoxide diol -- diol epoxide ion Idducts 
llý-toxification Other Glutathione Other 
I 
epoxides conjugates diol epoxides 
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It has been demonstrated that the stereochemistry of the 
epoxy-diol is important in the carcinogenic effect of these 
compounds. Benzo(a)pyrene, for example, can form two sets of 
diastereomeric 7,8-diol-9,10-epoxides of which the (±) anti- 
00 
0 00 09 00 
HCr 
HH 
anti-diol epoxide (I)syn-diol enoxide 
BP-diol epoxide is the more active, and this has been shown 
to be caused by the (+) optical entantiomer. The structure 
of its guanine adduct has been establishedlS7 as shown below: 
< 
N, 
fL, , 
NH 
Prc 
N el-L 
OH 
1 
HNN 
eH 
0 
HH 
A OH w 
OH 
H OH H 
However, all four possible conformers of the diol epoxide are 
capable of forming guanine adducts, in vitro the isomer ratios 
depending on reaction conditions. fhe syn-diol epoxide is 
ZM 
capable of intra-molecular hydrogen bonding resulting from 
the juxta-positioning of the epoxy and syn hydroxy oxygens. 
This would assist in the epoxy C-0 bond fission and lead to 
enhanced nucleophilic activity of the syn-form. Therefore, 
this species is more likely to react with DNA via an SN1 
mechanism involving the carbonium ion which can be stabilized 
by internal ion pair formation. The tumorgenic anti-form, 
6- 
0 
H- 
HCr" 
a 
however, will probably form adducts with DNA involving SN 2 
attack since the SN1 ring opening at the benzylic position 
(C-10) is not 17avoured as intra-molecular hydrogen bonding 
158 '' is possible. It is found that the syn-form is approxima- 
tely 30 times more reactive chemically than the anti-form 
which is opposite to their biological action. One is led., 
therefore, to postulate the presence of two enzymes(which 
may differ only in conformation) that are responsible for 
the differing biological activity and/or formation of the 
diol-epoxides - so that the relative levels of these two 
enzymes (which might conceivably be two forms of cytochrome 
P-450) at the site of action will determine the outcome of 
pAH metabolism. 
Quantitative Structure-Activity Relationships 
A survey of the literature 
1S9 
shows unsatisfactory attempts 
at rationalizing the activity of PAHs. Qualitative studies 
appear to be Of little value and the'few quantitative analyses 
have been hampered by low correlations and the inability to 
explain the high activity of c: ompounds such as benzo(a)pyrene 
and the low activity of compounds like anthracene. It was 
thought that MO calculations would yield parameters more 
capable of providing an interpretation of PAH activity. A 
series for which a number of different biological parameters 
are available, were subjected to MINDO/3 calculations. 
Various parameters used in regression analysis with MO data 
areshown in Table 7.1 below. 
Table 7.1 
abCde log ýK log A log R loc, M 1OCT P PAH 0 
Benzene 2.13 
Naphthalene 4.52 0.7782 - -1.0458 3.37 
Anthracene 5.72 0.1461 3.0641 -2.0000 4.45 
Phenanthrene 5.24 0.8129 2.7016 -0.6021 4.46 
Pyrene 5.74 0.3424 3.0060 -1.6990 5.08 
Chrysene 6.21 1.5038 3.4842 1.5798 5.91 
Benz (a) anthracene 6.35 1.5587 3.5816 1.0414 5.69 
Dibenz(a, h)anthracene 7.05 1.7497 3.5262 1.0414 6.93 
aK is the binding constant for binding to Human Serum Albumin 
(from Ref. 159(c)) 
bA is the % repression of DMN demethylase (from Ref. 159(a)) 
cR is the rate of formation of hydroxybenzo(a)pyrene 
160 
dM is the revertants/nmol of a strain of S-typhimurium 
(TA 100)159(d) 
eP is the octanol-water partition coefficient (estimated 
using Ref. 159(b) 
Some of the MO parameters obtained are given in Table 7.2. 
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Table 7.2 
PAH 
Benzene 
Napthalene 
Anthracene 
Phenanthrene 
Pyrene 
Chrysene 
Benz(a)anthracene 
Dibenz (a, h) anthracene 
YSE 1091SN E (HOMD) E (LEW) AHf 
0.0870 2.0627 0.9841 -9.1798 1.2498 28.4287 
0.1671 3.3185 1.2S40 -8.1985 0.4748 69.4463 
0.3420 4.548S 1.1449 - 7.5005 -0.1238 101.9004 
0.2518 4.5502 1.3843 -8.0379 0.4097 94.4791 
0.3408 5.11S8 1.2181 -7.4515 -0.0992 119.4344 
0.3153 5.7910 1.5970 -7.7376 0.1374 131.6880 
0.3597 5.7837 2.0047 -7.6527 0.0254 134.4415 
0.3848 7.0366 1.8100 -7.6645.0.0650 159.7668 
Single and multiple linear regression analyses revealed a 
number of interesting relationships. 
First of all, the sum of elect rophilic superdelocalizability 
ISE shows a high degree of parallelism with log P, the partition 
coefficient. Hansch found that there is some dependency of 
log P on carcinogenic activity, and even though it would be 
naive to assume that the relative degree of hydrophobicity could 
possibly explain what is clearly a complicated biochemical 
process, it is desirable to have a theoretical parameter which 
relates well with membrane transport. The regression equation 
is as follows: - 
E qn. Relationship n D. F S R F 
7.1 log P=0.9738 ISE + 0.1017 8 1,6 0.0863 0.9986 2147.9 
It was found that log K, the HSA binding constants, depends 
upon ISE and the inclusion of IQT, the sum of the net atomic 
charges over the whole molecule, gave a significantly better 
correlation as shown below: - 
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Eqn. - Relationship % n D. F s R F 
7.2 log K=0.6729 1 SE + 2.355 7 1,5 0.1686 0.9819 134.64 
7.3 log K=0.5121 ý SF + 3.0015YQT 7 2,4,0.1176 0.9930 141.49 
+ 2.2587 
Substitution of frontier orbital energies, E(HOMO) and E(LEMO) 
for IQT yields a highly significant relation with log K. 
Eqn. Relationship n D. F SRF 
7.4 log K=0.6627 ISE - 2.6926 E (Ha4O) 7 3,3 0.0731 0.9980 246.25 
- 3.5896 E(LENIO) - 18.0009 
Thus the protein binding of PAHs can be adequately explained 
in terms of transport/lipophilicity factor, ISE, and a total 
charge density factor, IQT, which suggests that the binding 
is electrostatic in origin. However, the presence of frontier 
orbital terms point to a charge-transfer mechanism of inter- 
action and to show the goodness of fit between experimental 
and calculated values of log Kby the latter, the following 
Table is presented. Figure 7.1 shows Equation 7.1 graphically. 
Table 7.3 
log K (expt. ) log K (calc. ) Difference 
4.52 4.569 -0.049 
5.72 5.654 0.066 
5.24 5.187 0.053 
5.74 5.809 -0.069 
6.21 6.178 0.032 
6.33 6.346 - -0.016 
7.05 7.066 -0.016 
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It was though t that the % inhibition of DMN-demethylase 
might be a better indication of potential carcinogenicity than 
merely protein binding, and it was interesting to note the 
appearance of a different parameter, the total nucleophilic 
superdelocalizability, logj S NI in regressions. The results 
as shown below do not appear to be of such high statistical 
significance as the correlations with logK, though inclusion 
of log P and_ IQT adequately explain the biological data. 
Eqn. 
. 
Relationship n D, F SRF 
7.5 log A=1.7643 log ISN 1.64 7 1,5 0.2772'-0.9154 25.867 
7.6 logA=1.23021091SN 5.9530 7 3,3 0.1002 0.9936 77.709 
JQr + 0.4523 log P- 
1.3266 
A comparison of experimental and calculated values of log A 
is given below in Table 7.4. Figure 7.2 shows Equation 7.5 gra- 
Table 7.4 phically. 
log A (expt. ) log A (calc. ) Difference 
0.7782 0.7458 0.0324 
0.1461 0.0590 0.0871 
0.8129 0.8950 -0.0821 
0.3424 0.4411 -0.0987 
1.5038 1.4345 0.0693 
1.5587 1.5722 -0.0135 
1.7497 1.7442 0.0055 
The correlation with nucleophilic superdelocalizability, 
log Is NI suggests that electron-transfer from receptor to 
substrate occurs, whereas the net molecular charge, IQT,, 
shows that the initial interaction is electrostatic in origin. 
1. 
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214 
Importance of lipid solubility is implicated by the inclusion 
of the log P term. The induction of aryl hydrocarbon hydroxy- 
lase (AHH) as measured by the log R parameter is another 
indication of biological activity, though this-does not 
necessarily signify a causal relationship with carcinogenicity: 
which can also be said of log A and log K Log R did not 
appear to correlate well with any of the reactivity indices 
employed to date, though there was a certain degree of corres- 
pondence with ISE - no positive inference could be made on 
that result. 
Though there is still a great deal of controversy about the 
comparability of mutagenicity and carcinogenicity, it was 
thought useful, if indeed necessary, to establish any relation- 
ship between bacterial mutagenicity, log M, and theoretically- 
desired parameters. The results of regression analyses for 
this is given in Table 7.5. 
Table 7.5 
Parameters D. F RF 
109 YSN i's 0.8801 17.183 
Q(8)HOMO, SN(9) 2,4 0.952 19.364 
Q(8)LEMO, SN(9) 2p4 0.9683 30.014 
SE(9), log ISN 2,4 0.9512 19.007 
In view of the interest in, and obvious importance of, diol- 
epoxides of PAHs and their formation, it was deemed appropriate 
to include electron densities, frontier electron densities, 
and superdelocalizabilities of individual carbon atoms into 
the regression analyses. Results are shown in Table 7.6 
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Table 7.6 
Q (7) HOMO Q (8) HOMO Q (9) HOMO Q(10)HOMO E (HOMO) E (LEMO) 
A 0.3473 0.1228 0.1872. 0.3397 -8.1985 0.4748 
B 0.3630 . 0.0298 0.0186 0.3504 -7.5005 -0.1238 
C 0.0405 0.0856 0.3104 0.2776 -8.0379 0.4097 
D 0.1617 . 0.1617 0.0938 0.0001 -7.451S -0.0992 
E 0.1899 0.1946 0.1250 0.2737 -7.7376 0.1374 
F 0.1192 0.1697 0.0481 0.0368 -7.6S27 0.0254 
G 0.1440 0.1610 0.0688 0.0028 -7.6645 0.06SO 
Q(7)LEMO Q(8)LEMO Q(9)LEMO Q(10)LEMO E. E. T. E. 
A 0.3448 0.1203 0.1940 0.3368 -6591.211 -1383.906 
B 0.3678 0.0328 0.0192 0.3568 -10826.038 -1919.549 
C 0.0303 0.0777 0.2992 0.2504 -10904.438 -1919.871 
D 0.1585 0.1568 0.0971 0.0001 -13298.219 -2172. S49 
E 0.2056 0.2117 0.1118 0.2706 -15758.805 -2455.307 
F 0.1008 0.1515 0.0415 0.0490 -15680.845 -2455.188 
G o. 1086 0.1492 0.0445 0.0159 -20942.888 -2991.140 
SE (7), SE (8) SE (9) SE (10) SN (7) SN (8) SN (9) SN (10) 
A 0.2761 0.2721 0.2727 0.2747 1.4768 1.3471 1.3960 1.4573 
B 0.2814 0.2689 0.2711 0.2808 -2.0867 0.9885 I-15S7 -1.9919 
c 0.2740 0.2730 0.2762 0.2759 1.4539 1.4543 1.6499 1.6010 
D 0.2785 0.2785 0.2704 . 0.2724 -0.5123 -0.4913 0.1700 1.2846 
B o. 2785 0.2760 0.2765 0.2771 2.5912 2.6287 2.0386 2.9209 
F 0: 2742 0.2764 0.2721 0.2750 5.2313 7.0732 3.0504 3.3904 
G o. 2757 0.2758 0.2720 0.2747 3.0164 3.4082 2.3071 2.0898 
Q(8) (Q9) Q(10) QT YSE 1091SN Hf 
A -0.0126 0.0072 0.0049 -0.0076 0.1671 3.3185 1.2540 69.4463 
B -0.0201 0.0325 0.0259 -0.0179 0.3420 4.5485 1.1449 101-9004 
c 0.0155 0.0241 -0.0281 -0.0075 0.2518 4.5502 1.3843 94.4791 
D -0.0139 -0.0146 0.0331 0.0079 0.3408 5.1158 1.2181 119.4344 
E 0.0127 0.0119 -0.0077 -0.0078 0.3153 5.7910 1.5970 131.6880 
F -0.0013 -0.0092 0.0284 0.0090 0.3597 5.7837 2.0047 134.4415 
G -0.0066 -0.0063 0.0271 0.0143 0.3848 7.0366 1.8100 159.7668 
Key: A-Naphthalene D-Pyrene G-Dibenz(a, h)anthra- 
B-Anthracene E-Chrysene 
w cene C-Phenanthrene F-Benz(a)anthracene 
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A summary of the best correlations for logK is presented as 
follows: - 
ý- I- I- -7 '7 
Parameters D. F R F 
ISE) Q(9) HOMO 2)4 0.9956 228.378 
ISE,, Q(9) LEMO 2$4 0.9961 255. S88 
ISEý Q(8)HOMO, Q(9) HOMO 3)3 0.9986 362.962 
ISE, Q(8)HOMO, Q(9) LEMO 3p3 0.9987 394.501 
ISE, SE(8), Q(9) HOMO 3,3 0.9987 398.956 
ISE' SE (10) P, Q (9) HOMO 3,3 0.9993 685.463 
ISE., SEUO), Q(9) 3,3 0.9995 1046.217 
whereas, for log A the results of interest are shown below: - 
Table 7.8 
Parameters D-F R F 
SN(8) 1,5 0.9075 23.329 
SN(8), 109 ISN, Q(10)LEMO 3,3 0.9854 33.604 
SE(8), ISE, SNGO) 3p3 0.9856 34.054 
JQTý, ISE., 109 ISN 3,3 0.9896 47.466 
I. QT, SE, SN(8) 3,3 0.9947 93.819 
For loiz R. the following correlation was most significant: - 
Table 7.9 
Parameters RF 
Q(7) HOMO, Q(8) HOMO, 1091SN 3,2 0.9974 129.925 
In all cases, cross-correlations were eliminated from regres- 
sions. The implication of these results is that the biolo- 
gical activity of PAHs is dependent upon a bulk molecular 
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property, ISE, IQTI or 109 JSN; and upon an electronic 
property, Q(N), Q(N)HOMO/LEMO, or S E(N)ISN(N), pertaining 
to certain key atoms of the distal aromatic ring which are 
known to give rise to active diol-epoxides, Eence these 
results lend a good deal of support to the Bay-region theory 
and it only remains to be extended to include either more 
PAHs or to concentrate on the diol-epoxides to provide an 
explanation-for their variation in activity. 
There are a number of points worthy of mention by way of 
critical assessment of this work. It can be said that there 
is a degree of uncertainty about the validity of the biolo- 
161 
gical parameters used in the correlations The use of 
protein binding (log K) can be criticized because PAHs are 
generally taken in via the lungs, thus causing lung tumours 
rather than liver tumours (although metastasis can occur), 
which are usually studied in animal experiments using PAHs. 
The liver brings about metabolism, whereas the lungs do not 
and protein binding (HSA) which is reversible is not going to 
give much idea of carcinogenicity. In fact, this type of 
process is partly detoxifying in action. The inhibition 
of the enzyme DMN-demethylase (log A) also does not 
necessarily relate to the carcinogenicity of PAHs. Dimethyl 
nitrosamine (DMN) is very much more toxic than any PAH, and 
its mode of action and metabolism are quite different. The 
induction of benzo(a)pyrene-3-hydroxylase (log R) may not 
necessarily be related to carcinogenicity since this is a 
detoxifying mechanism. DNA binding, which is covalent and 
henceirreversible, should be a better regulator of carcino- 
A 
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genicity, though it certainly does not provide a complete 
picture. However., it has been found that DNA binding gives 
a good correlation with log A when other parameters such as 
logK and protein binding are included. The regression 
equation is given below and the data are reproduced in Table 
7.10. 
E qn. Relationship nsRF 
7.7 log A=0.7938 log K-1.7075 PRO 6 0.1093 0.9895 70.32 
-2.1855 
T. 8 log A=0.8520 log K-1.8671 PRO 6 0.1020 0.9939 S4.26 
-0.1520DNA- 2.3222 
Key: PRO = Protein binding DNA = DNA binding 
It is reasonable to say that there is still as yet no reliable 
quantification of carcinogenic activity. There is a great 
deal of mutagenicity testing in bacterial and animal systems 
but this does not seem to bear a simple relationship to 
carcinogenicity. There needs to be a set of reliable 
carcinogenicity indices for PAHs before a proper QSAR study 
can be carried out, even though there appears to be a good 
deal of evidence to support the Bay-region theory, some 
carcinogens do not possess a Bay-region and some non- 
carcinogens do. The reactivity of PAHs like benzo(a)pyrene 
may be caused by the fact that the ring system is distorted 
out of planarity by steric interactions between hydrogen atoms 
across the bay-region. This might bring out an increase in 
double bond character at the 7 and 8 carbon positions, thus 
explaining the propensity for epoxidation at this site. 
Finally, it is difficult to provide a rationalization for 
-NH2 attack by diol-epoxides on guanine since alkylation 
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Table 7.10 - 
Data used for generating equations 7.7 and 7.8 
Molecule PRO DNA log k log A 
Phenanthrene 0.72 0.05 5.24 0.8129 
Pyrene 
Benz(a)anthracene 
Dibenz(a, h)anthracene 
Benzo(a)pyrene 
1.15 0.31 5.74 0.3423 
0.76 0.70 6.33 1.5587 
0.95 0.44 7.05 1.7497 
0.78 1.41 6.60 1.6191 
Dibenz(a, c)anthracene 1.07 0.56 7.09 1.7364 
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is known to occur at the 0(6) or N(7) positions as predicted 
by molecular electrostatic potential maps. It may be that 
the amine function is better disposed for nucleophilic attack 
above the plane of the guanine ring. 
Table 7.11 
Eqn. Relationship nSRF 
7.9 log A =5-. 23 QS(HOMD) + 0.47 SN (9) 8 0.2193 0.9586 22.666 
-0.50 
7.10 logA=0.24 SN(7) + 0.60 
7.11 logA= 1.76 logjSN - 1.64 
7.12 logK= -52.13SE(8) + 302.95Hf 
+16.62 
8 0.2894 0.9075 23.3291 
8 0.2772 0.91S4 25.8667 
8 0.0356 0.9994 1565.9172 
7.13 log M= 12-70 Q(8) HOMO + 1.04SN (9) 
-3.67 
8 0.5431 0.9520 19.3637 
7.14 log M= 221.4 S. E (9) + 3.66 log 
I SN 8 0.544S 0.9SI8 19.2494 
-66.12 
7.15 log M= 13.02 Q(8) LEMO + 1.08SN(9) 8 0.4437 0.9683 30.0139 
-3.74 
7.16 logR = -4.94 Q(9) LEMO + 2.53 Q(7) 6 0.1138 0.9688 22.93 
+3.79 
In summary, Table7.1. Lshows the results of significant regression 
analyses between electronic parameters and biological activity 
for poly-aromatic hydrocarbons. Atom centres 8 and 9 are 
clearly important in defining the activity of these molecules, 
although some parameters for the whole molecule are sometimes 
necessary to provide a better explanation of the data. Those 
atoms involved belong to the distal bay-region of these Tiole- 
cules and hence lend strong support to the bay-region theory 
of carcinogenic activity. 
221 
Oxygen-aromatic hydrocarbon interactions 
The production of carcinogenic compounds from poly-aromatic 
hydrocarbons is brought about by the interaction between these 
substrates and molecular oxygen in the presence of the enzyme 
cytochrome P-450. It has been established that P-450 mediates 
in the epoxidation and hydroxylation of poly-aromatic hydro- 
carbons 
162 
. but the mechanism 
for this is not fully understood. 
Basically, there are two ways in which the oxygen molecule can 
react with an aromatic hydrocarbon. 
a) production of an epoxide: - 
00 
P-4 50: ý 
b) production of a diol: - 
(a 0 P-430 2 +H 20 
These are: - 
epoxide 
0 
+ 
oxygenated 
P-450 
OH ýC 
H 
OH 
diol 
The formation of an epoxide involves end-on interaction 
between oxygen and the substrate, whereas_diol formation is 
a result of edge-on interaction as shown below: - 
Fe 
---0 
F 
(a) end-on interaction (b) edge-on interaction 
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The type of interaction that is preferred in a given situation 
probably depe nds on relative reactivity of carbon-carbon 
bonds and electronic state of the oxygen molecule. The type 
of interaction is a result of orbital overlap between oxygen 
and substrate. It seems likely that oxygen has to be in an 
excited state (singlet oxygen or superoxide anion) for these 
reactions to occur and, therefore, the r6le of P-450 is to 
promote the electrons of ground state triplet oxygen into 
higher energy levels. A possible reaction scheme for 
oxygen activarion and interaction may be outlined as follows: - 
Fe 2+ +30 excitation Fe 
2+... 
. 
10 
2 
electron Fe 3+_O 2 
-* 
(P-450) triýlet by excited tT an sf eir" superoxide state P-450 singlet state anion 
RH 
ROH 
3+ Fe 
oxene 
It has been found from the study of molecular oxygen spectra 
163,164 that the singlet excited state lies about 94kJ above 
the triplet ground state as shown in the energy level diagram 
below: - 
Energy (kJ. mole-1) State Energy (eV) 
ý 1ý I+ 157.01- 4- X9 16.27 
94.21. Ag 9.76 
0- -110.0 II-9 
0(l) 0(2) 
Singlet/Triplet energy levels in the dioxygen molecule 
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It has been observed that during the course of binding of 
molecular oxygen to iron-porphyrins a movement of the 02 
molecule relative to iron occurs. This may result in (or 
be associated with) the change in charge distribution 
corresponding to the triplet/singlet inter-system crossing. 
Also, it is thought that the interaction of triplet oxygen 
with carbon-carbon 7T-bonds brings about a crossover to the 
oxygen singl et state. The reaction between oxygen and 
ethyne produces a dioxetane intermediate which then disso- 
165 
ciates back to singlet excited oxygen and the alkyne again 
Such an interaction between carbon-carbon Tr-bonds and oxygen 
CH 3 
CH-0 CH 
III 
+02 
11 1ý 111 +'02 
CH CH -0 CH 
dioxetene 
may be another link in the chain of oxygen activation by 
substrates prior to electron-transfer. The possibility of 
a dioxalkene intermediate in the dihydroxylation mechanism 
for diol formation from aromatic hydrocarbons has been in- 
vestigated in this work. The postulated mechanism would be 
as follows: - 
HH 
10 H20 OH 
+ Fe - 02 1, 
10 
OH 
(P-450) H (P-450) H 
benzene dioxocyclohex- diol 
adiene 
The transition from the intermediate to the diol needs to be 
mediated by an electron sink so it would Probably be attached 
to the iron P-450 complex. There is also a possibility that 
the dioxalkene can undergo decomposition to yield an epoxidep 
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as shown below: - 
H OH 
OH 
6' 
'C' 
N 
H% 411 Fe 
.7 
diol 
H 
H 
epoxide 
The P-450 oxene intermediate formed after mono-oxygenation is 
also an active species. This is able to react with water to 
form the hydroxyl radical OH which can further hydroxylate 
substrates. Also, it should be noted that the free super- 
oxide anion is able to react with hydrogen ions (present in 
excess in cancer cells) to form hydrogen peroxide and re- 
generate oxygen: - 
202 + 2H + H202 + 02 
+ +homolysis or 02 +H --+ OH* 
superoxide hydroxyl radical 
(active hydroxylating 
radical anion 
species) 
Due to the fact that previous MO calculations 
166 indicated 
that the intermediate dioxetanedione (thought to participate 
in chemiluminescence reactions 
147 ) was a stable entity, it 
was of interest to determine the relative stability of dioxo- 
cyclohexadiene, the postulated intermediate in P-450 hydroxy- 
lations. The rationale for this lies in a corollary of the 
22S 
bay-region theory. It appears that non-planarity of the 
ring system is a result of the possession of a bay-region 
(or pseudo bay-region) in poly-aromatic hydrocarbons. The 
effect that this has to enhance the reactivity of the mole- 
cule at certain key positions by conveying greater double 
bond character. 
The result of MINDO/3 calculations on the dioxygen-benzene 
adduct, dioxocyclohexadiene, indicated that the molecule was 
relatively stable with a preferred conformational geometry 
as shown below in Figure 7.3. 
1.541 
1.375 
_I 
I/ 
1.484 
\ 
1.486 
1.39 
Figure 7.3 
1.375 Preferred geometry of 375 
Dioxocyclohexadiene 
_H 
(Bond len ths are 
given in 
Ingstrom 
units) 
1.484 
89 0 891 
1.39 
H 
1.424 
An edge-on view of the same molecule is shown below in Figure 
7.4 where the conformation of the bicyclic system can be 
seen. 
Figure 7.4 
Dioxocyclohexadiene 
(Dreferred conformation) 
H 
226 
The hexadiene ring system is twisted out of planarity by 
about 40., whereas the oxygen atoms prefer to lie 30 out of 
alignment. The calculated heat of formation of this con- 
figuration is +18.76 kcal mol-1, whereas if the hexadiene 
ring is kept planar and the oxygen atoms are aligned in 
juxtaposition the molecule is less stable at +19.97 kcal mol-1. 
These results show that the intermediate is relatively stable 
and that its stability is increased if it is distorted out 
of symmetry. In a polyaromatic hydrocarbon such as benzo(a)- 
pyrene, whichýis a potent environmental carcinogen, the 
geometry is such that the ring system is non-planar 
167 
and 
this could be a contributory factor in its activation by 
oxygen. It is the presence of a bay-region that causes this 
non-planarity because of steric interactions between hydrogen 
atoms. One can envisage a similar non-planarity with concomitant 
carcinogenicity in certain methyl benzanthracenes. 
In addition, it was of interest to study the interaction 
between oxygen and an aromatic hydrocarbon to ascertain a 
likely mechanism for activation. MINDO/3 calculations on 
gr ound state and singlet excited state oxygen revealed the 
following information. 
ýJolecule E(HOMO) E(LEMO) E(NEMO) Bond length 
302 
102 
-10.0552 
-25.1765 
-0.1802 
-15.3503 
+5.7028 
-10.3398 
1.2061 
1.1404 
If one considers interaction with the benzene molecule, then 
inspection of the frontier orbital energies shows that the 
only possible mode of orbital overlap is as shown in Figure 7.5. 
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Figure 7.5 
Interaction between 
the next empty MO on 
singlet excited 
oxygen and the HOMO 
of benzene 
E(NEMO)102ý-10-3398eV 
E (HOINIO) benzene 
-9.1798eV 
Any other type of orbital overlap is unfavourable from energy 
considerations. The HOMO energies of other aromatic hydro- 
carbons are of the same order as benzene, although they are 
slightly less negative. It is possible that binding to the 
iron atom in P-450 tends to increase orbital energies on oxygen. 
The optimized bond lengths for the two oxygen species are 
interesting because crystallographic data for model iron- 
dioxygen complexes 
169 
show an unusually short oxygen-oxygen 
bond length of 1.15 
X. This has hitherto been inexplicable 
in terms of the electronic state of the oxygen molecule because 
ground state oxygen and the superoxide anion have substantially 
170 
greater bond lengths of 1.207 and 1.26 
X respectively The 
agreement between the optimized value for singlet oxygen and 
the experimental data is excellent and leads one to postulate 
the following mechanism for the interaction: - 
OU + 
101 
-1 
-1 4.1 
. 00. 
Fe 
H 
00 
e-, 
Fe 
%b 
/,. 
I- 
Fb 
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In summary, therefore, it can be said that MO calculations 
facilitate a study of aromatic hydrocarbon hydroxylations by 
activated oxygen in the presence of the enzyme cytochrome P-450. 
It remains to be seen whether calculations on model iron- 
porphyrin dioxygen complexes can completely elucidate this 
complicated metabolic pathway. 
CHAPTER 8 
NITROSOUREAS 
229 
Introduction 
The nitrosoureas form a recent group of tumour-inhibitory 
compounds that derive their clinical usefulness from high 
171 lipophilicity allied to low toxicity The three deri- 
vatives172 of the parent structure nitrosourea (NU) which 
have been particularly successful in effecting cures are 
BCNU (carmustine), CCNU (lomustine), and MeCCNU (semustine) 
Figure 8.1 
1,3-bis(2-chloroethyl)-l-nitrosourea 
1-(2-chloroethyl)-3- 
cyclohexyl-l-nitrosourea 
(CCNU) 
1-(2-chloroethyl)- 
3-(4-methylcyclo- 
hexyl)-l-nitrosourea 
(MeCCNU) 
Carmustine (BCNU) has shown clinical application in the 
173,174 
treatment of a wide range of tumours For example, 
brain tumours, colorectal tumours, adenocarcinoma, gastric 
adenocarcinoma, hepatoma, Hodgkin's disease, malignant 
melanoma, multiple myeloma and non-Hodgkin's lymphomas. 
It is highly lipid soluble, but also has water solubility 
conferred by a number of polar moieties. Apparently its 
as shown below. 
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mode of action is basically that of alkylation of DNA bases, 
and its possession of two chloroethyl groups enables cross- 
linking of D NA strands to occur. Also, it has been found 
to inhibit a number of enzymatic reactions connected with 
nucleic acid synthesis; for example, BCNU interferes with the 
incorporation of thymine residues into DNA, interrupts DNA 
polymerase activity, and inhibits DNA repair mechanisms. 
Lomustine (CCNU) displays therapeutic activity against brain 
tumours, colorectal tumours, Hodgkin's diseasel74(b) . multiple 
myeloma, gastr-ointestinal carcinoma, lung carcinoma and 
prostate tumours. It has a solubility similar to 
BCNU and probably acts in an analogous manner. That is, as 
an alkylating agent coupled with inhibition of several cellu- 
lar processes. CCNU is therefore not cell-cycle specific, 
though, like BCNU, it appears to have a propensity for arres- 
175 
ting cell growth in the G2 phase 
Semustine (Me-CCNU) possesses the wide range of anti-tumour 
activity shown by the previous agents. In fact, it has been 
found to have a greater activity toward solid tumours than 
176 
other tumour-inhibitory nitrosoureas . It has a greater 
lipid solubility than CCNU and 13CNU and also has the advantage 
(together with CCNU) of administration by oral dosage. Its 
biological mode of action is similar to the previous clini- 
cally useful drugs, BCNU and CCNU. 
Although the anti-tumour activity of the titrosoureas is 
relatively low, compared with other agents, they benefit 
from their low toxicity and ease of transport through lipid 
membranes for the treatment of CNS and lung tumours. 
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The mechanism by which nitrosoureas effect their biological 
177 
action is thoug t to proceed as follows: - 
0 
/CN OH 
E) 
CICH CH -N NHR 
ClCH CHF-N"CAQýý 
2221, ý I 
N, 
ý, -N 
H 
N 
1110 
0 
OH E) @ E) ClCH CH OH <- Cl H CH +N +OH <- ClCH CH 
nN= 
N,, OH + R-N =C=0 2222222 .r 
2-chloro ethanol 2-chloroethyl diazene isocyanate 
nucleic acid + hydroxide 
proteins proteins 
monoalkylation of nucleic acids +proteins 0 
and interstrand cross-linked DNA 11 protein-C-NHR 
carbamoylated 
proteins 
Table 8.1 Comparison of the lipophilicity and anti-tumour 
activity of the three main clinically useful nitro- 
soureas 
BCNU CCNU MeCCNU 
log P (octanol/water 
total % activity vs. 
tumour type 
Brain 
Brain (Gliomas) 
Hodgkin's disease 
Non-Hodgkin's 
jymphoma 
Melanoma 
Lung 
Breast 
Colorectal 
Head + neck 
Renal cell 
Cervix 
1.53 2.83 3.30 
29% 18% 12% 
47% 41% 27% 
45% 37% 23% 
44% 48% 26% 
28% 25% 18% 
18% 13% 12% 
11 % 16% lo% 
21% 12% 4% 
13 't 9% 11 % 
16% 8% 11 % 
7% 0% 
13% 
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Thus, at physiological pH, the nitrosoureas decompose to 
yield an isocyanate and 2-chloroethyl diazene hydroxide. 
The latter is a precursor of the 2-chloroethyl carbonium ion, 
which is thought to be the alkylating species.. The presence 
of isocyanate has been indicated by considerable carbamoy- 
lation of protein constituents., notably c-amino groups on 
lysine. At pH below 7.4, however, other mechanism occurs 
99 
with the formation of ethenediazohydroxide, CH 2=CH-N=-N OH 
which will spontaneously decompose to give the ethene car- 
bonium ion, CH 2=CH a strongly alkylating species. Reaction 
of this carbonium with water would yield ethenol and sub- 
sequently tautomerise to ethanal: - 
00 
R cR0 
CICH CH N"" ) C1CH CH N, . 001 22 _N CH C=NR 1q V- 22-12 
N, e 0HNC 
OH 
-N 
H N=O 
Vk 
CH 2 =CH-N=N-OH + R-N=C=O 
CH CH 
@=N+OH E) -N? 4. CH = CH 
0 OH 9b CH = CH-OH 2 Ký -22 
stabilised by proton transfer resonance 
CH 3 CHO 
Montgomery and co-workers 
179 have shown that the expected 
CH 3 CHO reaction products are 
indeed formed by the decompo- 
sition of I-alkyl-l-nitrosoureas, BCNU and CCNU in aqueous 
media. 
Reaction of nitrosoureas with nucleotides produces a number 
of alkylation products, e. g. for BCNU and PolY G--C the 
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following species are formed: - 
CF+ý 
I 
FPC IH Z) 
H 
HO&, 
Figure 8.2 
prodiicts of N-3 alky- 
lation of cytosine 
product of N-7 alky- 
lation of guanine 
H2 
7-(a-amino-ethYl) guanine 
Methyl-nitrosourea (MeNU) , however, has been found to methylate 
guanine at the 0-6 position; whereas BCNU produces 7-(R-amino- 
ethyl) guanine on alkylation product not formed by CCNU and 
so presumably derives from the 3-chloroethyl moiety. 
180 
A recent study on DNA interactions withMeNUat differing 
pH values indicates the possibility of a range of reaction 
products derived from various different reactive interme- 
diates. Since it has been establishedl8l that N(7)-methy- 
lation of guanine does not give rise to miscoding, whereas 
0(6)-methylation does - indicates a possible explanation for 
the high activity of MeNUand also of the low toxicity of BCNU. 
However, the effect of inter-strand cross-linking is likely 
to have relevance in the biological mode of action of BCNU, 
as is its potential for inter-base bi-alkylation. 
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Geometry Optimization 
The molecular structure of trans-4-methyl CCNU (MeCCNU) was 
available from the results of X-ray studies 
182 
, and this 
has been used as the basis for molecular geometry optimization 
of the nitrosoureas. The solid state structure of MeCCNU 
indicates that the nitrosourea framework of atoms (1 to 9) 
is approximately planar with the chloroethyl moiety forming 
on 880 dihedral angle to this plane. 
planar nitrosourea grouping 
showing atomic numbering 
system used in MINDO/3 
calculations 
The cyclohexyl ring is situated at a dihedral angle of 740 
with respect to the nitrosourea plane as shown in Figure 8.3 
Figure 8.3 
molecular structure of 
MeCCNU showing the cyclo- 
hexyl and chloroethyl 
moieties twisted out of 
the plane of the nitro- 
sourea group. 
Bond length data for this molecule are shown in Table 8.2 
below. The values are in close agreement with accepted bond 
lengths for similar compounds. 
23S 
Table 8.2 Bond Lengths, 
C(2) 0(l) 1.213 
C(2) N(3) 1.431 
N(3) N(4) 1.333 
N(4) O(S) 1.218 
C(2) N(6) 1.323 
N(3) C(9) 1.482 
The conformational dihedral angles of the chloroethyl and 
cyclohexyl groups were optimized during MINDO/3 calculations 
based on the crystal geometry. Results were found to be in 
good agreement with those of the solid state structure. 
Table 8.3 
Dihedral angles Exptl. MINDO/3 
Chloroethyl 88 0 870 
Cyclohexyl 740 80 0 
This optimized structure was then used to generate geometry 
calculations for all the nitrosoureas in the study. It was 
found that substitution of the cyclohexyl ring, especially 
in the 2-position brought about changes in the dihedral angle 
between the cyclohexyl and nitrosourea atom planes. The 
average values for dihedral angle between cyclohexyl and 
nitrosourea atom planes for 2-, 3-, and 4-substituents are 
shown below in Table 8.4 where the effect of proximity of 
Table 8.4 
Substitution Average dihedral 
angle 
2-substituents 66.5 0 
3-substituents 75.00 
4-substituents 77.50 
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substituent to the point of attachment with the nitrosourea 
moiety lower s the cyclohexyl twist angle. One of the com- 
pounds in this study was actually substituted in the 1-position 
and this produced a marked effect on the dihedral angle in 
bringing the two groups almost co-planar with a twist angle 
of 2.60. This was due to steric hindrance between the cyclo- 
hexyl substituent and the nitrosourea group. 
The molecular geometries of the simpler nitrosoureas MeNU, 
EtNU, chloroethyl nitrosourea (CNU), and BCNU, were optimized 
using CCNU as a basis structure by allowing relevant bond 
lengths and dihedral angles to achieve their respective minima. 
The preferred conformations of these molecules are reproduced 
below in Figures 8.4 to 8.7. 
Series of Compounds 
The nitrosoureas for which anti-cancer activity data was 
available were divided into two groups: those derived from 
methyl nitrosourea and those derived from cyclohexyl chloro- 
ethyl nitrosourea. The first group of 18 compounds183 
comprises three equal series of structurally similar nitro- 
soureas listed as follows: - 
Table 8.5 NO 
Alkyl nitrosoureas R--0 
N "- CONH 2 
R log 1/LD 50 log $ ILS 
' CH 3 (MeNU) -1.7559 
2.0374 
c2H5 (EtNU) -1.4771 1.5315 
CH 2 CH 2 
C1 (CNU) -0.7482 2.1173 
CH 2 
CH 2 CH 3 -1-7634 
1.4771 
CH 2 CH =CH 2 -2.000 
1.5051 
CH 2 CH 2 CH 2 
CH 3 -1.2553 1.4624 
237, 
Figure 8.4 
H- --H 
MeNU 0 
1.474 /. 
N-N 
/ 1.427 
Oýc 
1.3A 
11 -H / 
H 
mq 
Figure 8.5 
EtNU 1.522 
Figure 8.6 
CNU 
Figure 8.7 
BCNU 
1.521 
1.4 5 
. 427 
30.0 - 46.985 
0.398 -48.449 
Dihedral angles 
00 eo 
Of kcal. mol. -l 
0.398 180.0 
-28.076 184.698 
Dihedral angles 
ý0e0 
-50.200 
-S4.183 
AHf kcal. mol. -1 
-30.0 150.0 
-41.792 157.317 
Dihedral angles 
00 60 
-61.481 
-62.386 
AHf kcal. mol. -l 
220.0 180.0 
229.783 168.780 
Dihedral angle ýO Aff kcal. mol. - 
I 
-69.512 
-70.265 
23 ý- 
Table 8.5 continued 
NO 
k 
N-Phenyi Me Me-' 
Ný, COQýR' 
RI 
log l/LD so log % ILS 
H -1.3802 1.3424 
F -1.000 1.4624 
cl -1.5798 1.4472 
OMe -1.5051 1.5185 
C02Et -1.5563 1.8261 
C02H -1.4472 2.0128 
NO 
N 
Chloroethyl nitrosoureas ClCH CH'--"' CONHRII 22 
R" log 1/LDSO log % ILS 
CH 2 CH 2 Cl 
(BCNU) -0.4914 2.2648 
CH 2 Co 2 Et -0.9542 
1.4150 
CH -0.4914 1.9494 
CH 2 CH 2 
CN -1.0792 1.7243 
(CH 2)3 Co 2H -2.000 
inactive 
CH2ýýCH 3 -1.6128 
inactive 
The second group of 30 compounds consists of CCNU derivatives 
as shown in Tables 8.6 and 8.7 
Anti-tumour data for these nitrosoureas was obtained from the 
work of Montgomery et al, using the leukemia L-1210 test 
system 
184 
. MINDO/3 calculations were executed on these 
molecules and the results are tabulated below 
in Tables 8.8 to 
8.10. The order in which the narameters appear are the same as 
the order of the biological narameters. Pegression equations are 
shown in Table 8.11. 
23P 
Table 8.6 Cyclohexyl chloroethyl nitrosoureas'84 
NO 
14 
ClCH CH _,, 
N.,, CONHoý 6 
225 
Substituent Ilog 1ýLD, O Ilog l/EDSO I log CI Ilog P 
H -1.6812 -1.5682 0.1130 2.83 
cis 3-Me -2.0792 -1.6532 0.4260 3.30 
trans 4-But- -2.6739 -2.4771 0.1968 4.51 
trans 4-Me -1.6232 -1.2553 0.3680 3.30 
I-Co 2 Et -2.6990 -2.4914 0.2076 3.06 
3,5,5-tri Me -2.8751 -2.5740 0.3010 4.33 
cis 3-C02 Et -1.6990 -1.4393 0.2596 3.06 
trans 4-CO 2 Et -1.5185 -1.2304 0.2881 3.06 
cis 3- Bu t -2.2227 inactive inactive 4.51 
trans 4-Et -1.9731 -1.4914 0.4818 3.83 
cis 4-CO2 H -1.4150 -1.1903 0.2246 -1.14 
trans 4-CO2 H -1.4314 -1.2175 0.2139 -1.14 
trans 4-CO2 Me -1.4150 -1.1461 '0.2688 2.56 
trans 4-OMe -1.5798 -1.3617 0.2181 2.36 
cis 4-CO2 Me -1.7324 -1.1761 0.5563 2.56 
cis 3-CO2 H -1.5315 -1.3118 0.2197 -1.14 
trans 4-Cl -1.6902 -1.3522 0.3380 3.22 
trans 4-CH 2 O. Co. me -1.4472 -1.1461 0.3010 3.06 
trans 4-CH 20 2* CH -1-3424 -0.9823 0.3602 2.56 
trans 4-CH 2 Co 2H -1.6021 -1.0792 0.5229 -0.64 
cis 4-OMe -1.6021 -1.3010 0.3010 2.36 
cis 4-CH2CO2 H -1.7634 -1.4314 0.3321 -0.64 
cis 2-OCO. Me -1.6902 -1.4314 0.2588 2.56 
trans 2-OCO. Me -1.5563 -1.1461 0.4102 2.56 
trans 4-CH2C' -1.7924 -1.6335 0.1589 3.69 
trans 4-OH -1.6232 -1.1461 0.4771 1.00 
cis 4-OH -1.6628 -1.3324 0.3303 1.11 
trans 3-Me -2.0414 -1.7243 0.3171 3.30 
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Table S. 7 
CCNUs: Alkylating and Carbamoylating Acitivity 
Substituent 
H 
cis-2-Cl 
trans-2-Cl 
trans-4-Me 
trans-4-C02Et 
trans-4-Et 
cis-4-CO 2H 
trans-4-C02H 
cis-2-OCOMe 
trans-2-OCOMe 
trans-3-Me 
cis-4-OH 
trans-4-OH 
log k Calkylation) log k (carbamoylation) * 
-0.2840 1.0 
0.1024 0.3897 
0.1239 0.7418 
-0.2840 0.9086 
0.0414 - 
-0.3768 0.7192 
-0.57S1 - 
-0.5952 
0.0542 O. SO18 
0.0438 1.0188 
-0.3925 - 
- 0.719S 
0.3914 
* relative to CCNU 
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Table S. 8 
CNUs Electronic Parameters used in RegressiOn equations 
Q(6) Q (6 
.) 
HOMO Q (9) H0,110 Q (1) 11140 Q (3) LEMO Q (6) LENIO SN (4) SN (6) 
-0.2731 0.0065 0.1242 0.0706 0.1312 0.0301 2.8608 0.9758 
-0.2738 0.0043 0.1411 0.0712 0.1341 0.0305' 2.7637 0.969S 
-0.2694 0.0052 0.1432 0.0235 0.0777 0.0332 3.3543 1.0994 
-0.2740 0.0041 0.1524 0.0714 0.1340 0.0307 2.6925 0.9577 
-0.2729 0.0026 0.1293 0.0741 0.1538 0.0438 2.9868 1.0119 
-0.2741 0.0047 0.1602 0.0716 0.1341 0.0307 2.6626 0.9522 
-0.2444 0.0167 0.1019 0.1036 0.2655 0.2041 2.4416 1.1357 
-0.2349 0.0408 0.0055 0.0348 0.0835 0.1077 2.8508 1.4787 
-0.2407 0.0329 0.0464 0.0185 0.0442 0.0641 2.8781 1.54SO 
-0.2329 0.0286 0.0073 0.1117 0.2795 0.2370 2.3579 1.1067 
-0.2518 0.0154 0.1052 0.0174 0.0536 0.0246 3.3272 1.7137 
-0.2530 0.0144 0.1073 0.0126 0.0407 0.0165 2.7774 1.1690 
-0.2476 0.0083 0.1351 0.0004 0.0001 0.0016 3.3897 1.7894 
-0.2274 0.0282 0.1431 0.1190 0.1816 0.312S 5.7881 0.5111 
-0.2406 0.0121 0.1252 0.0932 0.2686 0.1886 2.8027 1.2954 
-0.2504 0.0086 0.1330 0.1058 0.2907 0.2458 3.2570 1.6088 
-0.2532 0.0120 0.1319 0.1068 0.2920 0.25S7 4.2306 2.3583 
-0.2484 0.0421 0.0615 0.0742 0.1953 0.2090 2.8243 1.5258 
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Table 8.9 
CCNUs MO parameters for biological activity and log P regres ions 
Q(2) Q (7) Q(1)LEMO Q(6)LEMO Q(7)LE'40 Hf Is E TE 
0.6477 0.1574 0.0595 0.1144 0.1122 -58.0143 5.6084 -2924-39 
0.6520 0.1569 0.0643 0.1368 0.1337 -53.696 
.9 5.9974 -3080.61 
0.6521 O. ls9l 0.0642 0.1366 0.1334 -21.5041 7.1744 -3548.44 
0.6521 0.1596 0.0645 0.1374 0.1343 -53.6911 5.9949 -3080.61 
0.6584 0.0674 0.0709 0.1689 0.1753 -88.1265 7.3633 -3984.70 
0.6519 0.1491 0.0645 0.1380 0.1350 5. S932 6.7911 -3390.86 
0.6532 0.1557- 0.0689 0.1610 0.1614 -118.6700 7.3299 -3986.02 
0.6524 0.1595 0.0685 0.1545 0.1542 -118.3890 7.3290 -3986.01 
0.6520 0.1576 0.0640 0.1357 0.1325 -23.3068 7.1731 -3548. S2 
0.6521 0.1595 0.0644 0.1372 0.1341 -46-6210 6.3882 -3236.71 
0.6531 0.1605 0.0688 0.1594 0.1598 -114.0780 6.4948 -3673.01 
0.6526 0.1584 0.0697 0.1596 0.1601 -131.7580 6.5119 -3673.77 
0.6525 0.1595 0.0689 0.1563 0.1563 -107.6250 6.9267 -3829; -13 
0.6523 0.1533 0.0667 0.1472 0.1455 -87.4535 6.3431 -3391.73 
0.6528 0.1606 0.0666 0.1508 0.1498 -106.3750 6.9294 -3820.08 
0.6537 0.1564 0.0705 0.1677 0.1690 -133.6520 6.4855 -3673.85 
0.6527 0.1539 0.0478 0.1301 0.1300 -64-3340 5.9697 -3257.08 
0.6528 0.1577 0.0668 0.1479 0.1463 -125.6150 7.3115 -3986.32 
0.6527 0.1602 0.0681 0.1534 0.1526 -112.8960 6.8904 -3829.36 
0.6529 0.1571 0.0679 0.1526 0.1518 -131.8690 6.9049 -3830.19 
0.6520 0.1540 0.0640 0.1367 0.1334 -84-8612 6.3646 -3391.61 
0.6529 0.1571 0.0689 0.1555 O. lS52 -121.6810 6.8936 -3829-74 
0.6502 0.1139 0.0667 0.1464 0.14S2 -127-4180 6.9699 -3829.99 
0.6472 0.0809 0.0592 0.1231 0.1185 -110.6000 6.9930 -3829.26 
0.6527 0.1574 0.06S8 0.1480 0.1469 -61.2306 6.3727 -3413.36 
0.6523 0.1533 0.0670 0.1372 0.1463 -100.6330 5.9372 -3235.89 
0.6520 0.1543 0.0640 0.1372 0.1340 -98.4476 5.9638 -3235.79 
0.6520 0.1569 0.0646 0.1381 0.13S1 -43.5770 5.9936 -3080.17 
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Table S. 10 
CCNUs MO parameters for alkylating activity regressions 
QM Q(6) Q(7) SE(2) ys E E(LEMO) 
2 
-0.6025 -0.2267 0.1574 0.1770 5.6084. . 0.1586 25.8471 
-0.6007 -0.2208 0.1288 0.1748 5.9841 -0-1350 20.6579 
-0.5961 -0.2184 0.1305 0.1748 5.9839 -0.169S 35.3728 
-O. S983 -0.2250 O. lS96 0.1760 S. 9949 0.0891 27.2S78 
-0.5957 -0.2261 0.1595 0.1747 7.3290 -0-0103 35.6911 
-0.5984 -0.22SO 0.1595 0.1760 6.3882 0.0901 26-8801 
-0.5983 -0.22'57 0.1605 0.1742 6.4948 -0-0517 12.8709 
-0.5954 -0.2262 0.1584 0.1743 6.5119 -0.0455 33-0913 
-O. S983 -0.2159 0.1139 0.1763 6.9699 0.1060 37.5329 
-0.5939 -0.2147 0.0809 0.1772 6.9930 0.1236 29-5338 
-0.5986 -0.2248 0.1569 0.17S9 S-9936 0.0826 26.1663 
MO Parameters for carbamoylating activity regressions 
Q (1) Q (2) SE (2) sE (3) Q (3) HCINIO Q (5) HCMO QT 
-0.6025 0.6477 0.1770 0#3551 0.3327 0.5504 3.8432 
-0.6007 0.6520 0.1748 0.3530 0.3346 0.5525 4.1583 
-0.5961 0.65S3 0.1748 0.3536 0.3345 0.5516 4.2343 
-0.5983 0.6521 0.1760 0.3553 0.3341 0.5534 3.9125 
-0.5984 0.6521 0.1760 0.3554 0.3341 0.5534 3.9928 
-0.5973 0.6SO2 0.1763 0-35SS 0.33-44 0.5513 6.1264 
-0.5939 0.6472 0.1772 0.3566 0.3334 O-S546 6.2957 
-0.5969 0.6523 0.1752 0.3537 0.3344 O. S525 4.8392 
-0.5989 0.6S20 0.1762 0.3558 0.3341 0.5535 4.8411 
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Table 8.11 
CNUS 
Eqn. Relationship n S R F 
8.1 log l/LD =17.04Q(6) + 2.89 18 0.3844 0.5837 8.2688 
8.2 log l/LD =24.92Q(6) + 4.34 18 0.3570 0.6834 6.5725 
Q(9)HOMO 
8.2 log l/L D =38.34Q(6) + 8.88 18 0.3107 0.7894 7.7165 
Q (9) HOMO - 0.33S N (4) + 8.36 
8.3 log ILS -3.09Q(6)LEMO +1.86 18 0.5384 0.5263 6.1303 
8.4 log ILS = -0.72SN (6) - 8.8Q (1) 18 0.4964 0.6510 5.5171 
LEMO + 3.0 
8.5 log ILS = -19.83Q(6)HOMO - 18 0.5278 0.6261 3.0096 
l. 49Q(l)LEMO-2.39Q(3)LEM0 
+ 2.29 
These equations 
activity with a 
particular thos 
the regressions 
implications of 
discussion. 
show that it is possible to correlate 
number of electronic parameters, in 
e situated on nitrogen atom (6), though 
are not highly significant. The possible 
these equations are dealt with in the 
24S 
uantitative Structure-Activity Relationships of CCNUs 
Multiple regression analyses for up to 40 variables including 
MO data, biological and chemical data yielded a large number 
of relations. The best regressions in eacb-case have been 
selected and are tabulated in the following equations 8.6 to 
8.30. The results of correlations with alkylating and carbamo- 
ylating activity (where known) are also included. 
Inspection of these equations reveals the following features: - 
1. The relative ease of transport through lipid membranes as 
estimated by log P, the partition coefficient, appears to be 
dependent on the bulk molecular parameters, total super- 
delocalizability, XSE, and total energy, TE* The heat of 
formation, Hf, which is also to some extent a function of 
molecular size and shape, figures in a number of the equations. 
2. The toxicity of these compounds can be related to these 
parameters (but not to TE), and, when electronic factors are 
included, the regressions become more significant. This in- 
dicates that transport plays a part in the toxic effect of 
these molecules. This is also sensitive to electron density 
in the carbamoyl (1,2,6,7) region of the molecule which 
suggests that carbamoylation is responsible for toxicity. 
3. Therapeutic activity appears to be a function of bulk 
molecular properties, to a certain extent carbamoylation, 
and also more interestingly to the nitroso oxygen atom 
The implications of this are pursued in the discussion. 
4. Alkylating activity yielded relatively poor regressions, 
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Table ý. 12 
CCNUs 
Eqn. Relationship n S R 
8.6 log P=0.032 Hf+5.05 28 1.244.3 . 
0.7085 26.2118 
8.7 log P=0.036 Hf+1 is ISE 28 1.1233 0.8909 19.5310 
8.8 log P=5.751SE +0.0094TE 28 1.1196 0.7825 19.7408 
-2.45 
8.9 log P=5.641SE-124.0 28 1.0228 0.8303 17.7S84 
Q(l) LEMO -ý 0.0084TE + 2.74 
8.10 log 1/LD, =-0.0076Hf- 2.45 28 0.2743 0.7387 31.2361 
8.11 log l/LD =-0.0088Hf -0.32 28 0.2270 0.8372 29.2867 
ISE 
8.12 log l/LD =-0.008SHf+ 6.20 28 0.1926 0.8906 30.6733 
Q(7) - 71.39Q(2) +43.11 
8.13 log l/LD =-0.0089Hf-0.26 ISE 28 0.2070 0.8725 25.4975 
-0.55Q(2) + 35.09 
8.14 log l/LD =-0.0097Hf+6.89 28 0.1994 0.8823 28.1061 
Q(7) -30.49Q(1)LEMO-1.66 
8.15 log l/LD =-O. OllHf+6.77Q(7) 28 0.1831 0.9018 34.8274 
-13. 57Q(6)LEMO -1.76 
8.16 log l/ED =-0.0080Hf - 2.17 27 0.3072 0.7018 24.2675 
8.17 log l/ED =-0.0099Hf-0.381SE 27 0.2517 0.8203 24.6899 
-0.14 
8.18 log l/ED -O. OllHf - 1.428 27 0.2572 0.8115 23.1355 
Q(7) LEMO 0.39 
8.19 log l/ED = -0.012Hf +7 . 24 27 0.2034 0.8918 29.7961 
Q(7) --16.01Q(6)LEMO -1.24 
8.20 log CI = 69-43Q(S)HOMO - 27 0.0964 O. S236 9.4419 
38.06 
8.21 log CI = -0.00065H f +76.34 27 0.0953 0.5649 5.6250 
Q(S) HOMO - 41.94 
8.22 log CI = -0-00089Hf-0.042 27 0.0951 O. S915 4.1252 
ISE + 81.34Q(5)HOMO - 44.45 
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Table 8.13 
CCNUs Alkylating Activity 
Eqn. Relationship nSRF 
8.23 log k(alk)=44.217Q(6)+9.651 11 0.2039 0.7114 9.2213 
8.24 log k(alk)=-6.995Q(7)+0.801 11 0.2171 0.6636 7.0829 
8.25 log k(alk)=38.866Q(6)+O. OOqV2 11 
+8.197 
8.26 log k(alk)=414.947S (2)-3,1946 11 E 
E(LEMQ) 0.2631SE- 74.638 
0.2045 0.7473 5.0594 
0.1618 0.8707 7.3134 
8.27 log k(alk)=452.003S E(2) - 11 0.1445 0.9136 7.5753 
4.473 E(LEMO)-48.616Q(l) 
+0.4401SE-111.324 
Carbamoylating Activity 
8.28 log k(carb) =-276.382Q(3)HOMO 9 0.1845 0.7001 6.7296 
+93.031 
8.29 log k(carb) =149.443Q(l) -90.0634 0.9827 28.1115 
123.889Q(2)-77-11SQ(S)HOMO 
-0.399QT + 215.255 
8.30 log k(carb) =123.477Q(l) 9 0.0672 0.980S 24.9119 
+631.576SE(2)-308.717SE(3) 
-0.280QT + 74.317 
but show a parallelism with toxicity correlations. Howeverf 
carbamoylating activity was well related to total net atomic 
charge, QTI in conjunction with electronic parameters of the 
nitrosourea backbone containing the electro-negative oxygen 
atoms (1 and 5) as well as the carbonyl carbon (2). 
Discussion and Conclusion 
The usefulness -of nitrosoureas in cancer chemotherapy is 
brought about by their low toxicity and relatively good 
lipid solubility. This enables them to successfully treat 
leakemias by passage through the blood-brain barrier to 
reach the CNS which is known to be a pharmacologic sanctuary 
185 for leukemic cells Thus it has been fortunate to obtain 
correlations between total net atomic charge (QT)I total 
superdelocalizability (IS E) and log P; for it provides a 
method for assessment of the lipid solubility of a drug based 
on theoretically-derived electronic parameters. 
It has been recognised186 that MeNU exerts its biological 
effect by methylation of guanine residues at the 0-6 position 
since 0(6)-methyl guanine is found in the DNA of rat mammary 
glands after dosing with MeNU. Presumably BCNU has, as one 
of its modes of action, a propensity to form cross-linked 
dimethylene bridges with DNA. One active metabolite of 
BCNU may be the chloroethyl carbonium ion 
@ CH 2 CH 2C1 which 
can alkylate one strand of DNA and then, by nucleophilic 
substitution, lose chloride and add to another complementary 
strand as shown below. 
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0 
ClCH 2 CH 2- 
N"-Cý'NHCH 2 CH 2 cl ClCH 2 
CH 2- N=N-OH + I- 
N ClCH 2 CH 2- N= C=0 
BCNU ýo I 
CICH 2 CH 2+N2+ 
OH carbamoylation of protein 
DNA 
N - /ON H? cl f CH 2 +Cl 
The OCH 2 CH 2 species is stable due to the 
formation of a cyclic 
Cl 
chloronium ion, viz. CH-CH 22 
MeNU probably effects its cytotoxic action by demethylation 
to form the methyl carbonium ion CHO or singlet/triplet 3 
cl 
chloronium ion, viz. CH-CH 2 
carbene CH 2: by virtue of electron withdrawing groups as shown 
in Figure 8.8 below 
O\ 
Figure 8.8 
The demthylation process might proceed via a similar route 
to DTIC187 since electron-withdrawal also activates this 
molecule as follows: - 
250 
CONH 
N 
0 
Me 
N N=N-N v "*Me H 
-osomes ONH 2 
02N electron 
dithýcadiraiwal H j 
N=N-N 
Me 
H1 
DTIC 
non/nzymatic 
/ pathway 
N 
ONH2 
C9 
NH2 
+ CH 3 
ED 
+N2 
N 
I 
H AIC 
It is generally thought by Hansch, Montgomery, et al. 
188 
that 
the presence of hydrophilic groups on the nitrosoureido 
carrier moiety gives rise to a good congener - that is, an 
agent with low toxicity and reasonable activity. However, 
Hansch's correlations with the hydrophobic parameters log p 
and log P2 which, incidentally show very low regression 
coefficients-indicating non-causal relationships, suggest 
that in order to achieve greater activity with concommitant 
lower toxicity log P needs to be minimized. By increasing 
the number of hydrophobic groups this will clearly work but 
only up to the point where log P tends to zero. In other 
words, the partition coefficient tends to unity. II 
At this 
point the lipophilicity and hydrophilicity of the molecule 
just balance - though this does not seek to explain activity, 
merely transport capabilities. 
What is of possibly greater importance is to comprehend the 
liver microsomes 
NADP + 02 
4 
N-- 
, --)V, e-, I, ectron 
%T-ithdrawal H 
"'ai 
ýN=N-N 
N 
11 
Me 
mode of action of nitrosoureas, and then attempt to vary the 
2S] 
electron density on key atoms so that the drug displays 
greater activity and lower toxicity, without expending its 
transport facilities. Some authorities argue that the 
nitrosoureas will be of more value in cancer therapy when 
congeners are designed which have not necessarily greater 
tumour-inhibitory effect, but lower toxicity and better 
transport. Therefore the aim would be to attain localization 
in tumour tissue by increasing the specificity and selectivity 
of the drug. 
If one compares the plasma half-lives 
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of nitrosoureas 
with other anti-cancer drugs, it can be Seen that the former 
are retained in the system substantially longer as shown in 
Table 8.14 
Table 8.14 Plasma half-lives of anti-tumour agents 
Drug Half-life 
CCNU 16 - 48 hrs 
MeCCNU 24 - 48 hrs 
DTIC <20 mins. 
5-Fluorouracil 5- 30 mins. 
6-Mercaptopurine 20 50 mins. 
Methotrexate 0.5 2 hrs 
cis-Pt(NH3)2 cl 2 <1 hr 
Procarbazine 5- 20 mins. 
Vinblastine <5 mins. 
The greater half-life of MeCCNU compared with that of CCNU 
is probably due to the fact that during the metaboli§m of 
CCNU, the cyclohexyl ring is hydroxylated in the 4-position. 
2S2 
Therefore 4-chloro CCNU is more prone to 4-hydroxylation 
and subsequent conjugation and elimination, whereas the 
4-methyl CCNU is less likely to be metabolised in this way 
due to the inductive effect. It is more likely to become 
hydroxylated on the methyl group to -CH 20H, conjugated, and 
then excreted in the usual way. 
It is interesting that some of the metabolites of CCNU have 
greater alkylating activity and, generally, lower carbamoy- 
lating activity than the present compound. However, they are 
more toxic than CCNU itself and hence their therapeutic 
indices tend to be lower than those of CCNU. This suggests 
that hydrophilicity has a role in alkylation, though this 
may be an electronic effect rather than a bulk molecular one. 
The results of electronic structure calculations can give some 
insight into likely pathways for the decomposition of nitro- 
soureas and their action with DNA. This can be achieved by 
comparisons between electron densities on atoms of the nitro- 
soureido moiety, their relative dependency on activity, and 
how these electronic changes affect the predominance of one 
pathway over the others. For simple N-alkyl nitrosoureas 
the mechanism is likely to proceed as follows: - 
0 H OH 
N 
-N CH 
H 
r7 
3 
c H 
11 
MeNu 0 
-OH -OH N-N'r 
CH3 
xl-ýý 
+ 
CH 3 
ED 
+N2+ OH 
alkylate nucleic acids 
H N=C==O 
I 
carbamoylate 
proteins 
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The series MeNU., EtNU, PrNU show reduction in activity with 
increase in carbon chain length. This may be due in part to 
the relative stabilities and reactivities of the corresponding 
ions, though the nucleophilic superdelocalizabilities to N(3) 
and C(2) decrease in that series with concomitant increase in 
electrophilic superdelocalizability on 0(5). This suggests 
that increasing the alkyl chain decreases the ability of C(2) 
and N(3) to accept electrons (necessary for the proposed 
mechanism) and this inevitably results in increasing electron 
density in the-O(S) frontier orbital. 
When the N-substituent is a 2-chloroethyl group, several 
mechanisms may be put forward to explain the decomposition of 
nitrosoureas to give reactive intermediates. These schemes 
are summarised as follows: - 
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CH CH Scheme 322 
chloronium ion 
The third mechanism is more favourable than the first two 
due to the fact that Cl is not a very good leaving group. 
However, the nature of the R substituent is likely to 
influence the type of mechanism undergone by the nitrosourea. 
Recent studies on the decomposition of BCNU and CCNU in 
aqueous solution support a preference for the third scheme. 
MINDO/3 calculations in the present work also indicate that 
this is the most probable route because an increase in nucleo- 
philic superdelocalizability on N(3) is commensurate with an 
increase in activity in the series MeNU, CNU, and BCNU. 
Additionally, electronic terms on this atom, together with 
those on N(6), figure in the activity regressions of CCNUs. 
The appearance of reaction products like 7-(hydroxyethyl) 
guanine from the action of BCNU and CCNU on DNA provides 
further evidence for the existence of the, chloronium ion 
intermediate (scheme 3), as hydrolysis would give rise to 
2-chloroethanol which reacts with guanine as shown: - 
".. 
cl 0cI 2CH 2 OH 6", H guanine 
C14 - -%CH 
20 Cl CH 2 CH 2 OH 2 from DNA' 
2SS 
Furthermore., the CCNU correlations between activity and 
structure yield the following information: - 
1. There is a predominance of the transport-Telated term 
ISE, the sum of the electrophilic superdelocalizabilities, 
which is known to correlate well with the hydrophobic para- 
meter log P in this and other series of molecules. This 
is in agreement with the work of Hansch and others. 
2. The calculated heat of formation, AHf, is the sum of 
bond energy contributions and it is possible that specific 
bonds are responsible for the biological profile. Neverthe- 
less, this is another bulk molecular property and is there- 
fore a transport-related parameter. 
3. The sum of the total atomic charges, IQT, appears in a 
number of activity correlations and appears to be rather 
susceptible to the nature of the cyclohexyl ring substituent. 
It is often allied with ISE in log P regressions and this 
is an indication of hydrophilicity resulting from charge 
distributions in the molecule. Thus it complements ISE 
which is a lipophilic parameter. 
4. The highest occupied (HOMOs) and lowest empty (LEMOs) 
molecular orbitals appear to be relatively evenly populated 
on the same atoms. This suggests that the molecule is as 
good an electron-donor as it is an electron-acceptor, and 
might explain the interaction with nucleic acids. 
S. The correlations between toxicity and those with activity 
are not significantly different, suggesting that the mode of 
action of these drugs is not too dissimilar in normal and 
2S6 
neoplastic ti ssue, and that the slight difference in pH is 
not sufficient to alter the mode of decomposition. This 
probably explains the narrow therapeutic range of nitrosoureas. 
6. The susceptibility of the cyclohexyl ring t'o, hydroxylation 
appears to be dependent on the nature of substituent groups 
and their position of substitution. Since hydroxylation 
increases alkylating activity with a concomitant decrease in 
carbamoylating-activity, plasma half-life, and lethal dose, 
it seems that it is only possible to increase the hydro- 
philicity of the compound at the expense of increasing the 
overall toxicity. These facts are summarised in Table 8.15 
Table 8,15 Properties of Hydrox 
CCNU 190 Alky- 
lating 
Compound log P Tj activitý 
CCNU 2.83 100 100 
cis-2-OH CCNU 1.60 
trans-2-OH CCNU 1.30 
cis-3-OH CCNU 1.25 
trans-3-OH CCNU 1.28 
cis-4-OH CCNU 1.11 
trans-4-Ofi CCNU 1. oo 
y CCNU derivative relative to 
Carbamoyl- 
atiýg LD ED CI 'activity 10 50 
100 100 100 0.77 
76 177 1 98 56 0.44 
66 329 6 41 16 0.29 
91 133 21 98 47 0.37 
84 112 61 74 41 0.42 
93 136 104 90 54 0.47 
87 140 100 82 36 0.33 
The values of log P and CI are absolute values, whereas the 
remainder are calculated relative to CCNU taken as 100. 
It is known that nitrosoureas such as BCNU and CCNU hit non- 
dividing, or resting cells, rather than growing cells and 
this may be due to protein interactions. This implies that 
2S7 
the carbamoylation of proteins is important in the overall 
toxicity of these compounds. With reference to Table 8.15 
it can be seen that 2-hydroxy CCNUs have markedly lower 
carbamoylating activity and there are two ways in which this 
could be explained. 
Molecular models of the hydroxy CCNUs show that, in the 
cis-2-hydroxy compound, hydrogen-bonding is likely to occur 
between the-hydroxyl and carbonyl groups as shown: - 
0/ CH2CH2Cl 
\\ 
c, N 0 N=O 
111*1 
CH CH 
H 
CH2 
I 
I 
CH 
CHr, CH2 
Hydrogen -bonding in 
cis-2-hydroxy CCNU 
The trans compound can also hydrogen bond in a similar way, 
but it is not conformationally favourable. Intra-molecular 
hydrogen-bonding cannot occur in the 3- and 4-hydroxy CCNUs. 
The effect of hydrogen-bonding is to make it difficult for 
cis-2-hydroxy CCNU to decompose to form the isocyanate species 
responsible for carbamoylation. In order to form the iso- 
cyanate, the carbonyl carbon has to change its hybridization 
from sp 
2 to sp and become colinear with the nitrogen atom: 
hydrogen-bonding will inhibit this. 
Also the cyanate formed will have reduced carbamoylating 
activity due to the effect of the 2-hydroxy group. The reaction 
whereby a protein is carbamoylated involves nucleophilic 
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()----H ----0 C"2 CH2 Cl 
c ý, ' N Nz*' 
x ýi ýz\ N=O ii--OH 
SD 
2 
carbon 
HO 
N=C=O 
sp carbon 
N --, 
HO 
W 
CH2CH2Cl 
(stabilized by 
intra-molecular 
hydrogen bonding) 
attack by an amino group at the carbonyl carbon atom of the 
cyanate moiety: 
0 
R- Ný C-10 R-N-CýO R-W -C 
N14 2@ 
NH2 NH 
protein Drotein protein 
carbamoylation of a protein by an organic cyanate 
In the 2-position on the cyclohexyl ring, the hydroxyl group 
will sterically hinder the nucleophilic attack of L-he incOmi'19 
amino group, and also it will push greater electron density 
toward the carbonyl carbon, thus making carbamoylation unfavourable 
This accounts for the very low carbamoylating activity of 
cis-2-hydroxy CCNU and, to an extent, that of the trans isomer. 
These effects will be reduced in the 3-hydroxy CCNUs and 
become negligible in 4-hydroxy CCNUs because the hydroxyl group 
will be too far away to have any influence. The increase in 
alkylating activity for the 2-hydroxy derivatives of CCNU is 
probably due to their decomposition via an alternative 
mechanism such as shown below: - 
ZS9 
0 
OF CH Gi Cl 
. -- 
cN22 
N 
HN 
1-1-- OH 
OH 11 
c ', N 
Ný, OH 
('T'ZCH2 Cl 
chloroethyl carbonium ion 
The chloroethyl carbonium ion is a strong alkylating agent 
and is able to cross-link DNA Droducing a more toxic effect 
than Just alkylation because cross-linkages are difficult to 
repair. 
Therefore, MO calculations on nitrosoureas can help to 
explain their biological activity, modesof action , and 
regression analysis yields relationships with a measure 
of predictive power. 
Figures 8.9 and 8.10 show the molecular electrostatic potential 
maps for BCNU and CCNU respectively. The appearance and 
magnitude of the potential wells are very similar and it is 
possible to superimpose these on the DNA base-pair maps to 
show likely modes of interaction. Overlap with the Guanine- 
Cytosine pair is preferable to the Adenine-Thymine pair, and 
it would appear that alkylation of the gu anine oxygen atom 
is a likely step in the biological action of BCNU and CCNU. 
There is also evidence for a frontier orbital overlap between 
the nitrosoureido moieties and part of the guanine aromatic 
ring system. 
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CONCLUSION AND DISCUSSION 
262 
Discussion 
The results of this work demonstrate adequately the advantages, 
applicability, and limitations of MO calculations in structure 
activity correlations. For the method to work one has to 
employ a series of compounds of similar structure and the 
biological data has to be valid., in that identical experimental 
conditions prevail for testing of all members in the series. 
The molecular structure of at least one compound has to be 
known accurately and crystallographic data are the most precise 
available at present. The possibility of other stable con- 
formations needs to be investigated since the solid state 
structure may not be the preferred conformation as far as the 
receptor site is concerned. 
The quantum pharmacologist needs to liaise with experimentalists, 
clinicians, and those interested in the design of new drugs 
so that certain ideas may be followed up and avenues of re- 
search pursued leading to a reduction in the time, expense, 
and number of animals used in the testing of drugs. Also the 
understanding of drug processes at the sub-molecular level is 
likely to yield more information of biological molecules than 
has previously been possible. 
One can envisage a state of affairs whereby a series of bio- 
active compounds are tested for a specific function, their 
electronic structures analysed by MO calculations, and their 
activities explained in terms of electron densities, energies, 
etc. Then MO-derived QSARs (MOQSARs) can be formulated for 
suitable predictions to be made about potentially active 
molecules that have not previously been tested. 
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Although only compounds of interest in cancer research have 
been studied in this work, the MO method is applicable to 
any pharmacologically active substances provided that the 
molecular size and complexity is not preclusive. The areas 
of medicinal chemistry of particular interest are: - cardio- 
vascular therapy, especially concerned with drugs which 
block the $-adrenoreceptor and used in migraine treatment; 
drugs which act on the opiate receptor site - as the formula- 
tion of non-narcotic opiates would be particularly useful in 
the treatment of heroin addiction; and finally in anti- 
epileptic drugs which have not been studied by MO methods. 
The results of regression analysis yield relationships of 
the type: - 
log A= af, + bf2 + Cf3 .... etc. 
where A is drug activity 
a, b, c etc. are numerical constants 
f1j, f2ý f3 etc. are electronic parameters 
The relative weighting of certain factors in the SAR indicate 
the importance of atom-centred electronic properties (e. g. 
electron density) and molecular properties (. e. g. dipole 
moment, superdelocalizability) to the overall effect. This 
approach therefore supercedes the Hansch method in biolo- 
gical correlations because MO parameters provide equations 
of higher statistical significance and biochemical insight. 
Basically, an MOQSAR is more refined than an ordinary QSAR 
and thereby reveals a subtlety in the molecular structure 
not visualised by Hansch analysis and provides a method for 
the separation of biological effects. 
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The Future Development of Cancer Chemotherapy 
Anti-cancer drugs have always suffered from the drawback of 
cytotoxicity towards other rapidly dividing cells such as of 
the bone marrow, hair follicles, and intestinal epithelium. 
A number of recent findings point to better methods of 
achieving cancer cures by selectivity and specificity. There 
has been a lot of current interest in the potential usefulness 
191 
of liposomes These are approximately spherical structures 
(20-30nm in diameter) composed of membranous phospholipids, 
such as lecithin, in micellar organization with solvated 
water to make concentric bubbles of lipid gel bilayers. The 
utility of liposomes lies in their ability to encapsulate 
drug molecules and transport themselves through body fluids 
until they reach the required site of action. The drug mole- 
cules are able to diffuse slowly through the liposome wall, 
thus prolonging their time of action. Liposomes have been 
used to deliver therapeutic doses of cytosine arabinoside 
(Ara-C) in the treatment of lung cancer - with the additional 
advantage of being able to be administered via the alveoli. 
It has been found that such a route of absorption considerably 
reduces the toxic effect of these drugs on non-cancerous 
tissue 
192 
. 
It has, for many years, been the goal of cancer therapists 
to design pro-drugs which become activated in the tumour as 
a result of a specific factor that differentiates tumour 
cells from normal tissue. One method193 relies on the fact 
that the plasmin of cancer cells can be activated by a specific 
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initiator, not found in other tissue types, to cleave 
tripeptide chains attached to an aniline mustard. The aniline 
mustard tripeptide prodrug is relatively non-toxic prior to 
activation by tumour cell plasmin and also any activated 
plasmin present normally is rendered impote. nt by the blood so 
that the drug is tumour cell specific. 
There is a plethora of information about cancer in the form 
of research papers, monographs, reviews, conference reports, 
etc. More is spent on cancer than on any other branch of 
medical research and in the United States, the cancer pro- 
gramme has a budget far in excess of the Space Administration. 
The record in terms of returns from cancer research is not a 
good one and this is due in part to the lack of understanding 
of the process whereby cancer is initiated and, in part, to the 
lack of responsiveness to therapy in many cases. 
It is clear that a large number of environmental agents are 
cancer initiators and promoters, and a great deal could be done 
to minimise the risk of exposure to these agents. It has been 
stated that there is a link between cancer and aging, and 
certainly cancer is a major cause of death among the aged. 
There may be other factors contributing to this fact since people 
tend to live longer because of the elimination of previous prime 
causes of mortality, and thus stand more chance of contracting 
cancer. With time, the body's defensive mechanisms of immu- 
nological surveillance tend to break down., DNA is not perfectly 
replicated, miscoding occurs and mutation results. The DNA 
repair mechanisms become faulty and the undifferented cells 
(which are only potentially cancerous)- become immune to attack 
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by lymphocytes and leukocytes, possibly due to the release 
of a substance which'switches off'the way in which cells are 
recognized by the immune system. 
Bacterial mutation tests are now providing information about 
which type of mutation is D, roduced by -potential canver 
ini- 
tiators. A number of different types have been identified, 
viz. base-pair substitution, frameshift, deletion and insertion 
mutations. By carrying this to its logical conclusion, the 
molecular basis of cancer initiation via gene mutation can be 
understood. 
An attractive theory 
194 
recently proposed involves the concept 
of a gene battery responsible for cellular control mechanisms. 
ntrol of entr), 
S phase re-olication ---- 4 Protein 2 into S phase 
I- I co 
Gene battery 
Protein control of gene 
direction Gene 1 mRNA 
I TI-battery 
of control ulation of control ligands 0 1 Protein 3-n control of 
L Gene 2 (MCPS) cell 
proliferation 
Gene 3 mRNA 
Gene 4 
Gene S-n 
The genes I-n are ODerons for the manufacture of proteins 
I -* n via the intermediary mRNA. Protein 1 controlsthe gene 
battery via control ligands which can pass from cell to cell. 
Gene 2 makes protein 2 which controls entry and re-entry into 
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the S phase of the cell cycle, whereas proteins 3-*n control 
the proliferation of cells and could be labelled mitotic 
control proteins (MCPs). It is generally accepted that 
tumorgenesis occurs in two stages: - initiation and promotion, 
and some agents are initiators, some are promoters. If one 
assumes that initiation deletes the Gene 1 function, then the 
cell switches to cycle in the S phase. It seems that initia- 
195 tion does not lead to carcinogenesis unless promotion occurs 
However, most chemical carcinogens are initiators and promo- 
ters, for example, the poly-aromatic hydrocarbons: - benzo(a)- 
pyrene, dimethyl benzanthracene, 20-methyl cholanthrene, etc. 
Benzo(e)pyrene, however, has been found to be a good tumour 
promoter - though it is not an initiator. Common promoters 
of skin cancer are the phorbol esters, e. g. tetradecanyl 
phorbol acetate (TPA), present in croton oil, which are non- 
tumorgenic without some initiating agent. Other promoters 
are benzoyl peroxide (which is a free radical precursor) and 
saccharin and cyclamate, which promote the formation of 
bladder tumours. It has been recognized that promoters show 
a receptor-type interaction rather than covalent binding 
as displayed by tumour initiators like the 7,8,9,10 epoxy- 
diol of benzo(a)pyrene . Bacterial systems pick up initiat- 
ors in mutation tests ' whereas animal systems show initiation 
and promotion stages. It is the promotional stage that 
results in cell proliferation which suggests that promoters 
block the formation of mitotic control proteins (deletion of 
Genes 3-*n in Gene battery). It is known that cancer cells 
are deficient in chalones, which are isolatable mitotic 
inhibitors that bring about regression when injected into 
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cancerous tissue.. Also cancer DNA has been found to be 
depleted in nucleohistones which are responsible for re- 
pressing gene activity. Changes in the nucleohistone sheath 
occurs during stages of the cell cycle, espeýcially during DNA 
replication where the unravelling of DNA strands brings about 
a reduction in the protecting influence of the histones. Thus 
DNA is susceptible to damage at this stage and therefore 
becomesprone to attack by cancer initiators. Presumably a 
potentially cancerous cell is not capable of synthesizing 
sufficient nucleohistone to Drevent further irreparable 
damage to its DNA resulting in cellular transformation into 
a cancer. Cyclic AMP, the so-called second messenger, is 
thought to play a vital role in cancer aetiology. Tumour 
cells have abnormally low levels of cAMP and the addition of 
cAMP inhibits cell proliferation of tumours by blocking the 
transformation mechanism. Cyclic AMP may thus be linked to 
chalonesp since adrenaline is a co-factor in contact inhibi- 
tion anO it i,; adrenaline which stimulates adenylate cyclase 
to manufacture ckMP. As cAMP stimulates glycolysis by 
activation of glycogen phosphorylase, and glycolysis is the 
main pathway by which cancer cells produce energy, then it 
seems that the high demand on cAMP for glycolysis produces 
this low cAMP level and a resultant loss in mitotic control. 
An interesting corollary to this is that cyclic nucleotide 
phosphodiesterase inactivates cAMP by conversion to SI-AMP 
and that the function of this enzyme is inhibited by excess 
ATP. However, imidazole stimulates the enzyme to hydrolyse 
cAMP and this fact could explain the anti-tumour activity of 
imidazole drugs such as AIC, Ph-AIC, and DTIC. 
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Me 
11,2 N OC)NH2 H2N ODNH2 N-N--N COINH 2 
Me 
NONH N0 NH No H 
Ph 
AIC Ph-AIC DTIC 
(amino imidazole 5-(dimethyl-l-triazeno) 
carboxamide) imidazole-4-carboxamide 
The low concentrations of Ca 
2+ ions in tumour cell: membranes 
can be explained by the fact that phosphorylase kinase activity 
is enhanced by calcium ions (and by lack of oxygen). This is 
an additional mechanism for the stimulation of glycolysis which 
is essential for cancer cells to survive and multiply. Also 
Mg 2+ ions are necessary for the production of cAMP, and so the 
alteration in levels of these ions is likely to bring about 
changes in the cell surface characteristics as experienced by 
cancer cells. The increased negative charge on the surfaces 
of cancer cells, brought about by reduction in Mg2+ and Ca 
2+ 
concentrations, is thought to be related to the lack of 
adhesiveness and concomitant cell motility. It is possible 
that interferon arrests this process by which metastasis can 
occur by increasing the cohesiveness of cancer cells and 
inhibiting their growth. Thus the agglutination of tumour cells 
by a lectin such as concanavalin A (Con A), and the action 
of interferon show that an as yet unidentified substance is 
responsible for the transfer of carcinogenesis from one cell 
to another via cell membrane characteristics. Connected with 
this cellular recognition is the ability of cancer cells to 
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switi: h off the immunological surveillance system due to a 
lack of tissu 
-e coding factors (TCFs). Burch 
26 
argues in 
favour of a complementarity between MCPs and TCFs which 
orientate themselves at both ends of the negative feedback 
loop discussed previously in connection with the gene battery 
responsible for the control of cell division. 
In order to effectively treat cancer by a chemotherapeutic 
drug, it must be as selective as possible in attack on 
tumour cells. Ideally, it should be necessary to discover an 
agent that breaks the re-cycling loop in S-phase so that DNA re- 
pair mechanisms of excision and replacement can be brought 
into play. One has to be knowledgeable of the differences in 
cancer DNA and cell characteristics for every variety of 
cancerous tissue type, since there are marked variations 
between tumours arising from different tissues. Because of 
the resemblance of tumour cells to embryonic cells, control 
of proliferation cannot occur as cells are not differentiated 
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enough to be recognized by lymphocytes Interferon is 
thought to act by maturing or aging cancer cells rapidly to 
'label'them for'demolition!. Cancer of the nerve cells (neuro- 
blastoma) only occurs in children because their neurones display 
a cell division which does not occur in adulthood. There- 
fore, dividing cells are susceptible to cancer formation due to 
their propensity to replicate (faster). A mechanism for 
switching off this replication must occur in mature nervous 
tissue and discovery of the agent responsible could lead to 
more effective cancer therapy. It may be important to note 
that there is a cAMP deficiency in neuroblastoma 
197 
, whereas 
ganglioneuroma show enhanced cAMP levels similar to those of 
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normal nervous tissue, implying a double-edged role of cAMP 
in cancer. 
Design of Potential Chemotherapeutic Drugs 
The major difficulty with anti-tumour drugs is their lack of 
specificity and the inability to achieve an optimum thera- 
peutic ratio. Allied. to this is the high toxicity of many 
therapeutic measures and the nalvety of their design philo- 
so-phy as a result of lack of profound understanding of the 
nature of cancer. However, there is potentially great success 
to be achieved by chemotherapy which must stand as a cure 
until preventative medicine in the form of immunotherapy and 
greater vigilance of, and reduction in the levels of environ- 
mental carcinogens is implemented-. 
A number of indications of possible structures for prospective 
anti-cancer agents have arisen from the present work and from 
an overview of the literature. Some drugs, used clinically, 
such as methotrexate and vincristine display acute toxicity 
ul) to the point of being responsible for fatalities among 
cancer patients. Clearly, their use should be discouraged 
until the correct dosage regimens have been ascertained. 
Also the incorporation of the heavy metal platinum in a 
number of drugs appears to be a step in the backward direction 
towards an increase in cumulative toxicity in spite of their 
apparent therapeutic usefulness. The aniline mustards are also 
highly toxic, however, incorporation of amino acid residues 
into the carrier moiety to yield drugs like melphalan is 
advantageous in reducing toxicity - but this does not provide I 
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selectivity. The nitrosoureas display low toxicity, although 
are not of high efficacy, i. e. 'they have a low therapeutic 
ratio and small therapeutic range. Substitution of sugar 
residues into the parent structure of BCNU may provide impro- 
ved aqueous solubility and enhanced transport capabilities. 
Phenyl aziridihes have not undergone clinical trial because 
of their high speitificity for one particular experimental 
tumour line, Walker 256. However, the most active member 
of the series CB1954 shows a structural similarity with a 
clinically useful drug DTIC which is in possessing an amide 
CB 1954 
ý02 
CONH 2 
ol 
2 N=N-NMe 
NONH 
DTIC 
group adjacent to a substituent capable of metabolism to an 
amino group on an aromatic ring. This feature may have some 
relevance since the compounds AIC and Ph-AIC are known to 
inhibit the action of CB1954 and these also contain adjacent 
amide and amine moieties. This suggests a common mechanism 
of cellular activity which could involve metabolism to the 
CONF, 2 Nfi 2 
N0 NH 
""ýz 
COINH2 I\H 2 
No NH 
Ph 
AIC Ph-AIC 
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carboxylic acid where formation of a hydrogen-bonded structure 
provides some similarity to the Purine base guanine. For 
H\ 
0--- 
CONP. 1 NH 2 
CO 
2H 
NP2 0- (-ý 
\N-H 
enzymic H-bond Ln4 
N0 NHhydrolysi4sN NH NONH 
example, AIC could be metabolised to an hydrogen-bonded 
guanine-like amino carboxylic acid. For comparison, the 
structure of guanine has been represented as follows: - 
H\N NH2 
0ý 
/-H 
N 
The prODOsed pathway for AIC going to a purine via a 
carboxylation can be represented as follows: - 
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It is also possible for CB1954 to form a purine-like structure 
as follows: - 
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it would appear that 5-membered ring compounds containing 
hetero-atoms are favoured for Potential antineplastic agents. 
There is some further evidence to suggest this finding. 
Arginine and glyoxal are thought to form heterocyclics and 
this may be a reason for the antineoplastic action of 
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glyoxal A possiblescheme is shown below. 
2 N\ 
C==N H 
CHO 
I HO OH +H NH H+ -H 
+ 
CHO CH2)3N *'ýý N -H20 NN I 
H 2N*ý 
C 02 H 
NH2 NH2 
The drug metronidazole, a known bacterial mutagen (shown 
below), is used in the treatment of trichomoniasis and other 
N02 ý) H2 
N N-CH2CH reductiai 
a-N 
20H --CH2CH20H 
Me M 
ýe 
infections, can be carcinogenic if administered in large doses. 
Apparently, the nitro group is not reductively metabolised 
to an amino function, and oxidative products of the methyl 
199 
and alcoholic groups are the major metabolites The 
mechanism of action of this drug is thought to be due, in 
part, to its ability to act as an electron sink in inhibiting 
certain key redox reactions by which anaerobic organisms 
produce energy, thus providing a degree of selectivity for 
this and other nitroimidazoles. Metronidazole has been used 
as a sensitiser for radiotherapy of cancer. Under anaerobic 
conditionsý it is reduced to the corresponding amino com- 
pound, shown above, which can bind of DNA and thus block DNA 
27S 
synthesis. 
ND 
Histamine 
:D 
CH 2CH2 NH2 
N 
I 
H 
The related 5-membered ring compound, histamine, has been 
found to be responsible for the "tumour flush" experienced 
by some cancer sufferers. This indicates that such hetero- 
cyclics are involved in an immunological reaction to the 
tumour. 
The ubiquitous panacea vitamin C (ascorbic acid) is a 5- 
membered ring lactone (shown below) that readily undergoes 
" HO H u 
HH 
CH20H 
0 
CH 
OH H 0 
L-Ascorbic acid 
oxidation to the triketone, dehydroascorbic acid. 
00 
"-*, 
CH20H 
CH 
orýý H 
""'ýOH 
L-Dehydro ascorbic acid 
This property makes vitamin C the most powerful naturally 
occur-ring reducing agent of living tissue. Although its 
therapeutic value is still contentious, there is a great 
27 
deal of information in support of its activity as a tumour- 
200 inhibitory compound , an anti-viral agent, and in the 
treatment of anaemia, scurvy and other dietary deficiencies. 
It appears to stimulate the absorption of iron, to induce 
the immune response of T lymphocytes, alter cell membranes 
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inhibit cell transformation and proliferation, and assist 
in wound-healing. Work carried out in the People's Republic 
of China indicates that vitamin C inhibits the formation of 
nitros amines which are potent environmental carcinogens. 
It has been demonstrated that ascorbic acid inhibits the 
oxidation of 3-hydroxy anthranilic acid which is thought to 
bring about the formation of cancer of the bladder -a 
cancer of high incidence among cigarette smokers. 
NH2 
HO 
0 
C02H T( r 
3-hydroxy anthranilic acid 
The reducing nature of vitamin C may prevent the oxidation 
of poly-aromatic hydrocarbons to the corresponding diol 
epoxides that have been shown to be the carcinogenic meta- 
bolites of PAHs. It may be of relevance that anthranilic 
acid inhibits the action of CB1954 on the Walker 256 carcinoma. 
There is, therefore, evidence to suggest that 5-membered 
heterocycles would provide a new series of potential anti- 
tumour drugs based on the following parent structures: - 
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Ri 
H 
where R, = CONH2 or C02H 
and R2 = NH2 or N02 
It may not be essential for there to be a delocalised 7-system 
or for a ketonic funqtion, and substitution of the hydrogen 
atoms by aliphatic side chains containing hydroxyl moieties 
might provide greater specificity and selectivity. 
It is essential for a drug to be selective, and hence it must 
successfully exploit the differences between normal and neo- 
plastic tissue, For a drug to be specific for a certain 
type of cancer, it should be able to make use of the diffe- 
rences between cancer cell DNA, i. e. the genetic mutations in 
that cell type. The incorporation of purine or pyrimidine 
base-type moieties into DNA by structural analogy may provide 
a method of anti-mutation, or stimulate DNA repair mechanisms 
to effect excision of the mis-coding genes. The biochemical 
differences of altered enzyme levels, cAMP levels, and pH 
could be exploited more extensively and de-activation of the 
process which'switches off'the cell recognition system to- 
wards cancer cells could bring about their destruction by T 
lymphocytes and other immunological defence mechanisms. 
In conclusion, this theoretical approach to drug activity 
correlations and design enables a substantial reduction to 
be made in the number of experimental animals needed for 
screening tests., thus producing a large saving in the time 
and expense of clinical trials for mýny compounds. Mole- 
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cular orbital calculations and allied quantum chemical 
procedures are applicable to a 'Wide range of substances of 
biological, medical, and chemical significance and can 
provide a greater insight into the mode of action of drugs 
at the submolecular level. It is hoped that further studies 
will lead to an understanding of a-adrenergic blocking 
agents used in cardiovascular and migraine therapy. Also a 
receptor modelling method could provide an explanation of 
the action and activity of opiate analogues and may result 
in the formulation of new structures of clinically useful 
drugs with specifically designed properties. 
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Appendix 1 
Trans-membrane Kinetics 
A. Passive movement 
The existence of a concentration gradient of solute molecules 
across a membrane tends to cause a net movement of solute 
molecules in the direction of this gradient. The rate of 
flow or flux, J, of these molecules is proportional to the 
dc 
concentration gradient, jx, as expressed in Fick's first law 
of simple diffusion: 
JD 
dc 
The diffusion coefficient, D, is made up of a mobility term, 
w, and an expression for the kinetic energy of the molecule. 
Thus, 
D= wRT 
where R is the gas constant 
and T is the absolute temp. 
Movement of ionized solutes is also influenced by electrical 
gradients, so that the overall rate of flow may be described 
by the Nernst-Planck equation: 
dc dý ] 
j= WC ý. RT . -rx + ZF ix- 1C 
where: Z= No. of electrical charges on the permeating molecule 
dý 
= F= the Faraday constant, U-x charge gradient 
The first term in the bracket is an expression for the con- 
centration gradient, and the second term an expression of the 
electrical gradient experienced by the diffusing solute. 
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B. Mediated permeation (active transport) 
The kinetics- of ion transport in a wide range of cells are 
similar to those of enzyme catalysis and it is thought that 
reversible binding to a carrier mediates in- the transport 
process. The rate of transport, V, depends on two factors: 
(a) The maximum rate of transport, V max' when all available 
carrier sites are full., and 
(b) The fraction of carrier, 6, loaded at a given substrate 
concentration, [s]. 
These may be expressed in the following equations: - 
6= 
Is] where: Km is the affinity, or 
Km+ [s] binding, constant 
V 
Vmax[s] 
Km+ Esl 
Uni-directional flux of solute across the membrane can be 
adequately described by a Michaelis-Menten 
202 
expression for 
a two-compartment model system. 
Jmax C1 
J 12 Km+ cl 
where: J12 is the flux from compartment 1 to 2,1 max 
is the 
maximum rate of flux; c, is the concentration of 
solute in compartment 1, and Km is the affinity con- 
stant (the solute concentration when J12 : -' Ijmax) and 
units of concentration, mol. dTq. -3. 
The net flux or rate of flow is given by 
jfCI C2 -I max Km+ Cl KM+ C2 J 
I 
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where c2 is the concentration of solute in compartment 2. 
In many systems involving mediated transport the elctro- 
chemical gradient is maintained by modifying the solute or 
removing it from the second compartment. The rate of mediated 
permeation is then closely approximated by: - 
cII 
max K+C, ) 
and a plot of J against concentration, cl, would appear as 
follows: - 
Jmax zeroth order part of curve 
max"I 
L 
lst order part of curve 
K cl 
This similarity to enzyme kinetics means that certain types 
of mathematical treatment of data developed for enzyme kinetics 
can be used to determine J max and 
Km. 9 and, dlso to character- 
ize inhibitors of mediated permeabilities. For example a 
double-reciprocal plot yields the following information, 
which is similar to Lineweaver-Burk 
203 
plot used in the 
analysis of enzyme kinetics. 
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Km 
max C Jmax 
Km 
slope = Jmax ' intercept= 
max 
If J is plotted against J/cl another straight-line relation- 
ship is produced which is similar to that of Eadie and Hofstee 
204 
. 
iJ+ Jmax 
KmKm 
i 
slope = -K m; 
intercept =J max 
J/C 
1 
ýp 
-IIKM 1/c I 
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Thermodynamics of transport processes 
The change in free energy, AG, of a transported species can 
be expressed as the summation of two terms, a concentration 
term, and an electrochemical term. 
Thus, 
RT ln Ll + ZF AV C2 (cf. the Nernst-Planck equation) 
where: R= thegas constant; T= the absolute temperature 
Cls, C2 = concentration of species in compartments 1,2; 
Z= cha'rge on the species; F= the Faraday constant; 
AV = potential difference across the membrane barrier. 
The second term is employed only if the species is ionic. 
For active transport, where energy has to be supplied to the 
system to effect movement of the molecular species, AGhas a 
positive value. Passive transport is a process which occus 
spontaneously and, therefore, AG is negative. For example, 
consider the transport of an uncharged species from a low 
concentration compartment, cl = 10-3 mM, to a region of high 
concentrationy C2 = 10- 
1 
mM. Calculation of the free energy 
of transport gives a value of AG = +11.87 kJ. mol-1 under 
physiological conditions (T =310K), which means that an energy 
sources such as the hydrolysis of ATP, would be needed for 
active transport of this magnitude to occur. 
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ADDendix 2 
Derivation of Molecular Properties for Molecular Orbital Methods 
205 
For molecules it is valid to describe the energy, E, of any 
electronic state in terms of the Hamiltonian operator, H, and 
the wave function, ý, by Hý =Eý where H=T+V 
K. E. P. E. 
the eigenvalue 
equation 
The expectati-on value (mean value)of E is given by 
dT 
iP dT 
where tP* is the complex conjugate of ip and dT indicates that 
the integration is over all space or, simply, by using 
Dirac's notation 
<iP I HI P 
<lp I P> 
The total energy of the molecule can be treated as the sum of 
electronic energy, Eel, and internuclear repulsion energy E nucl. 
The latter is given by 
E 
Z11 zv where Z11, vare charges on nuclei p, v 
nucl R of internuclear distance R Ij v pv pv 
Electronic energy is the sum of all KE termsP electron-nucleus 
attractions, interelectronic repulsions, and inter electronic 
exchange terms. This can be written as 
el 
HIj 
1) 
K 
1) i<j i<j 
where H, is the 1-centre core Hamiltonian given by: - 
28S 
Hi HC 0i d-ri HC Z Vi2 - 
K. E. 
v is the del operator 
92 22 
3X2 3y2 aZ2 
zz 
v, i r 
electron-nuclear 
attraction 
i 
ij is the electron-electron repulsion integral: 
e2(j) 02(j) dT dT ij 
fj 
r ij 
i 
K ij is the interelectron exchange integral: 
ij el W 02 W Tl 
el(j) 02(j) dT i 
dT 
ij 
The total energy may thus be written 
zz 
H. +Z (Jij-Kij) +Z 11 v tot 1 i<j ij<v Rpv 
Dealing with the Hi term, we first use the LCAO formalism 
for describing the MOs (i) in terms of the basis set of 
aos M as follows: 
MEc 
where av(i) is the spin 
v 
1P 
vPM V(i) 
factor (a or 
I V? -, 
Ir 
(i) d-r- Then Hi ýv(i) 
(- 
11r rril ýv i 
r L 2(i) dcr E cv r) ýo 
M V? -ZI]E Cv CF 
(i) dTi 0 P) 1r" ri afvi 
But f 
av 2(i)dal =1 and therefore, we get: 
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cr 
f 
ý; 
) 
(i) 
(I 
H. ccI 
Zr ] 
ýG(i) dT p vpý vrr ri 
These integrals may now be classified as follows in two types: 
ff 
[-iV? zr Zs 
(i) dTi 2ý (i) dT i +f ý* (i-) 
(-ý 
0p1r 
ri 
Ipp 
ks r sl 
p 
where the second term is the sum of the penetration integrals 
P 
PS representing 
the attraction of nuclei s for the charge 
distribution represented by ýP2 (centred on nucleus r). These 
terms are small and often neglected in semi-empirical methods. 
The first term in H 
pp 
is an atomic integral, which is usually 
assumed to have the same value as in the free atom. 
H 2V2 - 
Zr 
(i)dTi 
PC P 
(i) yT 
r ri 
If p and a are centred on the same atom, H PC = 
0. 
otherwise., HP, is the resonance integral and is a measure of 
covalent bonding. 
Treatment of J ij gives us 
ff EC 0 (i)zc ý (i ) -mL Ec (i)zc O(j)dT -dT -f cr2 (i) q2 (j ) do p lip pa va a rij T IJT Vv1 )1 v 
Since 'the spins integrate to unity, rearrangement gives that 
jljv=zEzz cccc ffý (i)ý (j) 
10 (i)o(j)dT dT 
P Cl TV Vp VU VT Vpar ij Tvii 
For 1-centre integrals, rpp, P= CF =T=V, such that 
ffý2(i) ý2(j) 
1 
dT. dT. 
ppppr ij 13 
If P =T and a =v but p ýa, we get the coulombic repulsion 
integral, r. a, where: 
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If Cy- 2( i) ý2 (i ) dT d-ri 
pai 
which may involve 2 centres if p and a are on different atoms, 
or 1"-centre if they are on the same atom. When p -r =v we 
get the exchange integral given by: 
ffý 
P(')ýa(j) r' 
Op Mo a (i)dT i 
dT 
ij 
which may be one- or two-centre. A shortened form of this 
utilizes the bra-ket notation of Dirac, i. e.: - 
pp 
= <Pplpp> 
pa= 
<pp I CFa> 
The following table summarizes the type of integrals required 
in a rigorous MO treatment. 
f0p0adT 
jfI Q) IV2 -ZzI 
]lp(i)dTi=Hpp 
p 
I- 
srA 
fo 
P 
(i)h(i)o M dT i=H Pa 
f0M -is (i) 
dT =H 
P rsi pi PS 
<pplpp> =r 
pp 
<Pplaa> = rpa 
<Papa> 
<PP PC> 
<PaIPT> , <PPICT> 
<palTV> etc. (8 in all) 
Overlap integral 
Core Hamiltonian 
Resonance Integral 
Penetration Integral 
1-centre coulombic 
repulsion integral 
2-centre " 11 
Exchange integral 
Hybrid integral 
3-centre integrals 
4-centre integrals 
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Appendix 3. Derivation of MO Parameters 
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The following. MO-derived parameters of interest in structure- 
activity work are given below indicating their method of 
calculation in the MINDO/3 scheme. MINDO/3 was ol-tained from 
the Quantum Chemistry Program Exchange at Indiana University. 
Electron density (electron population) 
Electron population density in a volume element dT is given by: - 
p (X, y, Z) =I jp2 I d-r 
Electron density, qi, on the ith atoms is given by: - 
occ 
qi nj c, j2 
where the summation is over all occupied orbitals 
nj is t he orbital occupancy(2 electrons for a filled orbital) 
cij are the orbital coefficients which comprise the 3th MO as 
a linear combination of atomic orbitals )(k (LCAO procedure) 
Icij Xk 
Net Atomic Charge 
The net atomic charge, Qi is the charge in excess of., or 
deficiency needed to neutralize the core charge of the ith 
atOM. 
Qi =N- qi 
where N is the core charge (total no. of electrons for free 
atom) - 
Frontier electron density 
This the electron population density (after Mulliken) in the 
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frontier orbitals - the highest occupied MO (HOMO), and the 
lowest empty MO (LEMO). 
i. e., 
2 Cj 2 
Superdelocalizability 
This is a term coined by Fukui et al. 
89 for the orbital-weighted 
electron density. For example, electrophilic superdelocali- 
zability, SE . is given by r- 
mC .2 E21 rj 
r j=l xj 
where j=1 -* m denotes occupied mos 
C 
rj 
is the coefficient of the rth ao in the jth mo 
X3 is the energy of the jth mo 
orbital Energy 
The orbital energies, Xj) are the energies of the Mos formed 
as a result of re-distribution of ao electrons using the 
LCAO procedure. They are the eigenvalues obtained from 
solutions of the secular determinant formed from the Fock 
matrix. See, for example, W. G. Richards, Quantum Pharmacology, 
pp 100-102. 
Bond Energy 
The bond energy, BEi j, 
between atoms i and j is the sum 
of the 2-centre energy terms, V, J, J, N and R as calculated 
in the NDO procedures (see text for details). 
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V= electron-nuclear attraction energy 
J= inteielectronic repulsion energy 
K= exchange energy 
internuclear repulsion energy 
resonance energy 
Bond Order 
The bond order P rs 
is the overlap electron population between 
atoms r and s summed over all occupied MOs, k. 
occ 
21C 
rk 
c 
sk k 
Ionization Energy 
The ionization potential, I. P., is calculated as the positive 
value of the highest occupied MO energy in eV. 
Heat of Formation 
The heat of formation, Hf, is calculated in MINDO/3 as the 
difference between the total energy of the molecule and that 
of the constituent atoms. Atomic energies are calculated 
from single configuration wave functions using the same 
procedures as in the MO calculation. 
Total Energy 
The total molecular energy, T. E... is the arithmetic sum of 
electronic energy, E. E., and core repulsion energy. The 
electronic energy is the summation of all one-centre and 
two-centre integrals for all atoms in the molecule with 
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the exception of the intermolecular repulsion energies, N. 
The core repulsion energy is the sum of all these latter 
terms: 
i. e. core repulsion energy IN for i atoms 
Dipole Moment 
For the purpose of calculating the dipole moment, the mole- 
cule is treated as a system of point charges, qi, situated 
at distances, ri, from the origin. The dipole moment is 
therefore written as: - 
qiri where q. are 
the net atomic 
chargeslon i atoms. 
The individual x, y, and z, components of the overall 
dipole moment are correlated and summed vectorially to give 
the total electric dipole amount of the molecule 
ie, 
x+y+k ji z 
where vx qixi, vy qiyi, UZ qizi 
and xi, Yi, z, are the cartesian coordinates of atom i 
A 
lp It k are unitary vectors in the x, y, z directions. 
Molecular Electrostatic Potential 
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The electrostatic potential V(r) experienced by a unitary 
positive charge (i. e. a proton) at a distance, r, from a 
molecule will be a linear combination of attraction from 
the electrons and repulsion from the nuclei of all the 
atoms in the molecule. This supposition is a corollary 
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of the Hellmann-Feynman theorem which enables some types of 
quantum-chemical calculations to be performed in apparently 
classical terms. 
From Maxwell's equations, the divergence or-net outward flow 
per unit volume of electric field E into a volume element 
must be accounted for by the presence of free charges at a 
density P(r) in that volume. 
form this be-comes: - 
Expressed in a mathematical 
7r 1) () 
where v is the nabla 
operator 
'a + ja + 
ka 
ax ay 3z 
Now, the electric field is the negative of the electric 
potential V (r)' i. e. 
E= -VV(r) 
and therefore we get the Poisson formula 
where V2 is the Laplacian 
V2V (r) 4 it p (r) operator a2 a2 a2 
TX-7 ay =5z 
P(r) can be represented as a quantum-mechanical charge 
distribution function and expressed in terms of Gaussian type 
functions, i. e. 
CCA _C, r2 A e- ot r2 
11v vi li 
(r )v (r) 
In the INDO procedure (as utilized in MINDO/3) Slater type 
orbitals of the form A )i 
(r)e-alj make up the basis set. The 
STOs are expanded over a limited set of Gaussian functions. 
As the product of any two Gaussian functions can be ex- 
pressed in terms of a new Gaussian function (see later), 
the contribution of each pair of Gaussian functions to p(r) 
"93 
can be calculated separately. For example, the contribution 
from an S-type Gaussian function can be calculated by the 
following procedure: 
If p(r) =e 
-ar2 
Then, V2V(r) = -4? Te-a 
r2 
For an S-orbital there is radial symmetry so that 
V2V 
1Za 
r2 -L V vil 
2 
V, 
(T) r ar 
Iar] 
(r) "ý (r) +r (r) 
Since 
rV 
2 V, 
r a=r 
V (r) +r (r) 
Substitution gives us the equality 
32 
rV4 Tre -ar2 r a=r 
Integrating twice obtains the potential V (r) 
2 Tr cc r2 e dr ++C (r) ar 
fo 
r 
Now when r=-V (r) =0 
and when r=0V (r) is finite Cl C2 0 
and the potential function becomes 
V= 
2n r 
e- ar2 dr (r) ar 
fo 
for small values of r, 
fr- ar2 1( r3 + rs r7 e dr =-I- 
o CL 
3 10 42 
v 
27T -1 Y2 
+ 
r4 r6 I 
(r) a7 
[3 
10 42 ''* 
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However, if r is extended to infinity-, then the integral 
becomes simply 
cm ar2 2 Tr I/ 
-7r 2 
3/2 
e dr VI and VI 
f 
cl (r) cir a 
The electrostatic potential at point P(r) is given by: - 
p(rj) za 
(r) 
fr-rIIr-R 
Where the first term is the elctronic term, and the second 
is the nuclear. term representing the contribution from the 
nuclear charge distribution in the molecule of nuclei a at 
distance R with atomic numbers Z aa 
z 
x 
In the Cartesian frame 
of reference, r, is 
distance of electrons 
from origin, 
R is the distance 
a 
of nuclei from the 
origin, and 
r is the distance of 
y 
the point P from the 
origin. 
J-r - r1l is the distance 
between the electrons 
at r, and the point P at r. 
jr-r. 1 is the distance between the nuclei at R. and the point 
P at r. 
Potential field calculations can be executed at great speed 
by modern computerssuch that a large number of molecular 
29S 
electrostatic potentials may be processed in the form of 
isopotential contour maps as shown in this work. This 
facilitates the process of receptor mapping (see main text) 
to yield important information of drug-receptor binding 
and to assess the relative contribution from individual 
points of interaction between receptor and drug molecule. 
The cautionary word is that the Hellmann-Feynman theorem 
is valid for-Hartree-Fock wave functions only and LCAO MO 
wave functions result in certain in-built errors. It should 
be noted, however, that in the INDO procedure, a de-ortho- 
gonalization of the MOs is not necessary. Program POTENT 
which generates electrostatic potential maps is listed after 
the reference section. 
The Two-centre Overlap Integral Calculation for Gaussian 
Orbitals on Two Nuclei at a Distance R apart 
For two Gaussians of the type: - e -a(X2+y2+Z2 
) 
e- 
b((x-R)2+ y 2+ Z2 
The overlap integral, S, is the product of these functions 
integrated over all space 
Co 
S e- 
(a+b)(y2+Z2 
e- 
aX2 
e- 
b(x-R)2 dxdydz 
The product of two Gaussians can be expressed as a third 
Gaussian centred at a new point. To find-this point we 
have to write the product: 
e- aX2 e- 
b(x-R)2 in terms of 
(a+b)(X-C)2 +k 
By inspection we find that 
where c and k are constants 
bR 
and k= 
b2 R2 bR 2 c- (a+b) (a +b) 
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Therefore the overlap integral can be rewritten as follows; 
Go 
S= bR2 b (a+b) x- 
bR 2+ 
y2 + Z2 fffe 
a+b e- (a+b) dx dy dz 
CO 
Operation on this and conversion to a single integral since 
the x, y and z dependencies are separated and identical, 
gives 
bR2 b e- 
(a+b) U2 du 8e( -(a +bT 0 
Tr 
a+ b] 
bR2 b 
e 
(-(a+b) 
Oo ar2 because 
fo 
e dr 
Polarizability 
IT 
a 
This is a useful term in drug-receptor interactions as the 
induced dipole moment, ý'Indl in a molecule by an external 
electric field F caused by either solvent molecules or a 
receptor molecule is given by: "Ind = aF where a is the 
polarizability of the molecule. 
The atomic polarizability, a A-' is given for A atoms as 
follows: - 
(A) (A) 
-c-c-c 1, p lv 311 v 
E. -E. 13 
where p and v refer to different atoms 
i and j refer to occupied and unoccupied MOs respecti- 
vely or orbital energy Ei and Ej. 
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The relationship above, derived from applying a perturbation 
from a constant electric field in the region of a molecule 
of A atoms, reduces to the following expression for self- 
atom polarizability. 
c2c 
13 3 
Such an expression can be rearranged in terms of superdelocal- 
izabilities SE- and SN as follows: - 
It can be shown. that 
11-1--EiEi 
Now, 
2 
cil, 2 
S EE 
and 2 
Cjl, 2 
S 
EN 
a' fsfS ANEEiN] Xij 
where fNj, fBi are frontier orbital electron densities of LEMO 
and HOMO respectively and xij is a constant given by 
E . E. - 1J 
(E) 2 
Since a is related to the partition coefficient P, so isS E 
and SN * 
The Relationship between the 2nd Order Perturbation Energy 
for Drug-Re. ceptor Interaction and Superdelocalizabilities 
The 2nd order interaction energy obtained from consideration 
of orbital overlap between two molecular species (in this case 
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drug and receptor molecules) is given by: - 
Cra ab, 
2 
rE Sb occ unocc occ unocc Cc AEI L-S ab 
rSsr Er -Es 
where r and s refer to MO labels on differerrt molecules 
aab is the resonance integral 
c ra, c sb are 
the orbital coefficients of ao's a and b 
in MOs r and s 
Er, q Es -are 
energies of MOs r and s. 
Expansion of the expression for AEI yields 
occ unocc 2cc$2 occ unocC 2( aý 
cracs0abj 
AW =II 
(ý, 
ra sb abi -yIEE 
rsEr-Essrrs 
utilizing the equality, 
1 
.11 
-ab 
(1 1) 2ý 
a-b 
(a 
b] (a - b)2 aF rs 
we get: - 
(unocc occ occ unocc occ unocc 
AE' = ýrs I Csb 2XSE-I cra 21 SN -I csb 21SN 
srrssr 
unocc occ I 
ra 
1SE 
rs 
which simplifies to the following for frontier interactions 
rs 
(QsLEMO ý SE - Qr 
HOMO I SN - Qs 
HOMO ISN+Qr LEMO Is El Iý 
rsrs 
In the majority of cases this reduces to a two or three term 
expression if only one molecule or other is considered. 
AE' = ýIIQT + ý21SE + ý31SN 
where IQT is the sum of the total atomic charges and 01,02, ý3 
are constants. 
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Frontier Orbital Theory 
An expression for the second order interaction energy between 
two molecular species R and S, which can be obtained from 
perturbation theory, is as follows: - 
-2 1111cI 
RS 
EAEi (R) j (S) mn 
jn mn 
C. R CS aRS 
2 
iýS) jl(R)l 
In 
)m in mn 
where AE = Ei-E Ei, Ei are orbital energies of orbitals i, j. 
M, n are atom labels on molecules R, S respectively. 
i, j are orbital labels on molecules R., S respectively. 
c are orbital coefficients, a 
RS is the overlap integral. mn 
If R and S are joined through one bond which links atoms m in 
and n in S, there will be one non-zero a term and the 
expression becomes: - 
-2 
( 
ýMRnS 
]2 (C 
R 
) 2 
I 
(CS ]2 
+ 
( 
(ý 
)2 ] 
C R 
2 
i M 
i (R) j ) (S jn ) (S 
n j R) 
M i 
Replacing the orbital coefficient summations with net atomic 
charges since ICS 
)2 
= qS /2 
j(S) 
( 
jn n 
and also using the normalization condition for the coefficients 
because 
I 
(C S )2 
+I 
[C S ]2 
(S jn i(s) in 
we can write 2 
C is" I-q 
S/2 
i(S) k in n 
Thenceý expression for El' becomes 
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RS 1 
"M 
[q 
S 
AE n 
RqR QM mI 
The interaction between the two molecules is said to be charge- 
controlled when there is a large difference in. net atomic 
charge between two key atoms on the interacting species, i. e. 
if qS >> qR or vice versa. This will give rise to a maximum nM 
value of the coulombic attraction between the two atoms, i. e. 
RS 
coul, 
qmqn 
R 
mn 
where Rmn = interatomic 
distance between m and n 
will maximize and R mn will 
decrease, so as to increase the 
size of Ecoul until equilibrium is reached. This will result 
in either the formation of a covalent bond between m and n 
or an ion pair, or an ion-dipole attraction. 
A frontier-controlled interaction is another limiting case of 
energy stabilization between the two molecules. This occurs 
when the difference in frontier orbital energies is very small, 
i. e. when ER HOMO 1ES LEMO- So that when the energy of the 
highest occupied MO is close to that of the lowest empty MO 
of the other molecule, a partial electron transfer process 
will occur, which is sometimes called charge-transfer (CT). 
In frontier-controlled interactions, the following terms will 
figure: - 
I CR 2 which is related to SR, E the electrophilic im. 
m superdelocalizability on the donor molecule. 
AE 
CS. 
S 
which is related to SNI the nucleophilic 
n nI superdelocalizability on the acceptor 
AE molecule. 
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and 
(iicRcs 
mn 
iM jn 
AE 
which is related to the electronic 
polarizability of the molecules. 
An interaction will be favourable, therefore, between two 
atoms having the largest coefficients in their respective 
frontier orbitals. 
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Appendix 4. Autocatalytic Model 209 for Dose-Response Rela- 
tionships 
The basis of this model is that the mechanism for autocatalysis 
is similar to that of receptor occupation according to rate 
theory rather than occupancy theory. 
In an autocatalytic reaction, a reactant or reactants produce 
products, one of which catalyses the reaction. Consider a 
reaction whe-re a reactant A produces products B and C: - 
i. e., B+C where C is a catalyst 
The rate depends on concentration of A and C in the following 
way: 
d Cc] 
= k[A I [cl - k[c]2 dt 0 
d[c3 . where Tt- is the measurable rate (i. e. increase in Ecl with 
time) 
is the rate constant 
EAO] is the initial concentration of A (i. e. at t= 0) 
At the start of the reaction the concentration of C is zero 
and the rate is zero. As the reaction proceeds the rate 
increases steadily to a maximum level and then levels off to 
zero again as the reactant A is used up so that a plot of 
[c] against time has a sigmoid appearance. 
[C] at t=0 [c] = 
d[c] 
=0 21-t 
at time t, when 
[c] = EA01 
once again 
d[c] 
Tf- 
t 
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In order to investigate this situation further, it is 
necessary to obtain the integrated from of the differential 
rate equation. This may be rewritten, for convenience, in 
the following form 
Fd ay + by2 , rearrangement and collecting terms X gives: - 
dy = ay dx - by2dx 
by2dx ay dx + dy =0 
y(by a)dx + dy =0 
If we make the substitution u= by -a 
then y=u +a b 
and du =b dy 
Putting these in the rate equation gives 
u+ a) u dx + clu =0 bb 
-* dx + 
du 
= u(u + a) 
Integration yields the following expression 
X+ .1 log aIa 
u+ 
ul = -C where c 
is a constant 
But u= by - 
log by -_a a(c + x) 
I 
by 
I 
N ow, a=k[Aol and b=k 
log 
I ky 
ky 
k[Aol k[Aol (c + x) 
which becomes 
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log k+ log 
Iy-y [An] 
= -k[AOI(c + x) 
Then, log k+ log y/y - log [Aol/y =- k[A01 (c + x) 
which leads to 
log k- log EA03 = -kEAOI (c + x) y 
and rearrangement gives 
- log y=k EAOI (C + x) - log[Aol + log k 
Applying boundary conditions, when x =0, -log y =0 
then 0= k[A03 (c + x) - logEA03 + log k 
which gives the constant of integration 
10 ([An]/k) 
k[Aol 
Substitution into the previous expression gives 
- log y= k[, Aolx + log. 
ý[A. Qfl - log[Aol + log k 
k 
which reduces to 
2-log y= k[Aolx 
or log y=- kCAolx 
If y is the biological response, R, and x is the logarithm 
of the dose concentration, 
then log R= -k[Aollog Dose 
Returning to the curve for autocatalysis, the rate of reaction 
at half catalytic concentration which corresponds to the linear 
middle portion of the sigmoid curve can be obtained by 
substituting 
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EAn I 
EC3ý 2 
in the differential rate expression. This leads to 
d[c] 
- 
k[Aol 2 k[Ao 32 
Tt- 24 
k[An 32 
4 
Therefore the equation of the line corresponding to the 
linear portion of the curve is of the form: - 
k[A 2 
y=x+x 
when y=0, x-1 klAol 
"-- [AOJ 
". c- 
and the equation reads 
k[Ao 32X 
_ 
[Aol 
44 
EAo] k [Aol x -1 74 
which shows that for the middle of the range of responses, 
the logarithm of the dose concentration is linearly related 
to the quantal biological response for this model. 
The quantity EAOI can be substituted by the maximal response, 
Rmax* This corresponds to total receptor occupation where 
k is the rate constant for the formation of the drug-receptor 
complex. So that if R is the fraction of the maximum response 
(related to the fraction of total number of receptors capable 
of occupation) we get 
R= Rma (k log D Rmax where D is the dose 4 
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Rmax R Rtax2 log D- jr- 4 
However, the quantal response will be related to the negative 
logarithm of the dose concentration by 
log IRI = -k R max 
log D 
A similar result is obtained by treatment of the general 
equation for the kinetics of biological response. That is, 
the rate of biological response is given by 
dR KA dC 2Ft dR 
where K is the equilibrium constant for the drug-receptor 
binding process 
is the probability factor relating to the relative 
ease of drug transport through the physiological media, 
dC - and ý[R- is the rate of change of drug concentration with 
biological response. 
The above equation can be combined with the equation for 
autocatalysis to yield a dose-response relationship as 
follows: - 
putting 
ýR 
aR - bR2 dt 
gives us 
aR bR2 cdC dR 
Therefore 
dC aR bR2 
NR -c c 
where a= kCAol., b =k 
where c=KA 
when 
ý-C 
=0 at a maximum dR 
R=a= [A I F0 
Integration yields, 
C= aR 
2 bR3 
+d 2c 3c 
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when c=0, R=0, . *. 
* aR2 
bR3 
cý 2-c - 3c 
Taking logarithms, 
log C= log aR log( bR] 
cc 
log C log R (b - a) 
k log R (1-[Aol) 
shewing that quantal response depends upon -log Dose 
(related to -log C by pharmacokinetics). 
because log R=- log C/ k(l-[Aol) 
A more precise mathematical treatment of autocatalytic kinetics 
involves integration of the equality 
dx +- 
du 0 where u= by -a u(u + a) 
taking the second term in isolation the integration of 
_ 
du is given as -2 
tanh-1 2u +a 
u4 + au aaI 
Therefore the total integration becomes: - 
x 
2tanh-1 2u +a 
-C where c is a constant aa 
But u by -a 
nh- So, 
2ta 
a- -C 
or, alternatively, 
tanh-1 
2by -a a(x +c) 
a2 
However, a k[Aol 
bk 
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so that 
tanh-1 
2ky - k[An] k(x + c) 
k[Aol 2 
and this gives 
tanh-1 
2y - EA01 k(x 
2 
+C) 
1AOJ 
when x=0.9 y0 
and we get - 
= 
kC -20 as tanh- I (-l) = -10 tanh- 1 (- 1) 7- 
Therefore 
tanh-1 
2y - EAo- kx - 10 [Aol -2 
which can be rearranged to provide the relation 
y= [Ao]tanh 
kx 
- 10 + [Ao] 2 
2 
which readily simplifies to 
y= [AOI/2 tanh 
( kx 11 
Taking logarithms of both sides gives us 
log y= log 
(L4a 
tanh ( kx 2 
log [A01 - log 2+ log tanh 
X] 
2 
s inh x New log tanh x log cosh x 
= log ex- e- 
e1 ex + e- X1 
12 
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= log ex - e- 
x 
ex+ e- x 
xxxx log (e - e- ) -log (. e .+ e- ) 
= (X + x) - 
= 2x 
Therefore the relationship becomes 
log y logEA01 - log 2+ 2(kx 2 
. *. log y= kx + logEAOI - log 2 
Substituting the response R for y, the logarithm of the 
dose D for x, and R max 
for EAOI we get 
log R= klog D+ logR 
max - 
log 2 
So the logarithm of the quantal response is related to the 
dose by: 
log 
(RRI=k 
log D- log 2 
max 
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Appendix S. Pharmacokinetics and Dose-response Relationships 
The log dose-response curves for many drugs show a sigmoid 
relationship, characteristic of co-operative binding of 
(cf. enzyme kinetics). Implicit in the concept of co-ope- 
rative binding is the non-rigidity of the active site, and 
anti-cancer drugs which intercalate DNA by expanding the 
base-pair interstice are examples of this. Many drugs dis- 
play a mode of pharmokinetics which is tri-phasic consecutive 
lst order and the expression for plasma or tissue concentration 
after time., E, from administration is given by 
Ct = Ae -at + Be -bt + Ce- 
ct AB =constants abc 
: : C) 
It is often possible to relate this concentration to the 
administered dose, C, by the equation 
Ct = C(l - e-a 
t) where a is a constant 
For a two compartment system of the type shown below in the 
block diagram: the differential rate equation 
k, 2 
ýcýentral 
k2 
I peripheral 
k10 
for rate of change of drug concentration with time is given 
by: 
dC kckCkC -at- 21 p 12 c 10 c 
where Cc = concentration in central compartment 
CP = concentration in peripheral compartment 
It is usual to consider the following (amended) two-compart- 
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ment system: for which the plasma concentration 
i. v - ------- 
plasma ------ 
i. m. compartment 1 
etc. (central) 
I 
kjo 
J, 
at time t is given by 
ki2 compartment 2 
(hepato-portal) 
k2 0 
k 21 
e- 
ýt 
e- at v 1(a-a) 
I 
This is called-the first pass effect concentration. 
On integration, this yields: - 
CC) 
C dt 
k 21 k 21 x0 
V, ( a-ý )ITa 
or, alternatively, 
[C 
dt 
10 
Since aý =k 12 k 20 
X0k 21 
vi k 12 k 20 
o= oral dosing 
and a+a =k 12 +k 21 +k 20 
For intravenous administration, the integral becomes: 
C dt 
or, alternatively, 
ý' 
co 
C dt 
0 
x0k2, (a-a )-k 20 (a-a) 
Vl(a-a) 
X0 21 +k 20 
1k 12 k 20 
oral., 
i. p. etc. 
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X0 is the administered dose 
V1 is the apparent volume of distribution of the lst component 
V=X, where X is the amount of drug in the body c 
C is the amount of drug in the. plasma 
XO/K -C dt fo 
The bioavailability of the drug is the ratio of oral to 
intraveneous integrates, i. e. 
Apparent availability = 
1 fo" 0C 
dt 
( CC dt 
II 
where C= plasma concentration. 
10 refer to intravenous and oral administration. 
It is often useful to know that the differential equation 
common to pharmacokinetics is (for a 1-component system) 
dc 
= -kc 
where c= concentration at time t 
Tf k= rate constant 
which readily transforms to the following on integration: 
c= Co e- 
kt 
where CO = dose concentration 
taking logs this becomes the standard rate law for a first 
order reaction: 
lnC = InCo - kt 
For a reversible reaction such as a drug-receptor inter- 
action or enzyme-substrate interaction, the following 
relationships arise. 
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For the linear portion of a dose-response curve 
Em log C+e 
and log C 
E-e 
m 
where C= plasma concentration 
E= intensity of effect or biological response w 
e= constant 
m= slope of log dose/response curve. 
For a fractional (or quantal) response, FR 
c 
K+C 
where C= drug concentration 
drug-receptor dissociation constant. 
Sometimes this is written in another form. as follows. 
B. R. AK 1+ AK 
where A= drug concentration (dose) 
K= drug-receptor or enzyme binding constant 
B. R. = Biological response 
whereas for co-operative binding, the relationship becomes 
B. R. =A2K 1+ A4K 
If the total drug profile is considered with the inclusion 
of transport terms and receptor binding terms, we have 
for the rate of change of response R with time, t: 
dk 
= A. C. K dt 
where A= probability or hydrophobic transport term 
concentration of drug in cells or plasma 
equilibrium binding constant 
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Expanding all terms we get 
dR 
--( 
Tr - Tr .2 at ýt -yt A G*/RT 
Ut - ae b 
(Ae- + Be- + Ce -e-I 
The first term is the Hansch substituent parameter term for 
transmembrane diffusion a= const. b= const. 
7T = substituent parameter 
7oý optimum Tr value 
The second term is the expression for the plasma drug 
concentration based on a three component model 
A, B, C = constants containing drug 
concentration terms 
constants containing rate 
constant terms 
time 
The third term is the drug-receptor binding constant. where: 
JA G* is the sum of the free energies of drua-receptor 
interactions 0 
gas constant T= absolute temperature 
If we consider a quantal (fractal) response, measuring the 
dose concentration to produce a certain percentage (or 
fraction) of the biological effect, then , 
dR =I for a unit rate of change of response Tt- 
and taking logs of both sides of the previous expression 
yields 
log a_ 
(7T-IT. 
Q) 
2+ 
log A- eLt + log B- st + log c- yt b 
_i 
AG* 
RT 
31S 
_: 0= log a- 
7T2 + TrTr' - 
12ý + log (A+B+C) - (a+ß+y) t-i 'ýG* bbb RT 
0 a' - 
blTr 2+ cliT + log(A+B+C)-(a+ý+y)t - 16G* RT 
Now A+B+C contain dose concentration terms Fhich may be 
extracted to give 
0=a1-b 17r 2+c1 Tr + log D+ log k1 -k"t -1 
AG* 
RT 
where D= dose for, say, 50% response 
k' = combination of rate constants from 
k" = another combination of rate constants 
pharmacokinetic: 
-+ -log D=a1-b 17r 2+c1 Tr + log k1- kIlt - 
AG* 1 
RT 
Combining the constant terms into a single constant all we get 
-logD = al' -b'Tr 2+ clu -, 
AG* 
RT 
which provides the validity for QSARs based on effective dose 
(EDSO) and lethal dose (LD50) measurements. The 7 terms 
explain the successful and wide applicability of the Hansch 
method, whereas the AG* terms may be computed from MO cal- 
culations, which incidentally also give numerical values 
related to 7r. This result may also be arrived at from a 
consideration of the dose-response relationship characteristic. 
Let us consider that biological response R is related to 
administered dose D by some arbitrary function f(D), i. e., R=f(D) 
Then dR = fl(D) dD where fl(D) is the first derivative 
of that function. 
Then let us return to the rate of change of response with 
time differential equation as follows: 
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dR where D= dose concentration 
TE =ADKm Km = binding constant 
A= probability of drug 
reaching receptor site 
Rearranging we get 
dý AK dt Dm 
substituting for dR, gives 
fI (D)dD AK dt Dm 
integrating both sides yields: - 
co t f 
f'(D)dD AKm dt 
o li 
(using the standard formula for the integration of a product 
of two functions of the same variable) 
-* -1 
ff'(D)dD 
- 
fR(-D 2 )dD =A Kmt D 
sice ffl(D)dD =R 
R- fR (-Iý)dD =AK 
1R log DAKt uDm 
A Kmt 
log D 
-log D=R A Kmt 
So that the negative logarithm of the dose concentration is 
related to the biological response. 
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Appendix 6 Regression Analysis 
212-217 
The statistical technique of regression analysis is essential 
to the formulation and critical assessment of quantitative 
structure-activity relationships (QSARs). With correct 
utilization of these methods it is possible to establish the 
existenceofcausal relationships between theoretically 
derived MO parameters and experimentally measured biological 
activity for series of compounds. 
It is important to emphasize the distinction between 
"regression" and "correlation" as these terms are often 
wrongly used synonymously. Regression describes the nature 
of a relationship between two or more variables, whereas 
correlation determines the strength of that relationship. 
To avoid confusion it would be better to use the term "multi- 
variate analysis" instead of correlation or regression 
analysis. However, the latter terms are widely used and 
readily understandable, therefore they tend to be retained 
by most workers in the field. 
Single Linear Regression Analysis 
Basically, regression analysis relies on a least squares 
method of fitting a number of data sets to a linear relation- 
ship. Consider a set of values for the parameter designated 
x and another set of values for the parameter y. 
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Y- Supposing that a roughly straight 
X1 Yi line relationship exists between x 
X2 Y2 
and y such that y depends upon x in X3 Y3 
X4 Y4 the fashion 
y= mx + c 
Xn Yn We designate y, t he dependent 
variable, and x, the independent 
variable. Since there is a certain degree of scattering 
of the (x, y) points we need to determine the equation of the 
best straight line through the points. Although this may 
be done crudely by a graphical method, the statistical 
method of employing least squares is to find the equation 
of the line y= mx +c for which the sum of the squares of 
the deviations from the line is a minimum. 
Let the deviation of a given point on the best straight 
line at x=xi (when yi bxi + a) and the actual observed 
point yi be yi' - yi- Then we require that the squares of 
these deviations summed over all values is as small as 
possible, 
n 
i. e. when (y I-y, 
)2 minimum 
The least squares method provides the values of m and c for 
the best straight line Y= mx +c as it can be shown that: 
n(zxZ) x(ZZ) 
n(Ex4) (EX)4 
mx 
where n= number of (x, y) points 
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Ex = sum of x values 
zy = sum of y values 
x= mean of nx values 
Exy = sum of (x y) values 
EX2'= SUM Of X2 values 
mean of ny values 
Two ways of assessing the goodness of fit of the best straight 
line to the n pairs of (x, y) values are by calculating the 
standard deviation of the estimate, s, and the correlation 
coefficient., r. These are given by: - 
Ey2 - (zy)2/n - 
(Exy - Ex EX/n)2 
S 
Exz- - (Ex)ý1-/n 
n-2 
r= 
Exy. - ExEy)/n 
V[Ex2 - (Ex)'/ni[Eyl-(Ey)7-/ni 
We can see that r and s are related by the equation 
VE1 - sl (n-2)/a2yn] 
where a2y 
E(Y-Y) and Ey the mean value of y nn 
The quantity a2y is called the variance of y and can be used 
to estimate the significance of the correlation. A particular 
regression can be assessed by inspection of the values of r 
and s. r can take any value from 0. -* 1, the closer to 
unity, the better the correlation. In the analysis of 
biological data an r value between 0.95 and 0.999 is consi- 
dered an excellent correlation, between 0.90 and 0.95 is 
considered to be very good, between 0.8 and 0.9 is good, 
between 0.7 and 0.8 satisfactory, and less than 0.7 is poor. 
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However, other statistical quantities also have to be assessed. 
The value of s assesses the reliability of a particular 
regression. § needs to take as small a value as possible, 
and generally acceptable limits are that two-thirds of the 
estimated values of y should lie within s units of the 
corresponding observed values and 95% of the estimates 
should lie within 25 units. Also the spread of y values 
should be over a greater range than the standard deviation 
or the regression equation does not adequately explain the 
data. 
It should be noticed that the correlation coefficient is 
very sensitive to the value of n, the number of data points. 
So that a small sample size will produce an artificially 
high correlation and lead to an erroneous conclusion about 
the significance of a correlation. 
The performing of simple regression analysis is not beyond 
the capabilities of many hand-held calculators which have 
built-in statistical routines for data handling. It is 
also of interest to calculate r2 and the value of F, the 
variance ratio, given by 
r2 
The size of the F values provides a better assessment of 
the regression equation than r due to the inclusion of r2p 
the fraction of the variance explained by the regression 
equation. 
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Multiple Regression Analysis 
In multiple regression analysis one is dealing with a number 
of independent or explanatory variables, xk against the 
dependent variable y. Thus an equation of the form 
y=a+ bIX2 + blx2 + ... bkxk 
has to be fitted to the data sets 
Xii, X21., ... Xkl' Yl 
Xint X2n, ... lxknl Yn 
such that 
yj =a+ blxli + b2X2i + *** b kxki + el 
where b, -* bk are the regression coefficients 
a is a constant, and e. is the deviation of predicted 
y from observed yý 
The best multiple regression equation is determined when the 
n 
value of e2 is a minimum. 
Consider a collection of data sets of n cases with k indepen- 
dent variable (x i) to be regressed against the dependent 
variable (yi) . 
The means of all k+l variables can be designated as 
Xlv X2Y X3) ***-% Xk' 
Let Sij signify the (k+l) x (k+l) matrix of the spms of 
squares and cross products of deviations from the means of 
all variables. Then the correlation matrix Rij of all 
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variables in the regression will be given by 
s ij 
I/S ii 
s kk 
The correlation matrix is useful for elimination of cross- 
correlations from significant regressions in the final 
analysis. The multiple regression programs ANYREG and 
ALLREG are used for statistical analysis of up to 40 
variables for the formulation of QSARS. Cross-correlation 
(or auto -correlation) is when two independent variables are 
found to be dependent on each other give rise to artificially 
high correlation coefficients and spurious variance ratios 
(F values). Employment of computer techniques facilitates 
handling of large matrices and enable fast calculation of 
inverses, products and quotients of matrices. 
Thus the regression coefficients, bi., can be calculated 
from the expression 
k 
1. Ci i Sj(k+l) for i, j = 1,2,... k 
J=l 
ij is given by 
R. . r. - 
ij 
13 13 
S. - 13 
where r ij is the (i, j)th element of the inverse of the R 
matrix. 
S i(k+l) 
is the sum of cross-products of deviations from 
means for independent variables xi and the dependent variable 
y. 
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The next set of quantities necessary for calculating further 
statistical parameters are the sum of the squares attributed 
to the regression, SSR, the sum of the squares of deviations 
about the regression, SSD, and the total sum of the squares, 
SST. These quantities are given by: - 
SST =S (k+l) (k+l) ' 
The sum of squares of devia- 
tions from the mean for the 
dependent variable, y. 
k 
SSR Ibjs j(k+l) j=l 
SSD = SST - SSR 
It is also useful to know the degrees of freedom attributable 
to the regression, DFR, the degrees of freedom of deviations 
about the regression, DFD, and the total degrees of freedom, 
DFT. These are simply the equalities: - 
DFR = 
DFD =n-k-2 
DFT = 
From this, the mean square attributable to the regression, 
MSR. and the mean square of deviations about the regression, 
MSD, are given by: - 
MSR = 
SSR 
DFR 
MSD SSD DFD 
Then the statistical quantities for the assessment of signi- 
ficance can be readily visualised since the variance ratio, 
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F. is given by: - 
MSR F rqg-D 
The standard error of the estimate, S, is - 
S= vrM -SD 
and the multiple correlation coefficient, R, is: - 
R- -S-S D 
SST 
The multiple correlation coefficient corrected for the degrees 
of freedom and then squared is given by: - 
2 SSD. DFT 
SST. DFD 
It is also necessary to compute the standard errors of 
individual regression coefficients. These are given by: - 
s. e. (b i) 
= VMSD. ci ii= 
1ý2 
One can see that simple linear regression analysis is a 
trivial special case of multiple regression analysis for 
which an expression of variance ratio, F value, can readily 
be obtained, since: - 
SSD 
=, R2 
so that 
SST - SSR R2 SST 
which also is equal to 
_F 
n-k2 
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for a single independent variable, k=l 
therefore 
SST - SSR IR2F SST n-3 
Now SST-SSR = (1-R 
2) SST 
which gives SSR =R2 SST 
and leads to 
SST = Evar. yln 
where Evar. yl is the variance of y. 
Now. the formula for F will be 
F-R2 SST (n-3) SST-FRZ SSTI 
which will become 
F=R2 Evar. yl n 
(n-3) 
Evar. yln - (Rz[var. yln) 
rvar. yln R (n -3) 
Evar. y]n I -R2 
Therefore F=R2 
(n-3) 
1- RL 
as given previously under simple linear analysis. 
In order that an equation should be regard, ed as a satisfactory 
predictory facility, the observed F-value should exceed the 
selected percentage points of the F-distribution. For a 
given regression, the percentage of the points which lie out- 
side the range of the F-distribution should be as small as 
possible. Therefore a highly significant regression is 
likely to show that less than 0.1% of the total data points 
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lie outside the limits of the F-distribution. Statistical 
tables 
218 
of'percentage points in the F-distribution for 
different values of degrees of freedom are available 
for the inspection of regression significance. 
The ALLREG 219 program calculates and prints out the values 
of R and F for combinations of five independent variables 
in a total set of up to forty. The program ANYREG 
219 
calc- 
ulates the regression coefficients, standard deviations, 
standard errors, correlation coefficients, and F-values for 
the most significant regressions in a set. It can handle 
multiple regression analysis for anything up to eight 
variables in one equation, though this is rarely used or 
necessary. In addition, ANYREG tabulates predicted y values 
against observed y values, and the discrepancy between the 
two figures for comparison. 
The generally accepted format for exhibiting regression 
equations, as employed in this work, is as follows: - 
Regression equation n D. F. sRF IL 
y=blxl + b2X2 + ... bkxk+a 10 11,8 0.110 0.912 56.37 0.1 
where: D. F. are the degrees of freedom 
n is the number of data points 
S is the standard deviation 
R is the correlation coefficient 
F is the F-value 
P is the percentage points outside the F-distribution 
327 
Correlations are regarded as good when 
a) the standard errors of the coefficients bk are small 
compared with b k' the regression coefficients 
b) the number of cases or data points, n, is reasonably 
large 
c) there is a reasonable number of degrees of freedom 
d) the standard deviation is small (i. e. 0.1 -* 0.2) 
e) the correlation coefficient approaches unity (i. e. 0.9 -* 
0.99) 
f) the variance ratio, F, is large (i. e. 10 -* 100+) 
g) the percentage point, p, is small (i. e. 0.1,0.25,0.5). 
With few exceptions 
regression analysis 
tical significance, 
the data employed. 
ANYREG are reproduc 
after the reference 
this will serve as a useful guide to 
and the assessment of degree of statis- 
validity, and adequate explanation of 
The listings of programs ALLREG and 
ed with permission of the author, T. Blair, 
section. 
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